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1 INTRODUCTION 
 
 
Eimeria bovis represents one of the most pathogenic Eimeria species causing 
cattle coccidiosis (Daugschies and Najdrowski, 2005). During its longlasting 
intracellular first merogony (14-18 days of duration) E. bovis forms large 
macromeronts of > 400 µm size containing > 120,000 merozoites in host 
endothelial cells (Hammond, 1946). Given that the invading sporozoite stage alone 
cannot provide all components necessary for this nutrient and energy demanding 
process, the parasite needs to scavenge molecules from the host cell. Especially for 
the offspring’s membrane production, large amounts of cholesterol are 
indispensable for a successful replication process. 
 
Overall, cholesterol is needed for several reasons during macromeront formation: 
i) for the enormous enlargement of the host cell plasma membrane, ii) for the 
formation of the parasitophorous vacuole and iii) for the formation of a multitude 
of merozoites I. Interestingly, cholesterol auxotrophy has been reported for some 
closely related apicomplexan parasites, such as Toxoplasma gondii, 
Cryptosporidium parvum and Plasmodium yoelii (Coppens et al., 2000, Labaied et 
al, 2011, Ehrenmann et al., 2013). However, cholesterol is an irreplaceable 
component of cellular membrane biogenesis in the eukaryotic system exhibiting 
several pivotal physiological functions (Ohvo-Rekila et al., 2002) and its 
metabolism is tightly regulated in the mammalian system (Brown and Goldstein, 
1986, Goldstein and Brown, 1990, Chang et al., 2006). To meet their cholesterol 
requirements for optimal parasite proliferation, T. gondii, P. yoelii and C. parvum 
scavenge cholesterol from their host cell by exploiting different pathways of 
cholesterol acquisition in a parasite-specific manner (Coppens et al., 2000; 
Labaied et al., 2011, Ehrenmann et al., 2013). 
 
So far, little data are available on E. bovis-triggered modulation of the host cell 
cholesterol metabolism. Transcriptomic and proteomic analyses of E. bovis-
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infected host cells indicate a parasite-induced alteration of cholesterol acquisition 
pathways in general (Taubert et al., 2010, Lutz et al., 2011), but do not deliver 
detailed data. Therefore, the current work intends to analyze the interference of E. 
bovis with its endothelial host cell on the level of low density lipoprotein-mediated 
cholesterol up-take and cellular cholesterol de novo synthesis via the mevalonate 
biosynthesis pathway. In addition, cholesterol processing in the host cell and 
parasite-mediated lipid droplet formation is analyzed in more detail and, overall, 
parasite-specific actions are highlightened. 
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2 LITERATURE REVIEW 
 
 
2.1 Eimeria bovis  
2.1.1 General introduction  
Eimeria bovis belongs to the class Coccidia within the phylum Apicomplexa 
(Levine, 1980, Adl et al., 2005). Apicomplexan parasites are characterized by 
their unique apical complex (Fig. 2.1.). The main components of the apical 
complex are: polar-ring complex, subpellicular microtubules, micronemes, 
rhoptries and dense granules (Chobotar and Scholtyseck, 1982). The polar-ring 
complex is localized at the very anterior part of apicomplexan invasive stages and 
consists of a ring of microtubules. The hollow-shaped conoid is located in the 
middle of the apical complex. Additionally, subpellicular microtubules are arising 
and anchored to this apical polar ring. These longitudinal subpellicular 
microtubules are associated with the inner membrane complex (IMC) which are 
important for the apicomplexan shape and physical stability (Morrissette and 
Sibley, 2002, de Souza and Attias, 2010).  
 
The rhoptries, micronemes and dense granules are well known as highly 
specialized apicomplexan secretory organelles being indispensable for parasite 
gliding motiliy as well as for host cell invasion activity. Thus, their secreted 
products are required for three essential apicomplexan parasite actions: i) gliding 
motility, ii) host cell invasion and iii) early intracellular life establishment by 
parasitophorous vacuole (PV) formation (Dubremetz et al., 1998, Morrissette and 
Sibley, 2002, Souza, 2006, Ravindran and Boothroyd, 2008, Blackman and 
Bannister, 2001). The rhoptries are tear drop-shaped organelles which are 
connected by a thin duct to the apical part of the parasite. The rhoptry numbers 
can vary from two to more than six depending on the apicomplexan genus, species 
and stage [e. g. sporozoites, merozoites, bradyzoites, tachyzoites, metrozoites, 
(Blackman and Bannister, 2001)]. Rhoptry content secretion occurs shortly after 
parasite adhesion to the host cell membrane and rhoptric molecules have been 
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described to participate in the parasite-cell membrane tight junction formation 
during the active host cell invasion process (Dubremetz et al., 1998, Sibley, 
2010). Furthermore, different rhoptry proteins have been described to be present 
either in the pheripheral or in the transmembrane part of intracellularly formed 
PVs (Sam-Yellowe, 1996). In this context, a merozoite-specific 22-kDa rhoptry 
protein of E. nieschulzi has been reported to be present in the PV membrane 
shortly after host cell invasion (Rick et al., 1998). In contrast to rhoptries, the 
micronemes are small elliptic-shaped organelles dispersed within the apical third 
of the parasite (Fig. 2.1.). These organelles are also relevant for host cell 
recognition, binding and gliding motility (Dubremetz et al., 1998). The dense 
granules are cytoplasmic, spherical-shaped organelles. Their contents are 
ultramicroscopically dense owing to their high protein concentration. The 
secretion of these proteins occurs after parasite internalization. Proteins of dense 
granule origin are components of the PV membrane and of the intravacuolar 
membranous network (Mercier et al., 2005).  
 
Fig. 2.1. Morphology of coccidian invasive stages (sporozoites and merozoites). 
A. Apical complex. The image was adapted from Scholtyseck, 1979.  
Fig. 2.1. Morphology of coccidian invasive stages (sporozoites and merozoites). 
A:  Apical complex. The image was adapted from Scholtyseck, 1979.  
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Endogenous invasive stages of E. bovis are the sporozoites, merozoites, macro- 
and microgametocytes. The invasive sporozoite stage of E. bovis is 15.6 μm long 
with 3.3 anterior and 3.7 µm wide. E. bovis sporozoites are characterized by one 
large refractile body at the posterior part of the body and one or two smaller 
refractile bodies situated proximal of the parasites nucleus (Hammond et al, 
1968). In total, the sporozoite stage possesses 24 subpellicular microtubules 
(Robberts and Hammond, 1970) and several amylopectin granules which are 
located in between the nucleus and the posterior refractile body (Speer, 1988).  
 
Merozoites I stage are approximately 13.5 μm long and 1.4 µm wide. As invasive 
stage it shows active flexing and gliding motility movements. E. bovis merozoites 
I possess 22 subpellicular microtubules being elongated from the anterior polar-
ring. Furthermore, merozoites I have two club-shaped rhopthries in the apical 
complex. In contrast to sporozoite micronemes, the merozoite I micronemes are 
rather tortuous and often with unclear borders. The nucleus is located in the 
posterior third of the body (Sheffield and Hammond, 1966) and is surrounded by 
amylopectin granules (Speer, 1988). Other organelles, such as the endoplasmatic 
reticulum, are adjacent to nucleus with its rough cisternae in the anterior and 
posterior region. The Golgi complex is situated close to the anterior part of 
nucleus (Sheffield and Hammond, 1966). Merozoites II are shorter than first 
generation merozoites with 6-7 μm of length (Hammond et al., 1963).  
 
2.1.2 Bovine coccidiosis and E. bovis life cycle 
The prevalence of bovine coccidiosis is generally high and can reach up to 100% 
in young animals (Fox, 1985, Cornelissen et al., 1995, Faber et al., 2002). The 
tenacious sporulated Eimeria-oocysts are found ubiquitously in the environment 
resulting in infections of calves and young cattle, the most susceptible age group. 
Calves at an age of 3 weeks to 6 months are in particular susceptible to clinical 
bovine coccidiosis, which rather reflects lack of immunity than age resistance 
(Gräfner and Graubmann, 1979). Nonetheless, high prevalences have also been 
reported to occur in yearlings (Cornelissen et al., 1995, Faber et al., 2002). Thus, 
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it is most probable that all animals kept under conventional farming conditions 
unavoidably are exposed to Eimeria spp. infections worldwide (Bürger et al., 
1983, Faber et al., 2002, Daugschies and Najdrowski, 2005). Infected animals 
may suffer from severe diarrhoea with sometimes even lethal outcome. However, 
given that the infection pressure is rather low, the animals were not infected by 
the most pathogenic Eimeria spp. or that the animals have previously been 
exposed and developed protective immunity against homologue Eimeria species 
(Hermosilla et al., 1999, 2012, Taubert et al., 2008, Suhwold et al., 2010), 
coccidial infections are not necessarily associated with clinical disease. 
 
Infection-induced, impaired performance, mortality and anticoccidial treatment 
costs frequently result in considerable economic losses (Fitzgerald et al., 1980; 
Fox, 1985, Daugschies and Najdrowski, 2005, Hermosilla et al., 2006). 
Presumably, the economic losses due to subclinical disease even exceed those 
resulting from clinical coccidiosis (Fitzgerald, 1980, Bürger et al., 1983, Faber et 
al., 2002) as the former occurs much more frequently and may though impair 
intestinal physiology, feed conversion and animal growth (Fox, 1985, Gräfner et 
al., 1985, Cornelissen et al., 1995). According to Fitzgerald (1980), the worldwide 
annual costs due to bovine coccidiosis in cattle approximate 731 million US $. 
Matjila and Penzhorn (2002) estimated that the loss in profit within cattle industry 
reaches up to US $400 million/year since animals having survived severe clinical 
coccidiosis always show retarded growth and most probably will never become 
profitable again (Fox, 1985, Daugschies and Najdrowski, 2005). 
 
Apicomplexan cattle Eimeria spp. all share a similar monoxenous life cycle, with 
an endogenous (parasitic) and an exogenous (environment) phase of life. They are 
all strictly host specific (monoxenous) enteropathogens which develop within 
specific host cells at specific sites of the intestinal mucosa. Most detailed studies 
on the biology of bovine coccidiosis have been carried out so far with E. bovis. 
Until now, thirteen different cattle Eimeria species (i. e. E. alabamensis, E. 
aubernensis, E. bovis, E. brasiliensis, E. bukidnonensis, E. canadensis, E. 
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cylindrical, E. ellipsoidalis, E. illinoisensis, E. pellita, E. subspherica, E. 
wyomingensis, E. zuernii) have been reported to occur worldwide. The most 
pathogenic species in cattle coccidiosis are E. bovis and E. zuernii, causing the 
classical ‘stable coccidiosis’ and E. alabamensis as the ethiological agent of 
‘pasture coccidiosis’. Extremely high doses of oocysts (108) are necessary to 
experimentally induce clinical ‘pasture coccidiosis’ with E. alabamensis 
(Hooshmand-Rad et al., 1994), whilst much lower doses of oocysts (104) of 
E. bovis and (105) of E. zuernii result in clinically apparent ‘stable coccidiosis’. 
E. bovis/E. zuernii-infected animals frequently show a severe haemorrhagic 
typhlocolitis (Daugschies et al., 1986, Hermosilla et al., 1999) with weight losses, 
dehaydration and even sudden death. In contrast, E. alabamensis-coccidiosis is 
rather characterized by profuse catharralic enteritis (Hooshmand-Rad et al., 1994). 
 
Under in vitro conditions, free-released sporozoites from oocysts might invade 
various cell types of different hosts. However, further development has been 
exclusively reported to occur within host cells of bovine origin and few gamonts 
and oocysts were only obtained in fetal gastrointestinal cells in vitro (Hermosilla 
et al., 2002). In the natural host, after the oral uptake of sporulated oocysts, free-
released sporozoites of E. bovis must traverse the intestinal mucosa epithelium 
without considerable alterations (Behrendt et al., 2004), in order to infect host 
endothelial cells of the central lymph capillaries of the ileal villi (Hermosilla et al., 
2006, 2012, Taubert et al., 2006a, 2010). Host cell invasion is accompanied by the 
release of parasitic antigens from diverse organelles located in the anterior part of 
the sporozoites (e. g. micronemes, rhoptries, dense granules) which play a 
significant role in host cell recognition, penetration through the host cell plasma 
membrane and the formation of the PV membrane (Heise et al., 1999a, b). Within 
the PV, sporozoites of E. bovis transform into trophozoites and then into first 
generation of meronts. One of the peculiarities of E. bovis is that intracellular 
sporozoites develop into huge macromeronts reaching sizes of up to 207-435 μm 
in vivo (Hammond et al, 1946) being accompanied by efficient modulation of 
infected host cells. Thus, cytoskeletal changes (Hermosilla et al., 2008), apoptosis 
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inhibition (Lang et al., 2009) and modulation of the host cell metabolism (Taubert 
et al., 2010, Lutz et al., 2011, Hermosilla et al., 2012) were reported. During 
macromeront formation, the lobes of spheroidal blastophores are subdivided from 
the meront cytoplasm. The anterior part of the offspring (merozoites I) is formed 
earlier than the posterior part. There is a thick inner membrane underneath to form 
the plasma membrane with the conoid opening in the offspring. This membrane is 
elongated forming a bud of early merozoites I stages containing cellular 
compartments, i. e. rhoptries, nucleus and Golgi apparatus. This membrane 
complex grows further forming the posterior body of the merozoites I. The 
individualized merozoites I are completely formed but still attached by their 
posterior part to the blastophore. When the merozoites I are released in vivo, this 
connection is solved (Hammond et al, 1946, Morrissette and Sibley, 2002). The 
free-released merozoites I then migrate to the caecum and colon in order to infect 
epithelial host cells where they undergo the second merogony resulting in 30-36 
merozoites II (Hammond et al, 1963). Free-released merozoites II then start sexual 
reproduction, the gamogony, and form intracellular macro- and microgamonts in 
caecum/colon epithelial host cells. After syngamy (fertilization of a female 
macrogamont by a male motile microgamete) the zygote is formed which further 
develops into the oocyst stage. After the rupture of infected epithelial host cell, un-
sporulated oocysts are shed via the faeces into the environment and the exogenous 
phase of the life cycle begins. Within this phase, oocysts undergo sporogony 
(asexual replication) resulting in infectious sporulated oocyts containing four 
sporocysts with two sporozoites each. The speed of successful sporogony strongly 
depends on adequate environmental conditions, such as optimal humidity, oxygen 
and temperature ranges.  
 
2.1.3 Modulation of the host cell by E. bovis infections 
During first merogony, E. bovis intracellular development leads to a massive 
alteration of its host cell and the endothelial host cell has to tolerate a ~10-fold 
enlargement and the formation of >120,000 merozoites within its cytoplasm. 
Given that endothelial cells are are highly immunoreactive cells being able to 
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produce a broad range of adhesion molecules, cytokines and proinflammatory 
chemokines upon activation thereby initiating leukocyte trafficking e. g. by 
recruiting polymorphonuclear neutrophils (PMN), NK cells, T lymphocytes and 
monocytes to the site of infection (for reviews see Tedder et al., 1995, Ebnet and 
Vestweber, 1999, Wagner and Roth, 2000) it appears likely that this cell type will 
actively defend intracellular parasitism.  
 
In order to study both, parasite-triggered mechanisms allowing for successful 
replication and host cell derived defense actions, Hermosilla et al. (2002) 
established suitable in vitro cultures allowing for the entire merogony I, i. e., the 
development from the moment of host cell invasion to merozoite I production. An 
exemplary culture is depicted in Fig. 2.2. 
 
Fig. 2.2. E. bovis merogony I in bovine endothelial cells 
 
General profiling analyses heading for an overview of E. bovis-triggered host cell 
modulation throughout merogony I on both, the transcript and protein level 
revealed a multitude of functional categories to be altered in infected cells 
(Taubert et al., 2010, Lutz et al., 2011, Hermosilla et al., 2012) that may support 
Fig. 2.2. E. bovis merogony I in bovine endothelial cells.  
A: 1-5 days p.i.; B: 5-8 days p.i.; C: 8-12 days p.i.; D: 12-18 days p.i.; E: 18-23 days 
p.i.; F: 23 days p.i. onwards. Scale bars: 10 µm. 
A B C 
D E F 
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the parasites needs during intracellular development. However, host cell immune 
reactions were equally induced as molecules related to carbohydrate and lipid host 
metabolism as well as cellular transport and energy production (Taubert et al., 
2010, Lutz et al., 2011, Hermosilla et al., 2012). 
 
Targeted analyses on host cell defense mechanisms showed that endothelial host 
cells indeed react upon E. bovis invasion and intracellular development. Thus, 
several immunoregulatory molecules, such as adhesion molecules and 
chemokines were up-regulated in host cells (Hermosilla et al., 2006, Taubert et 
al., 2006a) and leukocyte adhesion to E. bovis-infected monolayers was enhanced 
relative to non-infected controls (Hermosilla et al., 2006; Taubert et al., 2007). 
Interestingly, comparative analyses revealed these reactions as considerably lower 
in E. bovis-infected host cells when compared to those induced by other coccidian 
parasites (Taubert et al., 2006b) indicating active counter-regulation by E. bovis. 
In agreement, E. bovis infections actively downregulated TNFα-stimulated PMN 
adhesion to infected host cells (Hermosilla et al., 2006).  
 
Massive host cell enlargement needs to be supported by structural elements, such 
as the cytoskeleton. E. bovis infections caused a significant accumulation and re-
organization of several cytoskeletal elements (Hermosilla et al., 2008). As such, 
actin, α-tubulin, acetylated tubulin and spectrin molecules were found altered in 
E. bovis-infected host cells forming compact structures adjacent to the 
macromeront (Hermosilla et al., 2008). Given that cytoskeletal elements do not 
only influence cell shape and mechanical properties but are also considerably 
involved in cellular transport (Ross et al., 2008, Balint et al., 2013), these 
modifications of the host cell cytoskeleton may be of outstanding importance for 
parasite proliferation. 
 
Parasite invasion and the final enlargement of the host cell far beyond the 
physiological size causes considerable stress to the host cell (Frias et al., 2007, 
Fisch et al., 2007) and cell stress, in turn, is well known to trigger apoptosis 
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(Green and Reed, 1998, Green, 2000). The parasite, however, depends on a live 
host cell to complete its development. In consequence and in agreement to other 
related parasites, such as E. necatrix, E. tenella (del Cacho et al., 2004), 
Cryptosporidium parvum (Chen et al., 1999, 2001), Theileria parva (Heussler et 
al., 1999, 2001, Kuenzi et al., 2003), Toxoplasma gondii (Goebel et al., 1998, 
1999, Caamano et al., 2000, Luder and Gross, 2005, Carmen et al., 2006, Keller et 
al., 2006) and Plasmodium spp. (Doolan and Hoffman, 2000, van de Sand, 2005), 
E. bovis was demonstrated to actively block host cell apoptosis by the up-
regulation of anti-apoptotic molecules thereby preventing early host cell death and 
guaranteeing its prolonged intracellular survival (Lang et al., 2009). 
 
2.2 Cholesterol 
Cholesterol is an essential constituent of plasma membranes of most eukaryotic 
cells, where it is distributed non-randomly in structural and kinetic pools 
(Schroeder et al., 1991, Liscum & Underwood, 1995). In contrast, prokaryotic cell 
structures are devoid of cholesterol (Alberts, et al., 2008). The highest abundance 
of cholesterol is found in the plasma membranes although being present in 
differing proportions depending on the cell type (Lange, 1991, Ohvo-Rekila et al., 
2002). Thus, in the liver cell plasma membrane cholesterol contents account for 
17 % of total lipids, for 23 % in the red blood cell plasma membrane and for 22 % 
in myelin, whilst membranes of mitochondria and endoplasmic reticulum contain 
only 3 and 6 % of total lipids, respectively (Alberts, et al., 2008).  
 
Cholesterol is an important regulator of physicochemical membrane properties by 
altering the fluidity and permeability of membanes (reviewed by Ohvo-Rekila et 
al., 2002, Ikonen, 2008). Cholesterol also modulates the functions of membrane 
proteins and participates in several membrane trafficking and transmembrane 
signalling processes (Simons and Toomre, 2000, Parton and del Pozo, 2013). 
Moreover, cholesterol metabolites function as signal transducers and solubilizers 
of other lipids (for review see Ikonen, 2008). 
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2.2.1 Cellular cholesterol sources 
Cellular cholesterol is either de novo synthesized by the mevalonate biosynthesis 
pathway or internalized from extracellular sources via lipoprotein up-take. 
Comparing these pathways quantitatively, a 70: 30 contribution of de novo 
synthesis vs. dietary intake was proposed (Grundy, 1983). 
 
Cholesterol is synthesized in the endoplasmic reticulum de novo via the multistep 
enzymatic mevalonate biosynthesis pathway using acetyl-CoA as substrate 
(Liscum, 2004; for an overview on enzymatic steps see Fig. 2.3.). Within this 
pathway, the rate-limiting step is the conversion of HMG-CoA to mevalonate by 
HMG-CoA reductase activity. Given that mevalonate is also utilized for the 
synthesis of non-sterol isoprenoids, the squalene synthase (+ downstream acting 
molecules) may be considered as the first enzyme that determines the switch 
topwards sterol biosynthesis (Bergstrom et al., 1995).  
 
Excess free cholesterol is toxic for cells and, in consequence, it is either effluxed 
from the cell or detoxified via biochemical cholesterol modification. The 
endoplasmic reticulum harbours enzymes for key cholesterol processing steps. 
Thus, cholesterol hydroxylation to generate oxysterols takes place in the ER 
rendering cholesterol to more hydrophilic. In general, oxysterols, such as 24-, 25- 
or 27-hydroxycholesterol, are present in cells only in minor amounts 
(approximately 1:1000 compared to cholesterol). In addition, cholesterol is 
modified via esterification leading to cholesteryl ester formation. 
Correspondingly, excess cellular free cholesterol activates acyl-coenzyme A: 
sterol acyltransferase (SOAT) (syn. acyl-coenzyme A: cholesterol acyltransferase, 
ACAT) enzymatic activity promoting cholesteryl ester formation. SOAT1 and 
SOAT2 are mainly located in the endoplasmic reticulum as integral membrane 
proteins. Whilst SOAT1 mRNA is ubiquitously expressed in mammalian tissues, 
SOAT2 is mainly active in the liver and small intestine (Chang et al., 2009). 
SOATs mediate the covalent binding of cholesterol and long-chain fatty acyl-CoA 
to form cholesteryl esters. In almost all cell types cholesteryl esters are present at 
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low levels in cytosolic organelles, the lipid droplets (LDs). Cholesteryl esters may 
accumulate in cells and are generally stored in cytosolic LDs (see 2.2.2) which 
can rapidly release free cholesterol upon demand by cholesteryl ester hydrolase 
activities (Buhman et al., 2000, Chang et al., 2006). 
 
Fig. 2.3. Cholesterol synthesis via the mevalonate pathway in mammalian cells. 
 
 
Fig. 2.3. Cholesterol synthesis via the mevalonate pathway in mammalian cells. 
Acetyl-CoA is converted to cholesterol by at least 20 enzymes. Four key intermediates 
(mevalonate, farnesyl pyrophosphate squalene, lanosterol) are highlighted in black. 
Geranylgeranyl pyrophosphate, is a nonsterol isoprenoid derived from farnesyl 
pyrophosphate. Other nonsterol isoprenoids derived from farnesyl pyrophosphate (dolichol, 
heme A, ubiquinone) and from isopentyl pyrophosphate (isopentyl group of tRNAs) are not 
shown. (The figure and the legend are taken from Goldstein et al., 2006) 
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Exogenous acquisition of cholesterol is mediated via lipoprotein internalization. 
The general structure of lipoproteins is depicted in Fig. 2.4. The most important 
cholesterin-transporting molecule in the blood is the low density lipoprotein 
(LDL) particle. The LDL molecule contains 47-51 % of cholesteryl esters and 10-
12 % of non-esterified cholesterol rendering LDL particles as the richest 
cholesterol carrier molecule amongst other lipoprotein subclasses, such as 
chylomicrons, VLDL and HDL (Jonas, 2004). LDL particles have a mass of 
approximately 3,000 kDa and measure ~22 nm in diameter (Brown and Goldstein, 
1986). Cholesterol molecules are located in the hydrophobic core of LDL with 
polar OH-group esterified to long-chain fatty acid. The core contains around 
1,500 cholesterol molecules and is surrounded by a monolayer of lipoprotein 
membrane which is composed of ~800 phospholipid and 500 unesterified 
cholesterol molecules. LDL particles furthermore contain one apoprotein B-100 
molecule in the outer sheet which mediates specific binding to the LDL receptor 
(LDLR) on cell surfaces (Albert et al, 2008).  
 
Fig. 2.4. General structure of a lipoprotein. 
 
 
Fig. 2.4. General structure of a lipoprotein. The core is primarily composed of 
triacylglycerides and cholesterol esters. They are encased by a phospholipid monolayer. 
Apolipoproteins embedded in the phospholipid layer confer structural and functional 
properties to the molecule. (Figure and figure legend are taken from Wasan et al., 2008) 
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Cellular LDL-uptake is performed by LDL receptor (LDLR)-mediated 
endocytosis (Brown and Goldstein, 1975a, b; Brown et al., 1975) involving 
clathrin coated pits of the cell membrane. An overview of the LDLR-mediated 
endocytosis procedure is given in Fig. 2.5. The LDLR is concentrated in certain 
regions of the plasma membrane being specialized for receptor-mediated 
endocytosis. These regions form pits, i. e. plasma membrane invaginations, which 
are lined with clathrin molecules. The invagination rapidly occurs when LDL 
binds to LDLRs and the molecules are endocytosed. The clathrin molecules are 
recycled from endocytosed vesicle by ATPase heat shock cognate 70 (HSC70) 
and auxilin activities resulting in uncoated vesicles which are transported 
intracellularly (McMahon and Boucrot, 2011). The LDL/LDLR complex fuse 
with early sorting-endosomes. The LDL molecules then dissociate from LDLR 
due to acidic pH conditions in the endosome and are hydrolized to cholesterol and 
protein molecules. The LDLR molecules are recycled to the plasma membrane 
through endocytic recycling compartments. Early-endosome contents are 
processed to late endosome via vesicular transport and or endosome 
transformation.  
 
Fig. 2.5. LDL receptor-mediated endocytosis pathway 
 
 
 
 
 
 
Fig. 2.5. LDL receptor-mediated endocytosis pathway. The entire cycle lasts 
approximately ten minutes. a | Nascent LDLrs are synthesized and packaged into 
vesicles in the Golgi complex. b | The vesicles are transported to and fuse with the 
plasma membrane. c | Functional LDLrs on the plasma membrane are clustered within 
clathrin-coated pits. d | LDL particles associate with LDLrs through interactions of the 
ligand-binding domain and ApoB100. e | Endocytosis of the coated pit internalizes the 
LDLr complex. Fusion with lysosomes decreases the pH of the vesicle causing the 
dissociation of LDL from the receptor. f | Intact receptors are transported back to the 
plasma membrane for re-use. g | The LDL particles are degraded into cholesterol and 
amino-acid components. (Figure and figure legend are taken from Wasan et al., 2008) 
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2.2.2 Cytosolic lipid droplets (LDs) 
LDs (syn. lipid bodies) represent spherical, lipid-rich organelles that are found in 
the cytoplasm of most eukaryotic cells. Besides their function as lipid storage 
organelles, they are also reported as dynamic and multifunctionally active 
organelles being involved in several aspects of lipid metabolism, membrane 
trafficking, cell signaling and in inflammation (for reviews see Bozza et al., 2007, 
Farese and Walter, 2009, Beller et al., 2010, Melo et al., 2011). LDs are composed 
of a neutral lipid core (containing mainly triacylglycerol, cholesteryl esters and 
diacylglycerol) being surrounded by a single phospholipid monolayer equipped 
with associated proteins that mediate protein-protein interactions (Bozza et al., 
2007, Melo et al., 2011). Cytosolic LDs are actively formed and increasing 
numbers are induced upon adequate stimuli. Furthermore, the volume/size of LDs 
can be enhanced either by augmentation of local lipid synthesis (Kuerschner et al., 
2008) or by LD fusion (Olofsson et al., 2009). 
 
LD formation is a multienzymatic and complex process involving fatty acid 
activation, synthesis of neutral lipids, remodeling and synthesis of phospholipids 
and integration of accessory proteins in LDs monolayered membrane (Pol et al., 
2014). LDs appear to be produced in the endoplasmic reticulum, and their outer 
monolayer is proposed to originate from one of the endoplasmic reticulum 
bilayered membranes (Fujimoto et al., 2008). LDs are well-known for their 
capacity to store lipids for both purposes, as metabolic energy carriers and as 
membrane percursor molecules. LDs are mobilized upon demand for energy by 
the activity of specific lipases or other metabolic enzymes. LDs are sites of key 
enzymes of cholesterol metabolism and fatty acid synthesis indicating that both 
anabolic and catabolic steps of lipid metabolism occur in LDs (Brasaemle et al, 
2004; Fujimoto et al, 2004). LDs also involved in cellular lipid and protein 
trafficking by direct contact of LD with other cellular membranes facilitating lipid 
transfer (Murphy et al., 2009). The actual composition of lipids and LD-associated 
proteins varies between different cell types and physiological states (Bickel et al., 
2009).  
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Besides acting as feeder organelle and host-derived nutrient supplier, LDs also 
play a role in inflammatory responses since they are described as sites of storage 
and synthesis of cytokines, chemokines and growth factors especially in immune 
cells (Bozza et al., 2007). Furthermore, they were reported to be elicited in 
response to inflammatory stimuli (for review, see Melo et al., 2011). Whithin 
inflammatory cells, LDs contain arachidonyl lipids for eucosanoid synthesis and 
relevant enzymes, such as cyclooxygenase, prostaglandin E2 synthase, 
lyoxygenases and leukotriene C4 synthase (reviewed by Bozza et al., 2007 and 
Melo et al., 2011). Pathogen-induced LD formation was reported for bacterial, 
viral, fungal and parasitic infection suggesting a role of LDs in intracellular 
survival and pathogen replication (d’Avila et al., 2008, van der Meer-Janssen et 
al., 2010).  
 
2.2.3 Intracellular cholesterol transport and regulation of homeostasis 
Cellular cholesterol transport is a highly complex multistep process. Cholesterol 
distribution within the cell, its processing and trafficking is summarized and 
described in Fig. 2.6., according to Simons and Ikonen (2000).  
 
Overall, cholesterol is permanently transported within the cell, either by vesicular, 
membrane-associated mechanisms or by non-vesicular routes. Non-vesicular 
transporting either uses direct membrane contacts or cytosolic lipid transfer 
proteins involving several organelle-specific molecules (reviewed in Ikonen, 
2008). However, so far, only some molecules being involved in cholesterol 
transporting are known, such as the Nieman Pick C (NPC1 and NPC2) molecules. 
Given that excess cellular cholesterol contens are toxic for the cell, cholesterol 
may either be biochemically modified and stored, i. e. in LDs (see 2.2.2), or it is 
effluxed. In the latter case it may be taken up by HDL particles, acting as major 
cholesterol acceptors and key molecules in the reverse cholesterol transport to 
liver cells (Tall, 1998, Ohashi et al., 2005, Yokoyama, 2005). 
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Fig. 2.6. Schematic presentation of cellular cholesterol distribution, processing, and trafficking circuits 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6. Schematic presentation of cellular cholesterol distribution, processing, and 
trafficking circuits. Cholesterol is synthesized in the endoplasmic reticulum (ER). Part of 
it is transported via the Golgi complex (1) and the trans-Golgi network (TGN) to the 
plasma membrane, where it is distributed either to raft (2, red) or nonraft (3, blue) 
microdomains. The majority of cholesterol, however, takes a Golgi-bypass route (4) to the 
cell surface. Cholesterol can be internalized from the plasma membrane by endocytosis 
via clathrin-coated vesicles (5) or other pathways, including caveolae (6). Endocytosed 
rafts are found in sorting and recycling endosomes. From the endocytic circuits, 
cholesterol may be recycled to the surface (7) or transported back to the ER (8). Also, 
retrograde routes from the Golgi complex (9) recycle cholesterol to the ER. There may 
also be a route involving transport via caveolae to the ER. Cholesterol is endocytosed in 
LDL via clathrin-coated pits (10) and transported to sorting endosomes (SE; 11). From 
there, it can be recycled to the surface either via a rapid route (12) or through slower 
circuits involving recycling endosomes (RE; 13, 14). Cholesterol is also transported to late 
endocytic structures [15, late endosomes (LE) and lysosomes (LY)] that can fuse with 
each other (16). Sorting, recycling, and late endosomes communicate with the exocytic 
pathway at the level of the TGN (17 through 19), thus exchanging cholesterol between the 
endocytic and exocytic routes. Cholesterol esters in LDL are hydrolyzed prior to release 
from the endocytic organelles, but cholesterol returning to the ER may become re-
esterified. Cholesterol esters (CE) are deposited in cytosolic lipid droplets (20) from 
where cholesterol can be mobilized upon ester hydrolysis (21). Cholesterol and 
cholesterol esters can also be exchanged directly between circulating lipoproteins and the 
plasma membrane. Caveolae have been implicated in the uptake of cholesterol esters from 
HDL (22), and free cholesterol can be taken up from LDL (23).Cholesterol can be 
released from cells, both from nonraft (24) and raft domains (25), the latter potentially 
involving caveolae (26). In some cases, this may involve endocytic uptake and resecretion 
of lipoproteins. (Figure and figure legend are taken from Simons and Ikonen, 2000) 
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Cholesterol homeostasis is tightly regulated to prevent toxic effects but to meet 
the needs of cellular cholesterol delivery (Brown and Goldstein, 1986, Goldstein 
and Brown, 1990). The cellular cholesterol concentration itself plays a pivotal role 
in cholesterol homeostasis. Whilst too high cholesterol concentrations block the 
mevalonate biosynthesis pathway and LDLR expression and enhance cholesterol 
esterification and storage (Goldstein and Brown, 1990, Brown and Goldstein, 
1986, Brown et al., 1975b, Fig. 2.7.), low cholesterol levels induce the gene 
transcription of HMGCR and other relevant molecules via a highly complex 
activation process of  special transcription factors, the so-called Sterol Regulatory 
Element Binding Proteins, SREBPs (Edwards et al., 2000, Shimano, 2001, Horton 
et al., 2002, Eberle et al., 2004). Besides being regulated via cholesterol levels, 
cholesterol homeostasis is also controlled by 25-hydroxycholesterol (25-OHC). 
Oxysterols, such as 24-, 25- and 27-OHC are produced in low concentrations in 
various tissues (Russell, 2000). In general, oxysterols are synthesized when 
cholesterol levels are high. High 25-OHC levels lead to the blockage of SREBPs 
thereby lowering cholesterol de novo synthesis (Radhakrishnan et al., 2007).  
 
 
Fig. 2.7. Regulation of cholesterol homeostasis 
Fig. 2.7. Regulation of cholesterol homeostasis [according to Brown and Goldstein (1990)]. 
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2.3 Modulation of host cell cholesterol metabolism by protozoan parasites 
Coccidian parasites in general and some apicomplexan parasites in particular have 
been described as auxotrophic in their capability to synthesize cholesterol by 
themselves (Furlong, 1989, Coppens et al., 2000, Bano et al., 2007, Labaied et al., 
2011, Ehrenman et al., 2013, Bansal et al., 2005, Coppens, 2013). Thus, 
cholesterol auxothrophy was reported for the coccidian parasites T. gondii and 
C. parvum (Coppens et al., 2000, Ehrenman et al., 2013); furthermore 
apicomplexan Plasmodium subspecies are considered as defective in cholesterol 
synthesis (Labaied et al., 2011). Given that the developing parasite stages of these 
obligate intracellular replicating protozoans indeed do contain cholesterol, they 
must scavenge this molecule from their host cell by exploiting different cellular 
pathways. Interestingly, different cholesterol synthesis-deficient parasites appear 
to follow different strategies of cholesterol scavenging characterizing the 
modulation of host cell cholesterol metabolism as a parasite-specific process. 
 
Most data on the presence of cholesterol in coccidian stages or on coccidia-
triggered host cell cholesterol exploitation concern T. gondii infections. In 
T. gondii tachyzoite stages, cholesterol was reported to be concentrated in the 
rhoptries and pellicules (Foussard et al., 1991a, b). Furthermore, free cholesterol 
was detected in the apical complex, the wide posterior-end of rhoptry membranes, 
inner membrane complex, the apicoplast and in the remaining mother-cell residue 
of the nascent tachyzoites (Coppens et al., 2000, Coppens and Joiner, 2003). 
Overall, lipid profiling experiments revealed cholesterol as the most abundant 
molecule in isolated rhoptries when compared to other lipid classes. Apart from 
the free form, cholesterol was also present in the esterified form in T. gondii 
(Besteiro et al., 2008, Charron and Sibley, 2002). It is worth noting that T. gondii 
itself has the capacity to express enzymes promoting cholesterol esterification 
(Nishikawa et al., 2005, Lige et al., 2013). 
 
Coppens et al. (2000) experimentally proved T. gondii as auxothrophic for 
cholesterol synthesis since tachyzoites revealed unable to convert radioactive 
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substrates of the mevalonate biosynthesis pathway to form cholesterol. They 
additionally showed that parasite growth is enhanced by addition of free or LDL-
incorporated cholesterol to the cell culture medium. However, the mode of 
cholesterol acquisition by T. gondii appears to be host cell-dependent, since 
different strategies were described in different host cell types. Thus, in CHO cells 
T. gondii exclusively utilized cholesterol derived from internalized LDL particles 
and did not profit from de novo synthesized cholesterol (Coppens et al., 2000). In 
contrast, transcriptomic data on T. gondii-infected fibroblasts indicated an up-
regulation of molecules involved in the mevalonate biosynthesis pathway (Blader 
et al., 2001). In addition, cellular de novo synthesis but not LDL-mediated up-take 
proved essential for parasite growth in macrophages as indicated by statin 
treatments and the use of LDLR knock-out cells (Nishikawa et al., 2011). 
However, up to date, all T. gondii-related reports indicate that only one alternative 
pathway is exploited by the parasite at a time.  
 
Overall, host cell cholesterol plays a crucial role already very early in T. gondii 
infection, i. e., when the parasite initially invades the host cell. Thus, host 
cholesterol governs parasite entry by modulating secretory-organelles discharge. 
Furthermore, it influences parasite internalization and contributes to the formation 
of the PV membrane (Coppens and Joiner, 2003, Cruz et al., 2013).  
 
In T. gondii-infected host cells, exogenously supplied cholesterol is inserted in the 
parasite plasma membrane and cholesterol-rich organelles and is furthermore 
esterified for  LD deposition (Coppens et al., 2000, Charron and Sibley, 2002, 
Sehgal et al., 2005, Nishikawa et al., 2005). Accordingly, host and parasite 
esterification activity was shown to be essential for parasite intracellular growth 
(Sonda et al., 2001). Correspondingly, T. gondii infection leads to enhanced 
cytoplasmic LD formation in skeletal muscle cell cultures indicating these 
organelles as a source of lipids for parasite survival (Gomes et al., 2014). 
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Host cellular LDL acquisition involves the LDL receptor (LDLR)-based 
endocytic pathway in T. gondii-infected host cells (Coppens et al., 2000). So far, 
the transport of LDL-derived cholesterol to the intracellular parasite residing 
within its PV is not fully understood. It is evidenced that compounds interfering 
with endolysosomal function disrupt cholesterol delivery towards the parasite 
(Coppens et al., 2000). Thus, the parasite appears to use a vesicle-based transport 
of host endolysosomal organelles being supported by transporter-like proteins 
present in the PV and parasite plasma membrane (Sehgal et al., 2005). 
Furthermore, T. gondii reorganizes the microtubule system around the PV and 
uses this system to sequester lysosomes from the host cell to the PV space 
(Coppens et al., 2006). Interestingly, microtubules form deep invatinations of the 
PV membrane leading to double membrane structures, termed “Host Organelle 
Sequestring Tubulo Structures”, which are thought to be involved in endosome-
mediated cholesterol delivery to the parasite (Laliberte and Carruthers, 2008). 
Electron microscopic analyses evidenced that gold-labelled LDL is indeed 
transported through these microtubule protrusions and found inside the PV as 
intact vesicular entities (Coppens et al., 2006).  
 
The delivery of LDL-derived cholesterol in addition requires host-P-glycoprotein-
based pumps, since delivery of cholesterol towards PV is inhibited in respective 
knock-out fibroblasts (Bottova et al., 2009). In T. gondii-infected skeletal muscle 
cells, increased numbers of LD are formed and recruited to the PV. Since direct 
contacts of LDs with the PV and parasite membrane were observed, the authors 
hypothesize a discharge of their contents as lipid delivery sytem (Gomes et al., 
2014). However, given that LD enhancement was not observed in fibroblasts, 
which were also present in skeletal muscle cell cultures, these features appear to 
be cell type-specific. 
 
The apicomplexan parasites Plasmodium yoelii and P. berghei also contain host 
cell-delivered cholesterol in the PV of their intrahepatic stages (Bano et al., 2007, 
Labaied et al., 2011). Furthermore, Plasmodium merozoites were shown to 
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integrate lipids derived from the erythrocyte membrane into the nascent PV (Ward 
et al., 1993). Plasmodium blood stages, which are residing within erythrocytes, 
mainly acquire cholesterol from circulating HDL particles and deliver cholesterol 
via a tubulovesicular network (Grellier et al., 1990). In hepatic stages, 
Plasmodium spp. appear to salvage cholesterol from both host cellular pathways, 
i. e. LDL-mediated up-take and de novo synthesis (Grellier et al., 1994, Labaied et 
al., 2011). However, host cellular cholesterol acquisition does not appear to be 
essential for optimal parasite proliferation since neither the reduced expression of 
LDLR nor the blockage of the mevalonate biosynthesis pathway interfered 
significantly with parasite development (Labaied et al., 2011). The authors 
interpret these results by a moderate parasite need of sterols and by an adaptive 
reaction to cholesterol-restricted conditions in terms of alternative source 
utilization. Although abundant LD formation was also reported for P. berghei- or 
P. falciparum-infected host cells (Rodriguez-Acosta et al., 1998, Vielemeyer et 
al., 2004), no cholesteryl ester formation was detected in Plasmodium-infected 
cells implying a certain lack of lipid storage activity (Nawabi et al., 2003, 
Palacpac et al., 2004, Vielemeyer et al., 2004, Coppens and Vielemeyer, 2005) 
which may argue for a continuous cholesterol acquisition from the host cell as 
hypothesized by Coppens (2013). 
 
By far less data are available on other apicomplexan parasites. C. parvum mainly 
acquires cholesterol from LDL particles and from micellar lipoproteins being 
internalized by enterocytes (Ehrenman, 2013). To a minor degree, C. parvum also 
scavenges de novo-synthesized cholesterol since treatments of parasite cultures 
with lovastatin or zaragozic acid had moderate effects on parasite proliferation 
(Ehrenmann et al., 2013). Furthermore, the NPC1L-mediated vesicular transport 
appeared to play a pivotal role for cholesterol acquisition within infected 
enterocytes (Ehrenmann et al., 2013). The involvement of membrane cholesterol 
in parasite entry and internalization was described for several other protozoa, such 
as Babesia bovis (Okubo et al., 2007), Trypanosoma cruzi (Fernandes et al., 2007) 
or Leishmania spp. (Pucadyil et al., 2004, Tewary et al., 2006). Furthermore, the 
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modulation of host cell gene transcripts being associated with cholesterol 
metabolism were also shown for L. amazonensis (Lecoeur et al., 2013) and 
T. cruzi (Nagajyothi et al., 2011, Chiribao et al., 2014). In the latter case, 
enhanced LD formation was observed in vitro in infected macrophages suggesting 
infection-induced lipid storage activities (Melo et al., 2003, 2006). Furthermore, 
accumulation of cholesterol and LDL was measured in in vitro cultures and in 
tissues of T. cruzi-infected mice (Johndrow et al., 2014) confirming an important 
role of lipids in this parasite infection.  
To date, data on cholesterol and its delivery in Eimeria-infected host cells are 
almost absent. The only report is given by Taubert et al. (2010) indicating that the 
gene transcription of several molecules being involved in the de novo mevalonate 
biosynthesis pathway and in the LDL-promoted cholesterol cellular up-take are 
up-regulated in E. bovis-infected endothelial host cells in times of macromeront 
formation.
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3 MATERIALS AND METHODS 
 
 
3.1 Cell culture 
3.1.1 Primary endothelial cell isolation and cultivation 
Materials 
1. Puck’s buffer: 8 g/l NaCl, 0.4 g/l KCl, 0.012 g/l CaCl2, 0.154 g/l MgSO47H2O, 
0.39 g/l NaH2PO4, 0.15 g/l KH2PO4, 1.1 g/l glucose (all Roth, Karlsruhe) 
2. Collagenase solution: 0.025 g collagenase type II (Worthington Biochemical 
Corp., NJ, USA, LS004174) in 100 ml Puck’s buffer, sterile filtered using a 0.2 
µm syringe filter (Millipore) 
3. Endothelial Cell Growth Medium (ECGM) containing supplement (complete 
ECGM, PromoCell, Heidelberg, C-22010) 
4. Fetal Calf Serum [(FCS), Biochrom, Berlin, S 0415)] 
5. Hank´s Balanced Salt Solution (HBSS): 1X HBSS (Gibco, 24020-117) with 6 
g HEPES/l, 1 % penicillin-streptomycin (Pen-Strep, PAA Laboratories, 
Coelbe), pH 7.4 ± 0.3 
6. Medium 199 (Sigma-Aldrich, Steinheim, M0393) 
7. Modified ECGM: 150 ml complete ECGM supplemented with 350 ml medium 
199 containing 1 % Pen-Strep and 2 % FCS 
8. RPMI 1640 medium (Sigma-Aldrich, R0883) 
 
Method  
Endothelial cells originated from bovine umbilical cords from calves born by 
sectio caesarea were supplied by the Clinic of Large and Small Animals, Justus 
Liebig University Giessen, and the Clinic for Cattle, University of Veterinary 
Medicine Hannover, Germany. Umbilical cords were kept and transported in 
HBSS buffer at 4ºC temperature and isolated according to Jaffe et al. (1973). 
Briefly, one side of the umbilical cord vein was closed with an artery clamp. 
Then, collagenase solution was infused into the vein lumen, the vein was closed 
and incubated at 37ºC in 5 % CO2 atmosphere for 20 min. Thereafter, the 
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umbilical vein was gently massaged, unclamped and RPMI 1640 medium was 
infused to wash the endothelial cells into a 50-ml plastic tube. Collagenase was 
inactivated by the addition of 1 ml FCS per 25 ml solution. The solution was 
centrifuged (600xg, 10 min), and the pellet was resuspended in complete ECGM. 
The cells were seeded in 75 cm2 cell culture flasks and fed every 2-3 days until 
confluency. BUVEC were cultivated using modified ECGM after the first 
passage. First to fifth BUVEC passages were used for E. bovis infection 
experiments in vitro. 
 
3.1.2 Endothelial cell subcultivation and cryopreservation 
Materials 
1. Trypsin buffer: 137 mM NaCl, 5 mM KCl, 7 mM Na2HPO42H2O, 5.5 mM 
Glucose, 0.8 mM Tris-Base (all Roth), 2.5 g trypsin (Serva, Duisburg, 
37294.02) 
2. Versen buffer: 137 mM NaCl, 2 mM KCl, 8.1 mM Na2HPO42H2O, 1.4 mM 
KH2PO4, 5.3 mM EDTA (all Roth), sterile filtered (0.2 µm syringe filter)  
3. Trypsin-Versen buffer: 1 part trypsin buffer + 4 parts versen buffer 
 
Method 
10 ml Trypsin-Versen buffer were added to each 75 cm2 tissue culture flask 
containing confluent BUVEC layers and incubated for 10 min at 37ºC. Flasks 
were shaken to facilitate cell detachment. Then 10 ml modified ECGM were 
added and the solution was collected in a 50 ml tube and centrifuged (600xg, 10 
min). The pellet was resuspended in ECGM medium and splitted into three new 
flasks. For cryopreservation, the pellet was resuspended in medium containing 10 
% DMSO. Cells were then incubated for 30 min at 4ºC, and stored at -80ºC. For 
longer storage, cells were transferred to liquid nitrogen (-196ºC). Thawing of 
BUVEC was performed by transferring the frozen cells directly into a 37ºC-
waterbath. After defrosting, modified ECGM was added immediately and the 
samples were washed (600xg, 10 min) to remove DMSO. The pelleted cells were 
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resuspended in modified ECGM and cultivated in three flasks for further 
cultivation. 
 
3.2 Parasite preparations 
3.2.1 Experimental animals 
Male Holstein Frisian calves were purchased from a local farmer at the age of 2 
weeks, treated with Baycox® (Bayer) and Halocur® (Intervet) in the second week 
after birth, assessed for parasitic infections and when deemed parasite free, 
maintained under parasite-free conditions in autoclaved stainless stell cages 
(Woetho) until experimental E. bovis infection. They were controlled for parasitic 
infections coprologically every 3 days. They were fed with milk substitute (Hemo 
Mischfutterwerke) and commercial concentrates (Raiffeisen). Drinking water and 
sterilized hay were given ad libitum.  
 
3.2.2 Animal infections with E. bovis 
At an age of 8-10 weeks calves were infected orally with sporulated E. bovis 
oocysts. Therefore, sporulated oocysts were washed three times with distilled 
water and centrifuged (400xg,10 min). The supernatant was discarded and 
pelleted oocysts were resuspended in sterile distilled water. Calves were infected 
orally with 5 x 104 oocysts and monitored during infection. The faeces were 
analyzed coproscopically for oocysts applying MacMaster technique three times a 
week. Briefly, 4 g faeces were mixed with sugar solution (specific density 1.27). 
The solution was then mixed thoroughly and filtered. Then, both sides of a 
McMaster counting chamber were filled and allowed to stand for 5 min. The 
samples were analysed microscopically applying a 10 x 10 magnification. The 
number of oocysts per gram faeces (OPG) was calculated by summing-up the 
oocyst counts of the two chambers and multiplying the total with the factor 50. 
The faeces were collected for oocyst isolation when OPG values exceed >1000. 
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3.2.3 Oocyst isolation from the faeces  
Materials 
1. Sugar solution prepared at the spesific density of 1.3  
2. 4 % (w/v) potassium dichromate (Roth) solution  
Method 
Faeces were meshed, mixed in tap water and filtered gradually using 300, 150 and 
80 µm pore-sized filters. Filtered faeces were sedimented in tap water for 2 h. The 
supernatants were discarded and the pellets were mixed with sugar solution (1.3 
specific density). Oocysts/sugar-solutions were adjusted to 1.15 final specific 
density, placed in plastic backets and covered with glass plates. Surfaces should 
be covered without any bubbles such that floting oocysts could directly attach to 
the glass. The glass plate was washed with tap water every two hours and 
respective suspensions were controlled microscopically for oocyst numbers. 
Solutions containing less than 5 oocysts per vision field were discarded. The 
oocysts were centrifuged (400xg, 10 min) and mixed 1:1 with 4 % (w/v) 
potassium dichromate. Solutions were stirred daily to infuse air and to improve 
the sporulation process. The oocysts were monitored microscopically for 
sporulation for up to 3 weeks. After sporulation, the oocysts were centrifuged 
(400xg, 10 min), resuspended and kept in potassium dichromate (2 % final 
concentration) at 4ºC until further use. 
 
3.2.4 Oocyst excystation 
Materials 
1. Excystation medium: 0.4 % (w/v) trypsin (Serva), 8 % bovine bile obtained 
from the local slaughter house (Giessen, Germany) in HBSS medium 
(Gibco), sterile filtered using a 0.2 µm syringe filter (Milipore).  
2. Incubation medium: 2 mM L-cystein (Serva, 17880.01), 20 mM natrium 
hydrogencarbonat (Roth). 
3. Percoll gradient:  
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Percoll stock solution: 9 parts Percoll (GE Healthcare, UK, 17-0891-01) and 
1 part 1.5 M NaCl.  
a. 50 % Percoll solution: 5 parts Percoll stock solution and 5 parts 0.15 M 
NaCl. The gradient was prepared by centrifugation (15,000 rpm, 20 min). 
b. 60 % Percoll solution: 6 parts Percoll stock solution and 4 parts 0.15 M 
NaCl. The gradient was prepared by centrifugation (15,000 rpm, 20 min). 
Method 
The oocysts were pelleted (400xg, 10 min), mixed with 4 % natrium hypochlorite 
solution and stirred on ice for 20 min followed by centrifugation (200xg, 5 min). 
The supernatants were collected and diluted 1:1 in distilled water. The suspension 
was centrifuged (400xg, 10 min) and pelleted oocysts were resuspended in a small 
amount of distilled water. This oocyst suspension was carefully layered on a 60 % 
percoll gradient followed by centrifugation (400xg, 20 min). Oocysts in specific 
layers of the resulting gradient were carefully aspirated, microscopically checked 
and layered onto a 50 % percoll gradient followed by centrifugation (400xg, 20 
min). The oocysts present in the gradient layer were collected and resuspended in 
a 75 cm2 flask containing 50 ml excystation medium. Then, CO2 was infused into 
the solution for 20 s and the flasks were incubated overnight at 37ºC in 100% CO2 
atmosphere. Then the oocysts were sedimented (400xg, 10 min), incubated in 
sterile excystation medium for 2-3 h and controlled microscopically for sporozoite 
release. When ≥ 90 % of the sporozoites were excysted, the specimens were 
washed thrice in sterile PBS (400xg, 15 min) and once in modified ECGM. 
Finally, the sporozoites were counted a Neubauer chamber.  
 
3.2.5 E. bovis in vitro infection 
Infection experiments were performed by utilizing at least three different BUVEC 
isolates to account for biological variation between individuals. As primary cells 
exhibit a limited life span, BUVEC passaged less than 10 times were used in all 
experiments. Infections were performed by adding freshly excysted sporozoites to 
80-90 % confluent BUVEC monolayers. The infected cells were kept overnight at 
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37ºC, 5 % CO2. Extracellular sporozoites were removed 24 h p. i. by medium 
change. Initial infection rates were calculated by microscopic counting. Therefore, 
photos were taken randomly at 10 power vision fileds of the infected cell layer 
using a phase contrast microscope (IX81, Olympus). Infection rates waere 
calculated by the following formula: 
 
 
 
 
For cholesterol staining and pulse-labelling BUVEC were grown on coverslips 
placed in 12-well cell culture plates and infected with 2x104 E. bovis sporozoites. 
For cholesterol quantification, BUVEC in 25 cm2 flasks were infected with 5 x 
105 sporozoites. For medium enrichment and inhibition assays, BUVEC grown in 
24-well plates were infected with 2 x 104 sporozoites. For cholesterol depletion, 
BUVEC grown in 6-well plates were infected with 104 sporozoites. For qPCR 
analysis, BUVEC cultivated in 25 cm2 flasks were infected with 5 x 105-106 
sporozoites. For immunoblotting, BUVEC in 175 cm2 flasks were infected with 6 
x 106 sporozoites. 
 
3.3 Cholesterol-related assays 
3.3.1 Cholesterol staining 
Materials 
1. Filipin (Sigma-Aldrich, F9765), working solution 0.05 mg/ml in PBS 
containing 10 % FCS 
2. 2 % paraformaldehyde (Sigma-Aldrich, P6148) 
3. 1 % glycine (Roth) in 1X PBS 
4. Prolong antifading mounting medium without DAPI (Life Technologies, 
P7481) 
5. 1X PBS containing 10 % FCS  
6. PBS: 171 mM NaCl, 3.4 mM KCl, 10 mM Na2HPO4, 1.9 mM KH2PO4 (all 
Roth), pH 7.4 
   number of infected cells 
          total number of cells 
X 100 (%) Infection rate =  
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Method 
In order to visualize free cholesterol in infected host cells and in parasite invasive 
stages, polyene antibiotic filipin staining was performed (Coppens et al., 2000, 
Gimpl and Gehrig-Burger, 2007). Therefore, infected BUVEC (1, 8, 14 and 17 
days p. i.) grown in coverslips were washed with PBS and invasive stages 
(sporozoites and merozoites I) were dropped onto poly-L-lysine coated coverslips. 
Specimens were fixed in 4 % paraformaldehyde (10 min), and washed three times 
in PBS and were incubated in 1 % glycine PBS (10 min) to quench non-specific 
signals followed by three washing in PBS. The samples were stained by filipin (2 
h, in the dark, at RT) and washed in PBS. Coverslips were then mounted in 
antifading mounting medium and analyzed using a fluorescence microscope (DMI 
4000B, Leica, Heidelberg, Germany) applying the UV filter set (340-380 nm 
excitation, 430 nm pass filter).  
 
3.3.2 Cholesterol quantification  
Materials 
1. Amplex-red® cholesterol assay kit (Life Technologies, A12216) 
2. Catalase (Sigma-Aldrich, C1345) 
3. Cholesterol standard (Sigma-Aldrich, C8667) 
4. Hexane isopropanol (3:2, v:v, all Roth) 
5. Isopropanol Nonidet P-40 [(NP40), 9:1, v:v, all Roth] 
 
3.3.2.1 Total lipid extraction  
Lipid extraction from E. bovis-infected (4, 8 and 17 days p. i) and control 
BUVEC were performed by extraction in hexane:isopropanol according to Hara 
and Radin (1978). The cells were washed twice in ice-cold PBS to remove any 
traces of medium. Then, the cells were trypsinized and total cell numbers were 
counted using a Neubauer chamber. Afterwards, cell suspensions were washed in 
PBS and centrifuged (400xg, 10 min). The supernatant was discarded and 
hexane:isopropanol (3:2, v:v) was added to the cells. Homogenization of the cells 
was performed by utilizing stainless steel beads (Sigma-Aldrich) for 10 min in a 
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homogenizer. After homogenization, the solution was centrifuged (8,000xg, 1 
min) and the supernatant was collected. The extraction was repeated once for each 
sample. The supernatants were then combined and dried manually under gentle 
liquid nitrogen stream. 
3.3.2.2 Total cholesterol quantification  
Total lipid extracts were reconstituted in 500 µl solvent isopropanol: NP40 (9:1) 
(Robinet et al., 2010) followed by sonication in a waterbath (RT, 30 min). Using 
96-well black clear-bottom plates (Greiner Bio-One), 5 µl of each sample were 
treated with catalase [(5 µl of 0.5 mg/ml) in 40 µl of 1x reaction buffer (37ºC, 15 
min)] before the enzyme cocktail of the Amplex-red® kit was added. Cholesterol 
standard (applying a titration of 10, 5, 2.5, 1.25, 0.625, 0.325 and 0 µM) and 
blanks (solvent only) were included in every experiment. Fifty microliters of 
enzyme mixture (0.1 M potassium phosphate buffer, pH 7.4; 0.25 M NaCl, 5 mM 
cholic acid, 0.1 % Triton X-100, 0.3 U/ml cholesterol oxidase, cholesterol 
esterase, 1.3 U/ml HRP, and 0.4 mM ADHP) were added and incubated (37ºC, 15 
min). Resorufin formation was measured by fluorescence intensities (excitation 
wavelength of 530 nm, emission wavelength of 580 nm) in the Varioskan™ Flash 
Multimode Reader (Thermo scientific). Total cholesterol of the samples was 
extrapolated to the values of the cholesterol standard. The total cholesterol content 
of each sample was normalized to its total cell number counts.  
 
3.3.3 Sterols enrichment 
Materials 
1. Cholesterol (Sigma-Aldrich, C8667) 
2. Desmosterol (Sigma-Aldrich, D6513) 
3. Ethanol (Roth) 
 
Method 
To estimate effects of sterol enrichment on E. bovis first meront development, 
cholesterol and desmosterol, a cholesterol intermediate precursor, were 
supplemented in excess to infected BUVEC. Both sterols were solubilized in 
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ethanol (Xu et al., 2005) and supplied for 30 days of culture. Therefore, infected 
monolayers were washed. Cholesterol and desmosterol were added in MECGM at 
5 µM final concentration. All experiments were performed using 5 different 
BUVEC isolates. BUVEC supernatants were collected at 20, 23, 26 and 29 days 
p. i. At the end of the culture period (30 days) merozoites I were collected 
together with the trypsinized cells. Cell supernatants were centrifuged (400xg, 15 
min) and pelleted merozoites I were processed for E. bovis microneme protein 4 
(Ebmic4)-specific qPCR (see 3.7.2) for quantification. In addition, macromeront 
growth in treated and non-treated infected BUVEC were also monitored. The size 
of meronts was estimated microscopically using an inverted IX81 microscope 
(Olympus) equipped with a software for size measurements (cellSens 1.7, 
Olympus). 
 
3.3.4 Cholesterol pulse-labelling 
Materials 
1. Endothelial cell basal medium without supplement (Promocell, C-22110) 
2. Fluorescent cholesterols: dansyl and rhodamine cholesterol/cholestanol (kindly 
supplied by Prof. Dr. Gerald Gimpl, University of Mainz, Germany) 
3. Medium 199  
4. Methyl-β-cyclodextrin (MBCD, Sigma-Aldrich, C4555) 
5. Prolong antifading mounting medium without DAPI (Life Technologies, 
P7481) 
 
Method 
To visualize sterol incorporation into E. bovis macromeronts, dansyl cholesterol 
(Wiegand et al., 2003), was delivered to the cell culture via MBCD complexes, 
consisting of mixture of cholesterol and MBCD molar ratio 1:10 (Christian et al., 
1997). At 17 days p. i, dansyl cholesterol (3.8 µM final concentration) was added 
to the culture (1 h, 37ºC, 5 % CO2) and washed-off twice with PBS. Coverslips 
were mounted in antifading mounting medium and the samples were analyzed 
applying a DAPI filter setting in a fluorescence microscope (Olympus IX81). To 
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analyze the ability E. bovis sporozoites ability to incorporate cholesterol, 
sporozoites were pulse-labelled with dansyl cholesterol. The method was adapted 
from T. gondii tachyzoite pulse-labelling described by Sehgal et al. (2005). 
Briefly, freshly excysted sporozoites were incubated in the basal medium 
containing dansyl cholesterol-MBCD-complexes as described above (1 h, 37ºC, 5 
% CO2), washed twice with PBS and pelleted by centrifugation (600xg, 15 min) 
to remove free dansyl-cholesterol-complexes. The sporozoites were resuspended 
in PBS and dropped onto poly-L-lysin coated glass coverslips. The samples were 
mounted in antifading mounting medium and analyzed applying a DAPI filter 
setting in a fluorescence microscope. Additionally, endothelial cells were pulse-
labelled with rhodamine cholesterol-MBCD complexes (1:10, 1 h, 37ºC), washed 
with basal medium and infected with sporozoites. Infected BUVEC were 
incubated (1 h, 37ºC, 5 % CO2) and analyzed applying a TRITC setting filter in a 
fluorescence microscope (Olympus IX81). 
 
3.3.5 Cholesterol depletion prior to infection 
Materials 
1. Methyl-β-cyclodextrin (MBCD) 
2. Modified endothelial cell growth medium (PromoCell C22010 and Sigma-
Aldrich M0393) 
 
Method 
To assess the role of cholesterol in the early phase of E. bovis infection, BUVEC 
and sporozoites both were depleted of cholesterol according to Christian et al., 
(1997). Infection with non-depleted sporozoites and BUVEC infection therewith 
served as negative controls. For host cell depletion, BUVEC were incubated in 10 
mM MBCD (30 min), infected with 105 freshly excysted sporozoites and washed 
in plain MECGM. For sporozoites depletion sporozoites were incubated with 10 
mM MBCD (30 min), washed in plain MECGM and used for infection. All 
treatments were performed in 6-well plates by using 5 different BUVEC isolates 
in 2 independent experiments. The medium was removed from treated BUVEC 
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layers 24 h after treatments to remove any remaining free sporozoites. The 
infection rates (see 3.2.5) were estimated in 10 randomly chosen power vision 
fields.  
 
3.4 Lipid droplet-related assays 
3.4.1 Lipid droplet staining 
3.4.1.1 Nile red staining 
Materials 
1. 4 % paraformaldehyde  
2. Nile red in DMSO (Cayman Chemical, USA, CAYM600055), working 
solution diluted 1:1000 according to manufacturer’s intructions 
 
Method 
Nile red is a LD- and neutral lipid-specific dye (Brown et al., 1988, Greenspan et 
al., 1985). Free parasite stages and infected/non-infected BUVEC were washed in 
PBS and fixed in 4 % paraformaldehyde (RT, 10 min). Thereafter, cells were 
washed twice in PBS and stained in Nile Red (15 min, RT, in the dark). After 
staining, samples were washed thrice in PBS and mounted in PBS prior to 
fluorescence microscopy (FITC filter, Olympus IX81). Images were processed 
using the cellSens 1.7. 
 
3.4.1.2 Bodipy 493/503 staining  
Materials 
1. 4 % paraformaldehyde  
2. Bodipy 493/503 (Life Technologies, D3922), working solution 1 µg/ml 
3. Prolong antifading mounting medium supplemented with DAPI (Life 
Technologies, P36941 
 
Method 
Bodipy 493/503 is a sensitive LD-specific dye (Gocze and Freeman, 1994). After 
fixation in 4 % paraformaldehyde, the cells were stained with bodipy 493/503 (10 
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min, RT, in the dark), washed three times in PBS and mounted in PBS prior to 
microscopy by applying FITC filter. Images were processed using the cellSens 1.7 
software. For confocal microscopic analyses, the cells were processed as follows: 
After bodipy 493/503 staining, samples were washed thrice in PBS and mounted 
in antifading medium supplemented with DAPI prior to microscopy. Images were 
acquired using a Leica confocal microscope (TCS SP2, Heidelberg, Germany) 
equipped with a krypton/argon laser. Images were processed with Adobe 
Photoshop CS3 (Adobe). Bodipy 493/503 staining signals were acquisited at 
excitation/emmission of 500/510 nm. UV light was applied for DAPI staining.  
 
3.4.1.3 Osmium tetroxide staining  
Materials 
1. Fixative: 2 % paraformaldehyde containing 0.1 % glutaraldehyde (EM grade 
Sigma-Aldrich, G7526) 
4. Osmium tetroxide (Sigma-Aldrich, 201030), working solution: 0.1 % 
 
Method 
For an alternative LD staining, osmium tetroxide was used according to Melo et 
al. (2011). Therefore, cells were washed four times in PBS, fixed with fixative 
(RT, 30 min) and osmium tetroxide-stained (RT, 30 min). The samples were 
washed thrice in PBS, mounted in PBS and analyzed in brightfield conditions 
(Olympus IX81). 
 
3.4.2 Lipid droplet quantification  
3.4.2.1 Flow cytometry analysis 
Materials  
1. Bodipy 493/503, working solution: 1 µg/ml  
2. Paraformaldehyde 4 %  
3. Trypsin buffer (for preparation see 3.1.2) 
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Method 
To measure the relative abundance of lipid droplets in control and E. bovis-
infected endothelial cells, relative fluorescence intensities induced by bodipy 
493/503 staining were determined by fluorescence activated cell sorting (FACS). 
This method was described elsewhere in a different system (Gimm et al., 2010) 
and adapted to endothelial cells. BUVEC were trypsinized at days 8, 17 and 21 p. 
i. and pelleted in PBS (400xg, 3 min, 4ºC). The resuspended cells were stained 
with bodipy 493/503 (10 min, on ice) and washed twice in 1 ml PBS followed by 
centrifugation (400xg, 3 min, 4ºC). The cells were resuspended in 100 µl PBS and 
transferred to 5-ml FACS tubes containing 200 µl of PBS. The cells were 
processed in a FACSCalibur™ flow cytometer (Becton-Dickinson [BD], 
Heidelberg, Germany) by laser excitation at 488 nm (FL2-H channel). 
Fluorescence intensities were acquired by the Cell Quest Pro software (BD).  
 
3.4.2.2 Semiquantitative assay of lipid accumulation  
Intracellular lipid droplet increment in single cells was reportedly quantified by 
automatic image analysis (McDonough et al., 2009). This method was modified in 
this experiment by utilizing the software ImageJ (NIH, USA, 
http://imagej.nih.gov/ij/download.html) with quantification procedures being 
adapted from different systems (Burgess et al., 2010; Gavet and Pines, 2010) to 
compare the relative fluorescence intensity signals obtained from E. bovis-
infected cells with those of non-infected ones. The terms of area (in pixel), 
integrated intensity and mean fluorescence values were obtained from the “set 
measurements” mode of the “analyze menu” in the software. The total 
fluorescence intensity of the cells was normalized to background intensities and 
termed as corrected total cell fluorescence (CTCF) intensity. The CTCF intensity 
was calculated by following formula: 
CTCF = integrated intensity – (area of selected cell x mean fluorescence of 
background readings). 
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Infected BUVEC from inhibitor treated and non-treated groups (see 3.6.2) were 
grown on coverslips. The samples were stained with bodipy 493/503 (see 3.4.1.2) 
at 2, 6, 10, 14 and 18 days p. i. Cells were analyzed via fluorescence microscopy 
applying FITC settings. Lipid droplets were identified as bright green dots. 
Images were acquired by cellSens 1.7 software in TIFF format followed by 
ImageJ processing. The cell fluorescence intensities were estimated from different 
single cells (n=10) of each experimental condition.  
 
3.4.2.3 Oleic acid enrichment  
Materials 
1. Bovine serum albumin (BSA) fraction V (Roth, 8076.1) 
2. Modified endothelial cells growth medium  
3. Oleic acid (Sigma-Aldrich, O1008) 
 
Method 
To enhance lipid droplet generation in host cells, oleic acid was supplemented in 
BSA formulation complexes (Martin and Parton, 2011). Direct conjugation was 
performed by mixing oleic acid-free BSA with oleic acid at the molar ratio of 6:1 
(oleic acid: BSA). To control for oleic acid cytotoxicity for BUVEC, MTT assays 
(see 3.6.1) were performed in preliminary experiments. Therefore, oleic acid was 
applied at different concentrations covering 200 μM to 2.5 μM. According to 
these preliminary assays, the following experimental conditions were chosen: 
BUVEC were treated with 5 μM oleic acid/BSA complexes for an induction 
period 1 h, then the concentration was lowered to 2.5 μM to prevent lipotoxicity. 
These treatments were repeated every two days from 8 days p. i onwards. The 
experiments were performed in 12-well plates using 3 different BUVEC isolates. 
The effects of oleic acid enrichment on merozoite I production were assessed by 
Ebmic4-specific qPCR (see 3.7.2). 
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3.5 Low density lipoprotein-related assays 
3.5.1 Quantification of surface LDL receptor expression 
Materials 
1. Accutase (Sigma-Aldrich, A6964) 
2. Mouse anti-human LDLR primary antibody (Antibody online, USA, 
ABIN235770). This antibody coss-reacts with the bovine receptor. 
3. Goat anti-mouse IgG2b isotype-phycoerythrin (PE) secondary antibody 
(Southern Biotech, USA, 1090-09) 
4. Washing solution: PBS containing 0.01 % NaN3 (Sigma-Aldrich, S8032) 
5. Lipoprotein-deficient serum (Sigma-Aldrich, S5394) 
6. Endothelial cell basal medium  
 
Method 
The surface expression of the LDL-receptor (LDLR) was estimated in infected 
and non-infected BUVEC applying a flow cytometry technique. BUVEC grown 
in 25 cm2 flasks were infected using 7.5 x 105 sporozoites per flask. The cells 
were cultured in lipoprotein-deficient serum (36-48 h, 37ºC, 5 % CO2). Prior to 
LDLR measurements the medium was removed and cells were detached using 
accutase treatment (37ºC, 5 min). The cells were centrifuged (400xg, 5 min, 4ºC) 
and the supernatants were discarded. The samples were resuspended in washing 
solution transferred to V-shaped 96-microtiter plates (Greiner Bio-One) and 
pelleted (400xg, 5 min, 4ºC). The supernatants were discarded and the cells were 
reacted with monoclonal antibodies against LDLR (1:25, 50 µl/well, RT, 1 h). 
After centrifugation (400xg, 5 min, 4ºC), pelleted cells were washed (400xg, 5 
min, 4ºC) and incubated in 50 µl of secondary antibodies (diluted 1:50, 5 µg/ml, 
30 min, in the dark). Secondary antibody controls were included for each 
experiment for signal normalization. After incubation, cells were washed (400xg, 
5 min, 4ºC), resuspended in 100 µl PBS, transferred to 5 ml-FACS tubes (Greiner 
Bio-One) containing 200 µl of 1x PBS and processed by FACSCalibur™ flow 
cytometer (Becton-Dickinson, Heidelberg, Germany) in the FL1-H channel (red) 
using the software Cell Quest Pro (Becton-Dickinson).  
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3.5.2 Low density lipoprotein (LDL) binding assay 
Materials 
1. 3 % NaN3  
2. 4 % paraformaldehyde  
3. Bodipy-labeled LDL (Life Technologies, L-3483) 
4. Bodipy-labeled acetylated LDL (Life Technologies, L-3485) 
5. Endothelial cells basal medium  
6. Lipoprotein-deficient serum (Sigma-Aldrich, S5394) 
7. Prolong antifading mounting medium without DAPI  
Method 
The binding of non-modified LDL and acetylated-LDL to receptors on the surface 
of infected cells and non-infected controls was estimated qualitatively using 
bodipy-labelled molecules. Therefore, BUVEC were grown on coverslips and 
infected with 2 x 104 E. bovis sporozoites. At 17 days p. i., cell layers were 
incubated in endothelial cell basal medium devoid of FCS and supplemented with 
10 % lipoprotein deficient-serum for 36-48 h before being further processed. Then 
bodipy-labelled LDLs (both 10 µg/ml) were added to the medium and cells were 
incubated at 4ºC for 1 h followed by 4 h of incubation at 37ºC. Then, the cells 
were washed in PBS to remove unbound labelled LDLs. Samples were fixed in 4 
% paraformaldehyde (10 min) and washed with PBS. Coverslips were mounted in 
antifading medium prior to fluorescence microscopy. To compare the relative 
binding and uptake activities between control and infected cell populations, 
BUVEC were treated with 3 % NaN3 (5 min, RT) to inhibit receptor recycling and 
washed with ice-cold PBS. Monolayers were detached by accutase treatment (5 
min, 37ºC), washed in PBS (400xg, 5 min) and kept on ice. Cells were then 
processed via flow cytometry (see 3.4.2.1).  
 
3.5.3 Low density lipoprotein (LDL) enrichment 
LDL was supplemented (10 mg/ml final concentration) to BUVEC (n=5) cultures. 
This method was adapted from Coppens et al. (2000). Therefore, infected BUVEC 
(see 3.2.5) were washed with MECGM to remove free sporozoites. LDL was 
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supplemented from 10 days p. i. onwards. Cell supernatants containing released 
merozoites I were collected at 20, 23, 26 and 29 days p. i. At the end of culture 
period (30 days p. i.) merozoites I were collected together with trypsinized cells. 
BUVEC supernatants were centrifuged (400xg, 15 min) and merozoites I were 
processed for Ebmic4 qPCR (see 3.7.2). Besides merozoite I production, 
macromeront growth was also monitored from 10 days p. i. onwards (see 3.6.2).  
 
3.6 Inhibition assays 
Materials 
1. Inhibitors:  
a. C75 (C5490, Sigma-Aldrich) was dissolved in DMSO (Sigma-Aldrich, 
D8418) as stock solution and titrated 1: 2 covering 200 µM to 6.25 µM 
concentrations 
b. CI976 (C3743, Sigma-Aldrich) was dissolved in DMSO as stock solution 
and titrated 1: 2 covering 200 µM to 6.25 µM concentrations 
c. Lovastatin (L0790000, Sigma-Aldrich) was dissolved in aceton (Roth) as 
stock solution and titrated 1: 2 covering 200 µM to 1.58 µM concentrations 
d. Zaragozic acid (Z2626, Sigma-Aldrich) was dissolved in ethanol (Roth) as 
stock solution and titrated 1: 2 covering 200 µM to 6.25 µM concentrations 
2. Isopropanol containing 0.04 N HCl (all Roth) 
3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [(MTT), Sigma-
Aldrich, M2128] 
 
3.6.1 Toxicity assay 
For toxicity assays, BUVEC were trypsinized, counted and 5 x 103-104 cells were 
seeded in each well of a 96-well plate. Cells were cultured in 200 µl MECGM to 
confluency. The inhibitors (C75, CI976, lovastatin, zaragozic acid) were 
substituted at indicated concentrations. Cytotoxic effects of the compounds on 
endothelial cell were measured by three parameters: active metabolism, alteration 
of the cell morphology and cell numbers. Cell metabolism was analyzed by MTT 
assays which estimates mitochondrial activities (van Meerloo et al., 2011, 
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Sylvester, 2011). MTT assays were performed 24 and 96 hours post inhibitors 
application. Therefore, 20 µl of 5 mg/ml MTT working solution were added to 
medium in each well. Plates were incubated (4 h, 37ºC, 5 % CO2), the 
supernatants were removed, and 150 µl acidic isopropanol were added. After 
incubation (30 min, 37ºC, 5 % CO2), formazan production was analyzed at 590 
nm using a Varioskan™ Flash Multimode fluorometer. Each sample was 
processed as 5-fold preparation. The percentage of viable cells was calculated 
relative to control cells using the following formula: 
  (test sample absorbance-background absorbance) 
                 x 100 % 
                 (control absorbance-background absorbance)  
 
The alteration of the cell morphology was assessed microscopically considering 
intracellular vacuolization and cell death. Cell proliferation at 7, 10, 13, 16 and 19 
days post inhibitor application was measured by direct counting of trypsinized 
cells in a neubauer chamber. The concentration of each compound that did not 
affect cell proliferation for more than 5 days was chosen for inhibition assay. 
 
3.6.2 Inhibition of  E. bovis proliferation in vitro 
Infected BUVEC monolayers (see 3.2.5) were washed to remove free sporozoites. 
Compounds were added at the following doses: lovastatin: 1, 0.5, 0.1, 0.05, 0.01 
and 0.005 µM; zaragozic acid, CI976 and C75: 5, 2.5, 0.5, 0.25, 0.05 and 0.025 
µM. Each dose was tested in 5 BUVEC isolates. BUVEC treatments were 
performed up to 30 days p. i. Initial infection rates of treated and non-treated cells 
were estimated microscopically in 10 randomly chosen areas at 2, 6, 10, 14, 18, 
22, 26 and 30 days p. i. To estimate the numbers of merozoites I being produced 
in treated and non-treated BUVEC cultures, supernatants were collected at 20, 23, 
26, 29 days p. i. and at the end of culture period (30 days p. i.), merozoites I were 
collected together with trypsinized cells. Cell culture supernatants were pelleted 
(400xg, 15 min) and processed for Ebmic4 qPCR (see 3.7.2). To determine the 
median inhibition effects of the compounds, a non-linear regression was 
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performed using GraphPad Prism 6.02 to generate a calculated sigmoidal model 
of dose-response curves based on four parameter fit according to Motulsky and 
Christopoulos (2003). The relative inhibition was calculated as a response of 
treatment as follows: (mean value of control-value of test sample)/(mean value of 
control) and was represented as percentage relative to controls (Ehrenman et al., 
2013, Labaied et al., 2011).  
 
3.7 Quantitative real-time polymerase chain reaction (qPCR) 
3.7.1 Gene transcription of cholesterol metabolism-related molecules 
3.7.1.1 Target genes, primers and probes design  
Primers and probes were designed targeting several host cell genes being involved 
in cholesterol metabolism. Overall, only coding sequences were used for the 
design of qPCR systems. To ensure exon-intron mapping of the amplicon, 
assembly analyses using the Ensembl (http://www.ensembl.org/) web page were 
employed to avoid false positive results due to undigested genomic DNA. Splice 
variants were also taken into account before choosing the best target sequence 
combination to be entered into the software designer for each assay (Bustin et al., 
2009). Primers and probes were designed using Beacon Designer 7 software 
(Premier Biosoft) in combination with the Primer3 NCBI software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) considering melting 
temperature, self complementarity, heterodimer formation, hairpin formation, 
primer dimers and alternate splicing. In silico-primers, probes and amplification 
products were controlled for Bos taurus identity by BLAST (Altschul et al., 1990, 
at www.ncbi.nlm.nih.gov/BLAST/) and for homology to the closest species of the 
Eimeriidae genus, Eimeria tenella, to confirm the host transcription target, the 
correct sequence and to avoid false-positive pathogen-derived mRNA 
amplification. The designed primers and probes, due to their short nucleotide 
length, were accepted when exhibiting in less than 70 % similarity compared to 
Eimeriidae. According to Taubert et al (2006a,b), GAPDH was used as 
housekeeping gene. The sequences of primers and probes used for the 
experiments are listed in Table 3.1. 
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3.7.1.2 Generation of qPCR standards 
Materials 
1. 10X PerfeCTa qPCR FastMix (Quanta, MD, 733-2108) 
2. 50 bp Generuler DNA molecular weight marker (Thermo Scientific, 
SM0373) 
3. 6X gel loading buffer (Thermo Scientific, R0611) 
4. Agarose (Roth, 3810.4) gel (1 % and 2 %) 
5. Ethidium bromide (Etbr, Sigma-Aldrich, E7637), 5 µl in 100 ml TAE-buffer 
6. BamHI restriction enzyme (R0136S) and NEB buffer 3 [(B7003S), all New 
England Biolabs] 
7. Colony PCR mixture: 25 μl total volume PCR reaction containing 2.5 μl of 
10X PCR buffer (PeqLab), 2.5 μl MgCl2 (25 mM), 0.5 μl dNTPs (10 mM 
peqGOLD dNTP-Set), 0.5 µl Taq polymerase (5 U FIREpol DNA 
Polymerase, Solis BioDyne), 1 µl of each primer [10 μM, SP6 
(5'CATTTAGGTGACACTATAG3') and T7 
(5'GTAATACGACTCACTATAG3')] and 17 µl dH2O 
8. Competent cells: NEB 10-β (New England Biolabs, C3020K) 
9. Luria Bertani [(LB), Roth, X968.1] agar plates: LB-medium containing 
ampicillin (100 µg/ml), Xgal (40 ug/ml) and IPTG (0.1 mM) 
10. pDrive-vector cloning kit (Qiagen, 231122) 
11. peqGOLD gel extraction kit (PeqLab, 12-2501-02) 
12. PeqGold plasmid miniprep kit (Peqlab, 12-6942-02) 
13. TAE: 4.84 g Tris HCl (Roth) and 1.142 EDTA (Roth) adjusted to 1 L of 
ddH2O, pH 8.0 
 
Method 
To verify whether the correct parts of the targeted genes showing correct length 
were amplified, control PCRs were performed using cDNA generated from 
uninfected BUVEC (see 3.7.1.6). The qPCR conditions were as follows: hold at 
95ºC for 10 min; 40 cycles at 95ºC for 10 s, 60ºC for 15 s and 72ºC for 30 s. Each 
sample was controlled for the molecular size via gel electrophoresis. Therefore, 10 
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μl of qPCR samples were mixed with 1-2 µl of 6X gel loading buffer and 
electrophoresed along with a 50 bp DNA molecular weight marker in a 2 % 
agarose gel at constant current (80 Volt, 30-45 min) in TAE buffer. The gel was 
stained with EtBr for 15 min and washed in dH2O. The amplified product was 
visualized via UV light and illustrated by a documentation system (Intas, 
Goettingen, Germany). PCR products of the correct size were purified from the 
agarose gel using a gel extraction kit. Briefly, each DNA fragment of interest was 
excised from the gel. The gel piece was weighed and an equal volume of binding 
buffer was added. The mixture was incubated at 55ºC until the gel was completely 
solubilized. The solution was transferred to a DNA-binding column and 
centrifuged (10,000xg, 1 min). The flow-through was discarded and the column 
was washed with 750 µl washing buffer I and washing buffer II. Then 50 µl of 
elution buffer were added and the samples were centrifuged (10,000xg, 1 min). 
The flow-through containing the purified DNA was collected and used for 
cloning. Therefore, 5 µl of purified DNA were added to 5 µl of 2x ligation buffer 
and 1µl pDrive-vector. The mixture was incubated at 18ºC for 2-3 h and 10 µl 
thereof were added to 100 µl competent cells and incubated (30 min, on ice). The 
samples were heat-shocked for 2 min at 42ºC and immediately cooled on ice for at 
least 3 min. Then 600 µl of LB-medium devoid of ampicillin were added followed 
by incubation (37ºC, 45 min). The sample was centrifuged (1000xg, 3 min) and 
the pellet was cultivated in LB-plates containing Xgal and IPTG (overnight, 
37ºC). Thereafter, positive individual bacteria colonies were selected and screened 
by conventional colony PCR. Briefly, a small amount of an individual colony was 
taken and mixed with 25 µl of PCR master mix. Cycling conditions of PCR was 5 
min at 950C, 35 cycles of 30 s at 95ºC, 45 s at 47ºC, 45 s at 72ºC, and a final 
elongation step for 5 min at 72ºC. PCR-positive colonies containing plasmids 
carrying target genes were transferred to 5 ml of LB-medium and cultivated 
(overnight, 37ºC, under constant shaking). Plasmid-DNA extraction from 
overnight cultures was performed by using the peqGOLD plasmid miniprep kit 
according to the manufacturer’s protocol. Briefly, overnight bacterial cultures 
were pelleted by centrifugation (10,000xg, 1 min). Then, 500 µl of solution 
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I/RNAse A were added per 5 ml culture pellet and cells were resuspended by 
gentle vortexing. 500 µl solution II and 750 µl of solution III were added and 
sample was centrifuged (10,000xg, 1 min). The supernatant was transferred to a 
DNA collumn and centrifuged (10,000xg, 1 min). The column was washed once 
with 500 µl washing buffer I and twice with 750 µl washing buffer II (10,000xg, 1 
min). The plasmid-DNA was eluted with 50 µl of elution buffer (5,000xg, 5 min). 
The plasmid-DNA was stored at -20ºC until further use. The plasmids containing 
sequences of interest were linearized according to the enzyme manufacturer’s 
instruction. To confirm plasmid digestion sites, CLC Sequence Viewer 5 (CLC 
bio, Qiagen) was utilized to draw a plasmid map. Since all systems designed 
showed similar maps, BamHI was chosen for the linearization of all systems. The 
digestion solution contained 1 µg of isolated plasmid, 10 U restriction enzyme 
BamHI, 10 µl of NEB buffer 3 and dH2O adjusted to 50 µl total reaction volume. 
The solution was incubated (at 37ºC, 2 h). Succesful digestion was controlled by a 
1 % agarose gel electrophoresis. All plasmids were sequenced employing SP6 and 
T7 primers flanking the multiple cloning site of pDrive vector to confirm the 
correct target gene sequence. Sequencing was performed by GATC Biotech AG 
(Germany). The identity of each amplicon was confirmed using ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
 
3.7.1.3 Analysis of qPCR efficiencies 
Linearized plasmids containing target sequences were used to estimate 
amplification efficiencies of the PCR systems. A 100 % efficiency is defined as 
the doubling quantity of an amplicon during a PCR reaction’s geometric phase 
(Pfaffl, 2001). The slopes of the standard curves generated by plasmid DNAs 
were used to estimate PCR efficiency of each system. To obtain these standard 
curves, amplification reactions covering 5 magnitude orders of 10 fold plasmid-
DNA titrations were performed each in technical triplicates. The respective were 
slope-corrected utilizing the “slope correct” and “dynamic tab” options of the 
Rotor-Gene Q software (Rotor-Gene® Q User Manual, Qiagen). These steps 
reduced background fluorescences and technical replicates errors. The threshold 
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was manually defined and positioned within the linear logarithmic amplification 
phase of each target system. The formula used for efficiency correction was:  
E= 10(-1/slope) -1 
Efficiency values are ideally taken into account for real-time PCR analysis (Pfaffl, 
2001). Only if housekeeper efficiencies are above 90 % and are not significantly 
different to the amplification efficiencies of target genes the calculation may be 
performed using delta-delta-Ct methods (Livak and Schmittgen, 2001) since this 
method does not account for efficiency values corrections. 
 
3.7.1.4 RNA preparation and cDNA synthesis  
Materials 
1. DNase I (Thermo scientific, EN0525) 
2. On-column DNAse I digestion kit (Qiagen, 79254) 
3. RNeasy isolation kit (Qiagen, 74104) 
4. SuperScript® III First-Strand Synthesis System for RT-PCR (Life 
Technologies, 18080-051) 
5. β-mercapthoethanol [(2-ME), Serva, 28625.01)] 
 
3.7.1.5 Total RNA isolation and DNA digestion 
Total RNA isolation was performed using the RNeasy kit according to 
manufacturer’s protocol. Briefly, control and infected monolayers were lysed 
within the cell culture flasks by applying RLT lysis buffer (600 µl/25 cm2 flask). 
After this step, lysed cells may either be stored at -80ºC or directly processed for 
total RNA isolation. For total RNA isolation, 600 µl of 70 % ethanol were added 
to the suspension, resuspended and transferred to the collumn. The samples were 
centrifuged (13,000xg, 1 min) and flow-throughs were discarded. Then the 
samples were washed with 500 µl buffer RW1 (13,000xg, 1 min). DNase solution 
(10 µl DNase I+70 µl buffer RDD of on-column DNase digestion kit) was added 
to the collumn and incubated (RT, 15 min). The samples were washed twice with 
500 µl buffer RPE (13,000xg, 1 min). Total RNA elution was performed by 
adding 30-50 µl of DEPC-treated water to the collumn followed  by centrifugation 
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(13,000xg, 1 min). Total RNAs were stored at -20ºC until further use. Examplary 
total RNA samples were controlled for their quality using Agilent bioanalyzer 
2100 (Agilent Technologies, USA). Here, RNA integrity values (RIN numbers) of 
8.5 were obtained for almost all samples. RNA concentrations were measured 
spectrophotometrically in terms of optical densities (OD) 260 nm and 280 nm. In 
order to guarantee absolute genomic DNA digestion, a second genomic DNA 
digestion step was performed. Therefore, 1 µg of total RNA was treated with 10 U 
DNase I in 1X DNAse reaction buffer (37ºC, 1 h). DNase was inactivated by 
heating the sample (65ºC, 10 min). The efficiency of genomic DNA digestion was 
controlled by including RT--controls in each real-time PCR experiment.  
 
3.7.1.6 cDNA synthesis  
cDNA synthesis was performed using the SuperScript® III First-Strand Synthesis 
System according to manufacturer’s protocol with slight modifications. For first-
strand cDNA synthesis, the following constituents were mixed: 1 μg of DNAse-
treated total RNA, 1 µl of 50 μM oligo d(T), 1 µl of 50 ng/μl hexamer primer, 1 µl 
of 10 mM dNTP mix and DEPC-treated water was adjusted to 10 µl total volume. 
The sample was incubated at 65ºC for 5 min and then immediately cooled on ice. 
For the second strand synthesis the following ingredient were added: 2 µl of 10x 
RT buffer, 1 µl 25 mM MgCl2, 1 µl 0.1 M DTT, 1 µl RNaseOUT (40 U/µl) and 1 
µl SuperScript III enzyme (200 U/µl). The sample was incubated at 50ºC for 60 
min followed by a 85ºC-incubation for 15 min. Thereafter, the sample was treated 
with RNase H (40 U/sample, 37ºC, 20 min). Finally, nuclease-free dH2O was 
adjusted to 200 µl total volume yielding a final concentration of 5 ng/µl cDNA. 
 
3.7.1.7 Quantitative real-time polymerase chain reaction (qPCR) assay 
Materials 
1. Primers and probes as listed in Table 3.1. (all were purchased from Biomers 
AG, Germany) 
2. PerfeCta qPCR FastMix  
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Method 
Real-time qPCR was performed in a 10 µl total volume containing 400 nM 
forward and reverse primers, 200 nM TaqMan probe, 10 ng cDNA and 5 µl PCR 
master mix. The reaction conditions for all systems were as follows: hold at 95ºC 
for 10 min, 40 cycles at 95ºC for 10 s, 60ºC for 15 s and 72ºC for 30 s. PCRs were 
performed utilizing an automated real-time PCR fluorometer (Rotor-Gene® Q, 
Qiagen, Hilden, Germany). Non-template controls (NTC) and RT- reactions were 
included in each experiment. Cycle threshold (Ct) values of 40 were considered as 
non-significant amplification. 
 
3.7.1.8 Data analysis 
The qPCR data analysis was based on the ΔΔCt method and data were normalized 
to GAPDH results as housekeeping gene (Livak and Schmittgen, 2001, 
Schmittgen and Livak, 2008). Therefore, the following equation used was as 
follows: 
Fold change expression compared to control= 2-ΔΔCt 
with: 
ΔCt control(control samples )= Ct controlhouskeeping gene - Ct controltarget gene 
ΔCt treated(test samples)= Ct treatedhouskeeping gene - Ct treatedtarget gene 
ΔΔCt= ΔCt control(control samples ) - ΔCt treated(test samples) 
 
3.7.2 qPCR-based E. bovis merozoite I quantification  
Materials 
1. 10X PCR buffer (PeqLab, 01-1000), diluted 1:10 in dH2O 
2. 10X PerfeCTa qPCR FastMix  
3. Lysis buffer containing 0.32 M Sucrose, 1 % Triton X-100, 0.01 M Tris-Cl (pH 
7.5) and 5 mM MgCl2 (all Roth) 
4. Proteinase K (Qiagen, 158920) 
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Method 
To circumvent laborious manual E. bovis merozoite I counting, a quantitative 
real-time PCR for merozoite I quantification based on the single copy gene of E. 
bovis microneme protein 4 (Ebmic4, Lutz, 2008). The following primers and 
probes were designed using Beacon Designer 7 software (Premier Biosoft): 
forward primer was 5’CACAGAAAGCAAAAGACA3’, reverse primer 
5’GACCATTCTCCAAATTCC3’, and probe 5’FAM-
CGCAGTCAGTCTTCTCCTTCC-BHQ13’. For real-time PCRs, the following 
constituents were used: 5 μl DNA of merozoites I samples, 0.8 μl (400 nM final 
concentration) of each primer, 0.4 μl of probe (200 nM final concentration) and 10 
µl PerFecta MasterMix in 20 µl total reaction volume. The PCR conditions were 
as follows: hold at 95ºC for 10 min; 40 cycles at 95ºC for 10 s, 60ºC for 15 s and 
72ºC for 30 s. For PCR efficiency analyses, a plasmid containing Ebmic4-
amplicon sequence was generated analogous to section 3.7.1.3. Ebmic4 specific-
efficiency of the qPCR was also estimated using E. bovis merozoite I DNA as 
template by following procedure: Supernatants containing freshly released 
merozoites I from infected monolayers were collected. Merozoites I were pelleted 
by centrifugation (600xg, 15 min) and counted in a Neubauer chamber. Serial 
dilutions of merozoites I were performed covering 6 magnitude orders of 10-fold 
(106-10). DNA was isolated by adding 200 μl of lysis buffer to each merozoite I 
pellet. Then, 100 μl 1X PCR buffer and 20 μl proteinase-K (20 mg/ml) were 
added and incubated (56ºC, 1 h). Proteinase K was heat-inactivated (95ºC, 10 
min) and the samples were frozen at 20ºC until further use. All samples were 
processed as triplicates. 
 
3.8 Immunoblotting 
Materials 
1. Acrylamide gel: 
a. 10 %: 3.3 ml Rotiphore gel 30 % (Roth, 3037.2), 2.5 ml Tris 1.5 M pH 
8.8, 50 µl SDS 20 % (all Roth), 4.1 ml dH20, 5 µl TEMED (Bio-Rad, 161-
0801), 70 µl 10 % APS (Sigma-Aldrich, A3678) 
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b. 4.5 %: 0.75 ml Rotiphore gel 30 %, 1.25 ml Tris 0.5 M pH 6.8, 25 µl SDS 
20 %, 2.95 ml dH20, 5 µl TEMED, 25 µl 10 % APS  
2. 10X Ponceau red: 2 g Ponceau S (Serva, 33429.01), 30 g trichloroacetic acid 
(Roth), 30 g sulfosalicylic acid (Roth) 
3. 10X Tris buffer saline: 60.57 g Tris, 85 g NaCl, pH 7.4 (all Roth) 
4. 5X SDS sample buffer: 10 % SDS, 12.5 % 2-mercaptoethanol (Serva, 
28625.01), 25 % glycerol (Merck, Darmstadt), 25 mg bromphenolblue 
(Merck, Darmstadt), 150 mM Tris-HCL, pH 6.8 (unless stated, all Roth) 
5. Amersham ECL plus kit (GE Healthcare, RPN2108) 
6. Blocking buffer: 1X TBST containing 5 % low fat milk (Roth, T145.3) 
7. Bradford protein assay (Bio-Rad, Muenchen) 
8. BSA protein standard (Thermo Scientific, 23227), diluted in 1x PBS 
9. Fiber pads (Bio-Rad) 
10. Filter paper (Bio-Rad, 170-3966) 
11. Immobilon® polyvinylidene difluoride (PVDF) membrane (Milliopore, 
Bedford, PR02531) 
12. Kodak film (Sigma-Aldrich, Z370398) 
13. Kodak GBX developer and replenisher (Sigma-Aldrich, P7042 and P7167) 
14. PageRuler plus prestained protein ladder 10-250K (Thermo Scientific, 26619) 
15. Primary antibodies: rabbit anti-human OLR1 (1:1000, Antibody online, USA, 
ABIN676988), rabbit anti-human CH25H (1:1000, Santa Cruz 
Biotechnology, sc-135228), rabbit anti-human SOAT1 (1:500, Antibody 
online, ABIN872876) and goat anti-human GAPDH (1:500, Santa Cruz 
Biotechnology, sc 20357). All antibodies are cross-reactive to bovine 
molecules. 
16. Protease inhibitor cocktail (Sigma-Aldrich, P8340) 
17. RIPA buffer: 50 mM Tris-HCl, pH 7.4, 1 % NP-40, 0.5 % Na-deoxycholate, 
0.1 % SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF (all Roth) 
18. Running buffer: 0. 125 M Tris, 0.96 M Glycin, 0. 5 % SDS (all Roth) 
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19. Sondary antibodies: donkey anti-goat IgG-HRP (1:10,000, Santa Cruz 
Biotechnology, sc-2020) and goat anti-rabbit IgG-HRP (1:10,000, Santa Cruz 
Biotechnology, sc-2030) 
20. Transfer buffer: 15 % methanol, 0.005 % SDS, 192 mM glycin, 25 M Tris 
(all Roth) 
21. Washing buffer: 1X TBS 0.1 % Tween20 [(TBST), all Roth] 
 
Method 
Infected and non-infected BUVEC were washed in PBS to remove any medium 
traces, trypsinized (see 3.1.2) and pelleted (600xg, 10 min). 200 μl of RIPA buffer 
containing 2 μl of protease inhibitor cocktail were added to the pelleted cells. 
Thereafter, the cells were sonicated (20 s, 5X) on ice and centrifuged (8000xg, 10 
min, 4ºC). The protein contents of the supernatants were measured by Bradford 
assay (Bradford, 1976). Therefore, the Bradford buffer was equilibrated at RT. 
150 μl of the protein standards representing 25, 20, 15, 10, 5, 2.5 and 1.25 μg/ml 
final concentrations and test samples were mixed with 150 μl of Bradford buffer 
(1:1) and incubated (RT, 5-10 min). The protein concentration was determined via 
595 nm photometric reading in a Varioskan™ Flash Multimode Reader. The 
protein concentrations of the samples were obtained by interpolating photometric 
values to the linear regression curve of the standard protein. For western blot 
analyses, 100 μg of the test samples were heated in reducing 5X SDS sample 
buffer (10 min, 95ºC). The samples were processed by SDS-PAGE (120 V, 1 h) 
and transferred to PVDF membrane by the wet transfer method using mini Trans-
Blot (Bio-Rad) systems (see Fig. 3.1.) applying 100 V at 4-8ºC for 1 h. Protein 
transfer efficiency was controlled by Ponceau red staining of the blots for 5 min. 
Thereafter, ponceau dye was washed off the membrane in dH2O. The membrane 
was incubated in blocking buffer overnight at 4ºC. Then it was reacted with 
primary antibodies diluted in blocking buffer (2 h, RT). The membranes were 
washed thrice in TBST (RT, 15 min) and incubated with corresponding secondary 
antibodies (1 h, RT). The membranes were then washed thrice in TBST (RT, 15 
min). Signals were detected by a chemiluminescence detection system according 
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to the manufacturer’s instructions. Therefore, membranes were incubated in 
reaction buffer (solution A:B= 40:1, RT, 5 min) followed by film developing. 
Signal development were performed in the dark. Therefore, the kodak films were 
placed on the membrane and fixed in a casette for several minutes (5-15 min). 
Films were developed in developer solution for 1 min, washed in dH2O for 30 sec 
and fixed in fixer solution for 30 sec. Protein sizes were controlled relative to the 
protein ladder of the prestained marker. 
 
 
Fig. 3.1. Sandwich set-up for membrane protein transfer 
 
3.9 Statistical analysis 
All data presented in the results part of this study were statistically analysed by t-
tests comparing treated and untreated groups using GraphPad Prism 6.02 
software. The p-values of each experiment are noted in Appendix I. 
 
ig. 3.1. Sandwich set-up for membrane protein transfer (Anonymous b,-). 
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4 RESULTS 
 
 
4.1 Cholesterol and lipid droplet localization in free parasite stages and 
infected cells 
4.1.1 Cholesterol localization in E. bovis stages 
Filipin represents a commonly used tracer of cholesterol (Gimpl and Gehrig-
Burger, 2007, Maxfield and Wustner, 2012) and was here used to detect non-
esterified cholesterol in invasive stages and in E. bovis-infected cells.  
 
Both investigated parasite stages, i. e. sporozoites and merozoites I, were 
intensively stained by filipin (Fig. 4.1.). The strongest reactions were detected at 
the apical part and in the outer membrane of these stages indicating a high 
cholesterol content of the apical complex and the pellicula (Fig. 4.1.). In addition, 
an intense staining was observed in the cytoplasm of sporozoites and merozoites I. 
These reactions may origin from intraparasitic organelle membranes since free 
cytoplasmatic cholesterol is generally described as toxic for cells (Tabas, 2002). 
However, the microscopic resolution did not allow for further detailed analyses. 
Unfortunately, filipin is a very fast bleaching compound hampering any laser-
assisted experiments (e. g. confocal microscopy) that would have been of benefit 
for organelle identification. 
 
Fig. 4.1.1. Filipin staining of invasive E. bovis stages 
 
ig. 4.1. ilipin staining of invasive E. bovis stages
E. bovis sporozoites (A) and merozoites I (B) were stained by filipin. Note the intense 
filipin-derived signals in the apical part of both stages (arrow; A, B). The arrow heads 
indicate reactions of the outer layers of merozoites I (B). Scale bars: 5 µm. 
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In E. bovis-infected host cells, cholesterol abundance significantly increased with 
ongoing macromeront formation (Fig. 4.2.).  
 
One day after host cell infection, filipin-positive signals accumulated very close to 
the parasites intracellular position as illustrated in Fig. 4.2.A. Given that 
sporozoites always reside in a parasitophorus vacuole (PV), cholesterol signals 
may co-localize with the PV or even with the membrane of the PV (PVM). 
However, since the shape of the cholesterol accumulation site is not always 
typically roundish as it should be if only the PV or PVM was stained, other cell 
compartments may be involved in cholesterol accumulation, too. 
 
Compared to non-infected control cells directly neighbouring infected host cells, 
the cholesterol abundance was significantly enhanced in immature- and mature-
meronts (Fig. 4.2.B, C). As such, the cholesterol content of infected host cells 
increased with ongoing development and increasing macromeront sizes. As 
depicted in Fig. 4.2.C, cholesterol accumulation occurred within the immature 
meront itself occasionally showing a punctuated morphology. Whenever E. bovis 
macromeronts were multichambered, the inner septae also reacted with filipin 
indicating these membranes also to contain cholesterol molecules.  
 
In mature E. bovis macromeronts the strongest reactions upon filipin-staining 
were observed in the outer layers of the infected host cells (Fig. 4.2.D). Owing to 
the enlargement of the host cell leading to a close position of PVM and host cell 
membrane, it cannot be concluded whether the signals originate merely from the 
parasite and its PVM or from the host cell membrane or both. In filipin-stained 
mature macromeronts, merozoites I could not be structurally identified although 
being visible in the phase contrast mode. Most probably, this was due to the 
strong signals of the outer membrane outshining the rather weak reactions of the 
merozoites I themselves. 
 Fig. 4.1.2. Filipin staining of E. bovis infected host cells 
BUVEC were infected with E. bovis sporozoites and were monitored for cholesterol 
contents during in vitro infection: (A) 1 day p. i. (invaded sporozoites, arrows), (B) 8 days 
p. i. (early immature meront), (C) 14 days p. i. (immature meront), (D) 17 days p. i. 
(mature meront). Scale bars: 10 µm.  
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Fig. 4.1.2. . Filipin staining of E. bovis infected host cells 
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Filipin staining at day 1 p. i. revealed a considerable accumulation of cholesterol 
surrounding the invaded sporozoite (see above). However, from these results it 
cannot be concluded whether these molecules were host cell-derived or originated 
from the parasite stage itself. Therefore, rhodamin cholestanol was used to 
exclusively label host cell-derived molecules prior to sporozoite infection. As 
depicted in Fig. 4.3. a clear accumulation of cholesterol close to the parasite was 
detected after rhodamin cholestanol supplementation indicating that host cell 
cholesterol is recruited to the parasites site after invasion. Given that the 
sporozoite resides within a PV these molecule may also contribute to the 
formation of the PVM. However, the resolution of the current assays did not allow 
for this conclusion. 
 
 
Fig. 4.1.3. Cholesterol distribution within E. bovis-infected BUVEC after rhodamin cholestanol labelling 
 
 
 
4.1.2 Dansyl-cholesterol incorporation into E. bovis stages 
In order to analyze whether free and intracellular stages of E. bovis are capable to 
incorporate cholesterol from an extracellular source, free sporozoites and 
intracellular meronts were pulse-labelled with dansyl-cholesterol, a fluorescent 
cholesterol analogue that is described to be comparably processed as non-
modified cholesterol within the cell (Wiegand et al., 2003, Shrivastava et al., 
2009).  
 
Fig. 4.3. Cholesterol distribution within E. bovis-infected BUVEC after rhodamin 
cholestanol labelling 
BUVEC were labelled with rhodamin cholestanol-supplemented. Thereafter, they were 
infected with viable E. bovis sporozoites. 1 day p. i. infected cells were processed by 
fluorescence microscopy applying the TRITC filter setting. Scale bars: 10 μm. 
A B C 
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The exposure of sporozoites to dansyl-cholesterol led to a rapid uptake of this 
tracer molecule and respective fluorescence patterns within these stages. Within 
the specimens, the reactions appeared concentrated in the apical part and, to a 
higher degree, in the refractile bodies of the sporozoite (Fig. 4.4.B). Given that 
dansyl-cholesterol is a non-esterified molecule and that these reaction patterns 
overlap with those of neutral lipid (bodipy 493/503) staining (see Fig 4.6.B, C), it 
appears likely to assume that dansyl-cholesterol was not only incorporated and 
transported to the apical complex but also converted to cholesteryl esters and 
deposited as such in the refractile bodies.  
 
 
Fig. 4.1.4. Dansyl-cholesterol-labelling of E. bovis sporozoites 
 
 
Exogenously supplied dansyl-cholesterol was also incorporated in intracellularly 
situated meronts I as depicted in Fig. 4.5.B. The bright staining of lipid body-like 
structures within the infected host cell and, most probably, within the parasitic 
stage itself, implies that dansyl-cholesterol was processed analogous to non-
modified cholesterol, i. e., it was esterified and stored in lipid droplets. The bright 
fluorescence of the meronts I after dansyl-cholesterol pulse-labelling (Fig. 4.5.B) 
confirmed an increase of cholesterol/cholesterylester abundance in infected cells 
when compared to non-infected controls. 
A BFig. 4.4. ansyl-cholesterol-labelling of E. bovis sporozoites
E. bovis sporozoites were stained with dansyl cholesterol-cyclodextrin complexes. Note 
the bright fluorescence of the refractile bodies of the sporozoite (arrows) and of the 
apical complex (arrow head). Scale bars: 20 µm. 
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Fig. 4.1.5. Dansyl-cholesterol-labelling of E. bovis meronts I 
 
 
4.1.3 Lipid droplet (LD) formation in E. bovis stages 
Since excess intracellular concentrations of free cytoplasmatic cholesterol are 
toxic for cells, this molecule is generally converted intracellularly to cholesteryl 
esters which then are stored in LDs (Chang et al., 2006). LDs represent dynamic 
lipid storage organelles found in any cell type which needs rapidly mobilized 
lipids. Thus, LDs are not only enriched in cholesteryl esters but also in 
triacylglycerol and phospholipids (Mahlberg et al., 1990, van Meer, 2001).  To 
monitor LD formation in invasive stages and infected host cells throughout the 
development of E. bovis macromeronts, three different stainings were here applied 
which all detect neutral lipids and are commonly used to detect LD formation 
within mammalian cells (Greenspan et al., 1985, Brown et al., 1988, Gocze and 
Freeman, 1994): Nile red® and bodipy 493/503 as fluorescent dyes and osmium 
tetroxide for bright field microscopy. 
Sporozoites and merozoites I of E. bovis all showed an intense staining by Nile 
red®- and bodipy 493/503-dyes, clearly indicating a high content of neutral lipids 
within analyzed stages. However, using Nile red® we failed to demonstrate 
structurally defined LD-like structures within the cytoplasm of these stages, whilst 
bodipy 493/503 staining resulted in strong fluorescing globular bodies. In 
merozoites I and sporozoites LDs were situated in the cytoplasma and differed in 
Fig. 4.5. Dansyl-cholesterol-labelling of E. bovis meronts I 
Dansyl-cholesterol-cyclodextrin complexes were administered to E. bovis-infected host 
cells (15 days p. i.). Note the bright fluorescence of LD-like structures in a meront I-
infected host cell (arrows). Scale bars: 20 µm. 
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numbers per specimen (Fig. 4.6.). Overall, up to 8 LD-like structures were 
detected per stage. The strongest reactions upon Nile red® or bodipy 493/503 
staining were found in the refractile bodies of the sporozoite stage (merozoites I 
do not contain any refractile bodies) (Fig.4.6.B, C) indicating the storage of 
neutral lipids within these apicomplexan organelles.  
 
Fig. 4.1.6.Neutral lipid staining in E. bovis invasive stages 
              
 
 
 
Given that bodipy 493/503 staining was superior to Nile red® if LDs were to be 
stained, we used the former staining to monitor LD formation in E. bovis-infected 
BUVEC. Soon after completing the invasion process, intracellular sporozoites 
seemed to lose the contents of their anterior refractile body since the fluorescence 
of these were clearly diminished when compared to free sporozoites (Fig. 4.7.A, 
arrows). 
 
Compared to non-infected controls, a considerable enhancement of LD formation 
was observed with ongoing macromeront development showing the most 
significant accumulation of distinct LD-like structures in immature macromeronts 
(15-17 days p.i.). Here, differential distribution patterns of these organelles were 
observed since they were either homogeneously spread within the macromeront-
carrying host cell (Fig. 4.7. B, D: macromeront at the left side) or found clustered 
in certain areas (Fig. 4.7. C). With maturation and merozoite I formation the 
fluorescence pattern changed from a spotty appearance illustrating single LDs to a 
rather cloudy and diffuse reaction indicating that lipid droplet contents were 
Fig. 4.6. Neutral lipid staining in E. bovis invasive stages 
Merozoites I (A) and sporozoites (B) were stained with bodipy 493/503 and Nile red® 
(only sporozoites, C) to visualize neutral lipids and LDs. LDs are situated within the 
cytoplasm of both stages (A, B, arrow heads). In addition, the refractile bodies of the 
sporozoites strongly reacted with both stainings (arrows, B, C). Scale bars: 5 µm. 
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almost totally exhausted or consumed for merozoite I formation (Fig. 4.7. D, 
macromeront at the right side).  
 
Fig. 4.1.7. Bodipy 493/503 staining of E. bovis infected host cells ig. 4. . odipy 493/503 staining of E. bovis infect d host cells 
BUVEC were infected with E. bovis sporozoites and were monitored for LD contents 
during in vitro infection: (A) 1 day p. i. (invaded sporozoites, arrows), (B-D) 17 days p. i. 
with homogeneously spread spotty (B), clustered (C) and cloudy (D) distribution of 
bodipy 493/503-positive reactions in meronts I. Scale bars: 20 µm. 
A1, B1, C1, D1: phase contrast;  A2, B2, C2, D2: bodipy 493/503 staining  
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Given that the fixation mode may alter LD integrity leading to dimmed LD 
appearance (DiDonato and Brasaemle, 2003), this study additionally used osmium 
tetroxide fixation which preserves lipid body structures. However, osmium 
tetroxide treatments led to similar results as bodipy 493/503 staining and thus 
confirmed the significant increase of LD abundance in E. bovis macromeront-
carrying host cells (Fig. 4.8.).  
   
 
 
 
 
 
 
  
 
 
Fig. 4.1.8. Osmium tetroxide staining of an E. bovis macromeront-carrying host cell 
In order to better define LDs position, structure and size within E. bovis-infected 
cells we extended our experiments by confocal microscopy applying bodipy 
493/503 staining. Analyses of host cells 17 days after infection revealed the 
presence of brightly fluorescing LDs throughout the meront I corpus since they 
were detected in each layer (Z-stack) of the specimen (Fig. 4.9.A-C). LDs showed 
classical globular shapes but were of differing sizes. Whilst most LDs were rather 
small (< 1 µm), some of them revealed a size of up to 5 µm in diameter. The 
simultaneous staining of the LDs (bodipy 493/503) and nuclei (DAPI) showed the 
Fig. 4.8. Osmium tetroxide staining of an 
E. bovis macromeront-carrying host cell 
E. bovis-infected BUVEC were stained by 
osmium tetroxide and illustrated by bright field 
microscopy. Lipid bodies (arrows) are 
represented as dark lipid-containing dot-like 
structures. Scale bars: 20 µm. 
(A) phase contrast of infected cell, 17 days p. i. 
(B) osmium tetroxide staining of the 
      respective cell 
(C) enlarged details of an osmium tetroxide- 
      stained infected cell  
20 µmC 
A B20 µm 20 µm 
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makromeronts to be densely filled with lipid sources and developing merozoites I 
(Fig. 4.9. D).  
 
Fig. 4.1.9. Bodipy 493/503 staining of an E. bovis macromeront-carrying BUVEC 
 
 
 
 
ig. 4. . odipy 493/503 staining of an E. bovis macromeront-carrying BUVEC 
Bodipy 493/503- (green= lipid droplets) and DAPI- (blue= nucleus) stained E. bovis-
infected BUVEC (17 days p. i.) were analyzed via confocal microscopy. A-C represent 
single Z-stacks of one bodipy 493/503-stained infected host cell, D shows an overlay of all 
stacks after bodipy 493/503- and DAPI-stainings. Note numerous nuclei of developing 
merozoites I (D, blue) and large globular LD-like structures (green). Scale bars: 20 µm. 
A B 
C D 
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4.2.Quantification of cholesterol and lipid droplet (LD) contents in E. bovis-
infected host cells  
4.2.1. Cholesterol accumulation in E. bovis-infected host cells 
To confirm the qualitative findings of cholesterol accumulation in E. bovis 
infected host cells (see 4.2), total cellular cholesterol quantification of infected 
cells was performed by using an enzyme-based fluorometric assay (Amplex Red® 
Cholesterol Assay). In this commercially available assay free and esterified forms 
of cholesterol were equally detected. However, the use of the provided solvent 
failed since the total lipid extracts were not properly dissolved in this agent. Thus, 
the method had to be adapted and the solvent was replaced by isopropanol-NP40 
according to Robinet et al. (2010). Given that the solvent isopropanol-NP40 
contained a certain level of residual peroxidase activity resulting in rather high 
background noises using the Amplex Red® Cholesterol Assay, we applied catalase 
treatments to each sample in order to inactivate peroxidase activity prior to be 
processed for cholesterol measurements. Overall, catalase treatments of 
isopropanol-NP40 significantly reduced background reactions resulting in a r2 
value of 0.99 for the standard curve (Fig. 4.10.). 
 
Fig. 4.1.10. Cholesterol quantification of catalase pre-treated samples 
 
i . .10. lesterol quantification of catalas  pre-treated samples 
Cholesterol standard was dissolved at different concentrations (0.5, 1, 2, 4 µM) in catalase-
treated or non-treated isopropanol-NP40 and quantified using the Amplex Red® Cholesterol 
Assay. 
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Cholesterol quantification in total lipid extracts revealed a significant increase of 
cholesterol abundance in E. bovis-infected host cells over time when compared to 
non-infected controls (Fig. 4.11.). Thus, significant differences were detected 
beginning with 4 days p. i. up to 17 days p. i. (4 days p.i: p < 0.01; 8 days p.i: p < 
0.01; 17 days p.i: p < 0.01), although the infection rates were rather low in times 
of meront I maturation (17 days p. i., 20-30% infection rate). Given that the 
cholesterol content of sporozoites (here the individual infection dose of 5 x 105 
sporozoites was analyzed) was rather low (Fig. 4.11.), the changes of host cellular 
cholesterol content did not originate from invading stages and resulted from 
infection-triggered alteration of the cholesterol metabolism. 
 
Fig. 4.1.11. Total cholesterol abundance in E. bovis-infected host cells 
 
 
         
  
Fi . .1 . tal cholesterol abundance in E. bovis-infe ted host cells 
The total cholesterol abundance was estimated in E. bovis-infected BUVEC (black bars) 
and in non-infected controls (white bars) using the Amplex Red® Cholesterol Assay 
following total lipid extraction. The data represent means ± SD of 7 different BUVEC 
isolates.  
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4.2.2 Lipid droplet (LD) accumulation in E. bovis-infected host cells 
To verify LD accumulation previously observed in E. bovis-infected host cells 
(see 4.1.3.) we established a flow cytometry-based assay allowing for LD 
quantification in E. bovis-infected cell layers and in non-infected controls by 
measuring bodipy 493/503-derived fluorescence signals.  
The LD abundance in E. bovis-infected BUVEC was significantly enhanced over 
time during macromeront formation resulting in highly significant values (p ≤ 
0.0001) for days 17 and 21 p.i., respectively. These results corroborated our 
previous qualitative observations on bodipy 493/503 and osmium tetroxide-
stained host cells (see 4.1.3.). 
 
Fig. 4.1.12. . Lipid droplet abundance in E. bovis-infected host cells 
 
Figure 4.12. Lipid droplet abundance in E. bovis-infected host cells 
Eimeria bovis-infected BUVEC were stained with bodipy 493/503 to trace LDs and 
analyzed at different time points p. i. (8, 17, 21 days p. i.) via flow cytometry. Infected 
cells were assigned according to their size and granularity. (A) Means and standard 
deviations of three isolates, (B-C) exemplary illustration of histograms of infected (black) 
and non-infected (white) BUVEC on days 8, 17 and 21 p. i., respectively.  
A 
B 
C 
D 
8 days p.i 
17 days p.i 
21 days p.i 
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4.3 Influence of cholesterol and lipid droplet (LD) enrichment on E. bovis 
development in vitro  
4.3.1 Effects of cholesterol supplementation on macromeront development 
To assess the effects of exogenously supplied cholesterol on E. bovis 
macromeront development, free sterols (cholesterol and desmosterol) were 
administered to cell cultures. Desmosterol is a cholesterol intermediate precursor 
and can replace cholesterol function in sustaining cell proliferation (Rodriguez-
Acebes et al., 2009). To avoid intracellular crystallization and cytotoxicity (Xu et 
al., 2005), low concentrations (5 µM) of these substituents were applied.  
Whilst infection rates and macromeront sizes were not significantly altered by 
cholesterol or desmosterol supplementation (Fig. 4.13.A), a significant beneficial 
effect (p ≤ 0.05) was observed on merozoite I production leading to enhanced 
offspring generation in both, cholesterol- and desmosterol-treated host cells (Fig. 
4.13.B). 
 
 
 
A 
to be continued 
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Fig. 4.1.13. Effects of cholesterol and desmosterol supplementation on E. bovis in vitro development 
 
 
                        
 
 
 
 
4.3.2 Effects of cholesterol depletion on E. bovis development in vitro 
The invasion of host cells by other apicomplexan parasites is reported as an active 
process requiring both, host cell- and parasite-derived cholesterol (Coppens and 
Joiner, 2003, Pacheco-Soares and De Souza, 2000). To assess the role of host cell- 
and parasite-derived cholesterol in the initial infection phase, E. bovis invasion 
assays were performed by alternatively using either cholesterol-depleted 
sporozoites or cholesterol-depleted host cells. As depicted in Fig. 4.14., the most 
significant effects (p ≤ 0.0001) were achieved by sporozoite cholesterol depletion 
since 91.1% less sporozoites invaded host cells compared to non-treated controls, 
although sporozoites remained vital after cholesterol depletion [as estimated via 
the trypane blue exclusion test (data not shown)]. Additionally, a significant 
Fig. 4.13. Effects of cholesterol and desmosterol supplementation on E. bovis in vitro 
development 
E. bovis-infected BUVEC were cultivated in non-supplemented (= controls) and 
cholesterol- or desmosterol-enriched medium. The effects of cholesterol and desmosterol 
supplementation on macromeront development (A) were assessed microscopically by 
estimating the rate of macromeront-carrying host cells (black bars: cultures treated with 
5 μM cholesterol; grey bars: cultures treated with 5 μM desmosterol, white bars: 
controls) and by measuring the sizes of developing meronts (circles: cultures treated with 
5 μM desmosterol; triangles: cultures treated with 5 μM cholesterol; quarders: controls). 
The effects on merozoite I production (B) were quantified using an Ebminc4-based 
qPCR (see 3.7.2) after 30 days p. i. 
B 
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reduction of intracellular parasites of approximately 51% was observed when 
cholesterol-depleted host cells were used (p ≤ 0.01).  
   
Fig. 4.1.14. Effect of host cell and sporozoite cholesterol depletion on initial E. bovis infection rates 
 
 
 
4.3.3 Effects of increased host cellular lipid droplet disposability on E. bovis 
merozoite I production 
Given that LDs play a pivotal role in E. bovis in vitro development, we here 
assessed the effects of an artificially enhanced abundance of LDs in host cells. 
Oleic acid is a well-known inducer of LD formation in several types of 
mammalian cells (Martin and Parton, 2011). Since endothelial host cells generally 
react rather sensitive upon any stimulants and as oleic acid treatments were 
reported as toxic for human umbilical vein endothelial cells (HUVEC, Hua-Hong 
et al., 2010), preliminary cytotoxicity tests (MTT assays) were performed to 
identify oleic acid concentrations which increased LD formation but did not 
damage BUVECs.  
Fig. 4.14. Effect of host cell and sporozoite cholesterol depletion on initial E. bovis 
infection rates 
Sporozoites of E. bovis (grey bar) or BUVEC (black bar) were depleted in cholesterol via 
MBCD treatment prior to host cell infection. Non-treated BUVEC were infected with 
non-depleted sporozoites and served as negative controls (white bar). Data represent 
means ± SD of five BUVEC isolates.
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MTT tests showed that BUVEC are very sensitive for oleic acid treatments since a 
high proportion BUVEC died even when low concentrations of oleic acid were 
applied (Fig. 4.15.). Thus, the application of 400 µM oleic acid, which is often 
used for cellular LD induction (Anonymous a,-), led to almost total cell death. LD 
generation in BUVEC was also controlled by bodipy 493/503 staining showing 
that long-term (24 h) treatments resulted in larger LDs than short term incubations 
(1 h, Fig. 4.16.A, B). Given that 2.5 µM oleic acid treatment induced a significant 
increase of (small) LD formation (Fig. 4.16.C), a combination of short-pulse 
induction by a relative mild dose (1 h, 50 µM) and maintenance in 2.5 µM oleic 
acid was chosen for E. bovis-related experiments. 
 
Fig. 4.1.15.MTT assay of oleic acid-treated BUVEC 
Fig. 4.15. MTT assay of oleic acid-treated BUVEC 
BUVEC were exposed for 24 h to different concentration of oleic acid supplemented in 
the cell culture medium before being processed for MTT test. Means ± SD of triplicates. 
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Fig. 4.1.16. Effects of oleic acid treatments on LD formation in BUVEC Fig. 4. 16. Effects of oleic acid treatments on LD formation in BUVEC 
BUVEC were treated with oleic acid and stained by bodipy 493/503 to visualize LD formation.  
(A): treatment with 50 µM oleic acid overnight, note large LDs (arrows).  
(B): treatment with 50 µM oleic acid for 1 h, note small-sized LDs (arrows). 
(C): treatment with 2.5 µM oleic acid overnight incubation 
(D): non-treated controls 
Scale bars: 20 µm, images at left side: phase contrast, at right side: bodipy 493/503 staining 
(green) 
A1 A2 
B1 
C1 
D1 
B2 
C2 
D2 
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Analyses on E. bovis merozoite I production in oleic acid-treated BUVEC 
confirmed the key role of LDs in parasite proliferation. Thus, significant 
beneficial effects of oleic acid treatments on merozoite I production were 
observed over time of in vitro cultivation (Fig. 4.17.A). Referring to the total 
merozoite I production, a significant (Fig. 4.17.B), 4.7 ± 2.9 fold increase of 
offspring production was estimated. 
 
Fig. 4.1.17. Effects of oleic acid treatments on E. bovis merozoite I production 
 
 
 
 
 
 
 
. 4.1 fects of olei  acid tr atments n E. b vis me zoi e I production 
E. bovis-infected BUVEC were were cultured in oleic acid-enriched medium (A, B, black 
circles/column). Cultures in non-supplemented medium were used for controls (A, B, white 
circles/column). At different time points p. i. the numbers of merozoite I present in cell 
culture supernatants were quantified applying an Ebmic-specific qPCR (see 3.7.2). (A) 
merozoite I production over time (oleic acid-treated cells: black circles, non-treated controls: 
open circles), (B) total merozoite I production in treated (black bar) and non-treated (white 
bar) BUVEC. 
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4.4 Involvement of LDL in E. bovis macromeront development in vitro 
4.4.1 Binding of LDL and acetylated LDL (acLDL) on parasite-infected host 
cells 
To assess whether LDL binding to the cell surface is altered in infected host cells, 
bodipy-labelled LDL was supplemented for short terms to in vitro cultures that 
had previously been starved in LDL-free medium. LDL binding was illustrated 
via fluorescence microscopy and quantified using FACS technology. 
Utilizing confocal and conventional fluorescence microscopy a considerable 
increase of LDL binding to the surface of E. bovis-infected cells was 
demonstrated (Fig. 4.18.). Reactions varied from rather defined areas of intense 
spotty fluorescence (Fig. 4.18.A) to more homogeneously distributed bodipy-
LDL-positive signals (Fig. 4.18.B) in the outer layer of infected BUVEC.  
 
Fig. 4.1.18. LDL binding on E. bovis-infected host cells 
 
 
Fig. 4.18. LDL binding on E. bovis-infected host cells 
E. bovis-infected BUVEC (17 days p. i.) were starved in LDL-free medium, exposed to 
bodipy-LDL, fixed and analysed using confocal (A1-A3) or conventional (B1-B2) 
fluorescence microscopy (scale bars: 20 µm).  
thick arrow: host-cell membrane; thin arrow: meront. 
blue: DNA-staining via DAPI; green: bodipy-LDL; grey: phase contrast 
A1 A2 A3 
B1 B2 
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Prolonged supplementation of bodipy-LDL for more than 5 h resulted in bodipy-
positive signals in different localizations within infected cells (Fig. 4.19.). Thus, 
analyses of single sections of Z-stacks identified these reactions to be located at 
both areas, i. e., the surface and the inside of the E. bovis macromeront-carrying 
cell indicating a certain degree of bodipy-LDL up-take within the macromeront. 
 
Fig. 4.1.19. LDL binding and up-take in E. bovis-infected host cells 
 
 
 
 
Fig. 4. 9. LDL bi ding and up-take in E. bovis-infected host cells 
E. bovis-infected BUVEC (17 days p. i.) were starved in LDL-free medium, exposed to 
bodipy-LDL for 5 h, fixed and analysed by confocal fluorescence microscopy. 
A1-3: DAPI, bodipy-LDL, and merge of a Z-Stack, respectively. 
B1-12: single sections of bodipy-LDL staining 
A1 A2 A3 
B1 B2 B3 B4 
B5 B6 B7 B8 
B9 B10 B11 B12 
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The LDL binding assays were extended to FACS analysis to obtain quantitative 
data. Indeed, a significant increase of bodipy-LDL binding was detected in 
infected cells when compared to non-infected controls (p < 0.0001, Fig. 20.). 
Overall, a 37.5-fold enhancement was measured. However, it has to be kept in 
mind that these reactions may not exclusively reflect surface-bound LDL but may 
also originate from a small proportion of internalized LDL. 
 
 
Fig. 4.1.20. Quantitative assessment of LDL binding to E. bovis-infected BUVEC 
 
 
 
Whilst most cell types are able to incorporate non-modified LDL via the LDLR 
pathway, only endothelial cells and macrophages have the capacity to internalize 
acetylated LDL (acLDL) via so-called scavenger receptors (Goldstein et al., 1979, 
Voyta et al., 1984). Consequently, acLDL up-take is routinely used for primary 
endothelial cell characterization (Voyta et al., 1984). Since the high demand for 
cholesterol in macromeront-carrying cells may also be met by modified LDL 
derivates, LDL binding assays were further extended to acLDL molecules. Short 
term supplementation of in vitro cultures with acLDL resulted in strong surface 
Fig. 4.20. Quantitative assessment of LDL binding to E. bovis-infected BUVEC  
E. bovis-infected (17 days p. i.; black bar/pannel) and non-infected (white bar/pannel) 
BUVEC were starved in LDL-free medium, exposed to bodipy-LDL, fixed and analysed 
by flow cytometry. (A) means of three different BUVEC isolates in triplicate, (B) 
exemplary histogram. 
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reactions of E. bovis-infected host cells (Fig. 4.21.) indicating an increased 
binding of acLDL in these cells.  
   
Fig. 4.1.21. acLDL binding on E. bovis-infected host cells 
 
In agreement, FACS-based quantification confirmed a significant (p < 0.0001) 
enhancement of acLDL binding on E. bovis-infected host cells (5.2-fold, Fig. 
4.22.). Overall, the relative increase was lower than that induced by non-modified 
LDL. 
 
Fig. 4.1.22. Quantitative assessment of acLDL binding to E. bovis-infected BUVEC 
Fig. 4.21. acLDL binding on E. bovis-infected host cells 
E. bovis-infected BUVEC (17 days p. i.) wer  tarved in LDL-free medium, exposed to 
bodipy-acLDL, fixed and analysed using conventional fluorescence microscopy (scale 
bars: 20 µm). (A) phase contrast, (B) bodipy-acLDL-based green fluorescence 
Fig. 4.22. Quantitative assessment of acLDL binding to E. bovis-infected BUVEC  
E. bovis-infected (17 days p. i.; black bar/pannel) and non-infected (white bar/pannel) 
BUVEC were starved in LDL-free medium, exposed to bodipy-acLDL, fixed and analysed 
by flow cytometry. (A) means of three different BUVEC isolates in triplicate, (B) 
exemplary histogram 
A B 
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4.4.2 Surface LDL receptor (LDLR) expression on E. bovis-infected host cells 
LDL binding assays indicated an increased binding of LDL to E. bovis-infected 
cells. To estimate whether these reactions originated from enhanced surface 
LDLR expression, a flow cytometry-based assay was established utilizing an 
LDLR-specific antibody and tested on E. bovis-infected BUVEC at 17 days p. i.  
As expected, the data revealed a significant (p < 0.0001), infection-induced 
increase of LDLR surface expression (1.92 fold) in macromeront-carrying host 
cells. These results indirectly confirmed the data obtained via LDL binding 
assays. 
 
 
Fig. 4.1.23. LDLR surface expression on E. bovis-infected host cells 
 
 
4.4.3 Effects of LDL enrichment on E. bovis in vitro development 
Given that LDL binding and LDLR surface expression is enhanced in E. bovis-
infected host cells, we here investigated whether exogenous LDL supplementation 
would be of benefit for E. bovis macromeront development in vitro. Treated and 
Fig. 4.23. LDLR surface expression on E. bovis-infected host cells 
E. bovis-infected BUVEC (17 days p. i.) were reacted with primary antibodies directed 
against LDLR and respective conjugates and proces ed via flow cytometry. (A) means ± 
SD of three BUVEC isolates, (B) exemplary histogram.  
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control BUVEC showed equal infection rates (25.2-25.4 %). Indeed, excess LDL 
stimulated macromeront growth. Thus, slightly increased macromeront sizes and 
rates were observed (Fig. 4.24.A). In addition, a significant (p < 0.01) effect of 
LDL enrichment on the total merozoite I production was observed (Fig. 4.24.B) 
resulting in a 1.54-fold enhancement of offspring synthesis most probably owing 
to an earlier maturation and release of merozoites I (Fig. 4.24.A).  
 
Fig. 4.1.24. Effect of LDL supplementation on E. bovis in vitro development 
 
 
 
 
 
Fig. 4.24. Effect of LDL supplementation on E. bovis in vitro development 
E. bovis-infected BUVEC were cultivated in non-supplemented (controls = white bars or 
open circles) and LDL-enriched (black bars or circles) medium. The effects of LDL 
supplementation on merozoite I production over time (A) and in total (B) were 
quantified using an Ebmic4-based qPCR (see 3.7.2) after 30 days p. i. The effects on 
macromeront development (C) were assessed microscopically by estimating the rate of 
macromeront-carrying host cells and by measuring the sizes of developing meront 
stages. Arithmetic means and SD of five BUVEC isolates. 
A B 
C 
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4.5 Gene transcription and protein expression of cholesterol metabolism-
related molecules in E. bovis-infected host cells 
4.5.1 Establishment and validation of qPCR systems 
To calculate real-time qPCR efficiencies for each target gene, titration assays 
were performed covering at least 5 magnitudes orders of 10-fold dilutions of 
technical triplicates using respective plasmid DNA (Fig. 4.25.A). Using efficiency 
plots the efficiency of each system was estimated by plotting Ct values against 
plasmid DNA concentrations (Fig. 4.25.B). Overall, the Ct values ranged from 
10-30. The calculated qPCR efficiencies for each system ranged from 0.93-1.08 
(see Table. 4.1.). Since all qPCR systems exceeded an efficiency value of 0.9, 
respective assays were analyzed by the delta-delta Ct method (Livak and 
Schmittgen, 2001, Schmittgen and Livak, 2008). 
     
   
Fig. 4.1.25. Exemplary amplification (A) and efficiency (B) plot of titrational assays on the OLR1 qPCR 
system 
 
 
 
 
Fig. 4.25. Exemplary amplification (A) and efficiency (B) plot of titrational assays 
on the OLR1 qPCR system 
OLR1-plasmid-DNA titrations covering 5 magnitude orders of 10 fold dilutions were 
processed by realtime qPCR. Data were analyzed for amplification efficiency and 
illustrated by an amplification (A) and efficiency (B) plot. 
A B
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Table 4.1. qPCR efficiencies 
Target gene qPCR efficiency  
OLR1 0.97 
LDLR 1.00 
HMGCS1 0.93 
HMGCR 0.94 
SQLE 0.93 
CH25H 1.00 
SOAT1 0.93 
ACAT1 0.95 
ACAT2 1.08 
GAPDH 0.98 
 
Since the quality of the RNA is crucial for achieving meaningful and reproducible 
gene expression data, exemplary RNA samples were analyzed for integrity and 
purity in an Agilent bioanalyzer (exemplary illustration in Fig. 4.26.). All RNA 
samples tested achieved RIN values of > 8.5 indicating good RNA qualities 
(Fleige et al., 2006).  
  
Fig. 4.1.26. Exemplary illustration of total RNA samples being processed by an Agilent Bioanalyzer 
Fig 4.26. Exemplary illustration of total RNA 
samples being processed by an Agilent 
Bioanalyzer 
(A) RNA gel electrophoresis and (B) the 
corresponding electropherogram of RNA quality.  
A 
B 
Results 
 
82 
 
4.5.2 Transcriptional profiling of different molecules relevant for host 
cholesterol metabolism in E. bovis-infected BUVEC 
Host cell de novo biosynthesis of cholesterol is a multistep metabolic pathway 
involving more than 30 enzymatic reactions (see Fig. 4.27.). In these experiments 
transcriptional profiles of several relevant molecules were analyzed during E. 
bovis macromeront formation in vitro. 
 
Fig. 4.1.27. Host cell intracellular de novo synthesis and uptake of cholesterol via extracellular lipid 
sources and indication of molecules of interest in this investigation 
 
. 4. . Host cell intracellular de ovo synthesis and up ake of chol sterol via 
extracellular lipid sources and indication of molecules of interest in this 
investigation 
Modified according to Goldstein and Brown (1990), Vance and Vance (2004), Ikonen 
(2008).  
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For the formation of acetoacetyl-CoA representing an important substrate of the 
mevalonate biosynthesis pathway, ACAT1/ACAT2 activities are needed (Vance 
and Vance, 2004). Gene transcription profiles of E. bovis-infected BUVEC in 
times of macromeront formation revealed the highest and significant upregulation 
(p < 0.01) for both molecules at 17 days p. i. indicating a high demand of 
acetoacetyl-CoA when merozoites I are to be formed (Fig. 4.28.). Overall, the up-
regulation of ACAT1 gene transcripts (11.03 ± 2.53-fold) was higher than that of 
ACAT2 (4.41 ± 2.7-fold). 
    
   Fig. 4.1.28. Transcriptional pattern of the ACAT1 and ACAT2 genes during E. bovis macromeront 
formation in vitro 
 
 
The initial steps of the mevalonate pathway are catalyzed by HMGCS1 promoting 
the formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), and by HMGCR 
which is described as rate-limiting step of this pathway triggering mevalonate 
formation. Mevalonate is an essential intermediate for the biosynthesis of both, 
sterols and non-sterol isoprenoids which are critical for eukaryotic cell growth and 
proliferation (Goldstein and Brown, 1990). In contrast, SQLE-mediated squalene 
fomation represents the key step for cholesterol production (Buhaescu and 
Izzedine, 2007, Goldstein and Brown, 1990).  
The gene transcriptions of HMGCS1, HMGCR and SQLE were all found to be 
up-regulated during E. bovis macromeront formation (Fig. 4.29.). Significant 
reactions were detected at 17 and 20 days p. i. for all three molecules analyzed 
Fig .28. scriptional pattern of the ACAT1 and ACAT2 enes during E. bovis 
macromeront formation in vitro  
E. bovis-infected BUVEC were analyzed for ACAT1 and ACAT2 gene transcription at 
different time points of macromeront formation (12, 14, 17 and 20 days p. i.) applying 
realtime qPCR. Data represent means of three BUVEC isolates ± SD. 
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(HMGCS1: p < 0.05, HMGCR and SQLE: p < 0.01) and additionally for SQLE at 
20 days p. i. (p < 0.05) (Fig. 4.29.). These data explicitly indicate that E. bovis 
macromeront development interfers with the host cell de novo synthesis via the 
mevalonate biosynthesis pathway. Given that all molecules were equally found 
up-regulated, these reactions may mirror the strong need of the parasite for excess 
cholesterol synthesis. 
    
    
Fig. 4.1.29. Transcriptional pattern of the HMGCS1, HMGCR and SQLE genes during E. bovis macromeront formation in vitro 
Following de novo synthesis, cholesterol may either be recycled to the membranes 
or be detoxified [excess of free cholesterol molecules is toxic for eukaryotic cells, 
(Tabas, 2002)] via further enzymatic steps. Therefore it is rapidly esterified by 
SOAT1 or hydroxylized via CH25H (for review see Ikonen, 2008).  
 
Analyses on E. bovis-infected BUVEC revealed that both pathways of cholesterol 
processing were up-regulated at times of macromeront formation (Fig. 4.30.). 
Thus, SOAT1 gene transcripts were found significantly increased for 3.31- and 
10.2-fold at 14 and 17 days p.i. ( both p < 0.01), respectively, when compared to 
Fig. 4.29. Transcriptional pattern of 
the HMGCS1, HMGCR and SQLE 
genes during E. bovis macromeront 
formation in vitro  
E. bovis-infected BUVEC were analyzed 
for HMGCS1, HMGCR and SQLE gene 
transcription at different time points of 
macromeront formation (12, 14, 17 and 
20 days p. i.) applying realtime qPCR. 
Data represent means of three BUVEC 
isolates ± SD. 
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non-infected controls. Since cholesteryl esters are stored in LD, these results 
indirectly confirmed the data on enhanced LD genesis in E. bovis-infected host 
cells (see 4.2.2). The overall strongest up-regulation of all gene transcripts tested 
was measured for CH25H (Fig. 4.30.). Hence, significant enhancements of gene 
transcription were detected at days 14, 17 and 20 p. i. (p < 0.0001, p < 0.0001, p < 
0.01, respectively) suggesting a crucial role of 25-hydroxycholesterol (25-HCH) 
synthesis in the development of E. bovis macromeronts. 
      
Fig. 4.1.30. Transcriptional pattern of the SOAT1 and CH25H genes during E. bovis macromeront 
formation in vitro 
 
 
 
Besides being synthesized via the mevalonate pathway, cholesterol is also 
incorporated by cells from exogenous sources via LDL (Brown and Goldstein, 
1986). LDL-mediated cholesterol internalization is a receptor-dependent process 
involving LDLR (present on most cell types) or scavenger receptors, which are 
restricted to certain mammalian cell types (Twigg et al., 2012). Analyzing LDLR 
and OLR1, we accounted for two molecules being known to be involved in the 
receptor-mediated pathway.  
 
Transcriptional profiling of LDLR and OLR1 in E. bovis-infected host cells 
showed significantly enhanced mRNA levels for both molecules (Fig. 4.31.). 
Compared to non-infected controls, significant reactions were detected for LDLR 
at 12 and 17 days p. i. (both p < 0.01, respectively) reaching an up to 9.49-fold 
Fig. 4.30. Transcriptional pattern of the SOAT1 and CH25H genes during E. bovis 
macromeront formation in vitro  
E. bovis-infected BUVEC were analyzed for SOAT1 and CH25H gene transcription at 
different time points of macromeront formation (12, 14, 17 and 20 days p. i.) applying 
realtime qPCR. Data represent means of three BUVEC isolates ± SD. 
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increase. OLR1 gene transcripts were significantly enhanced during the entire 
period of investigation, i. e. throughout total meront I formation (12, 17 and 20 
days p. i.: p < 0.01, 14 days p. i.: p < 0.5, Fig. 4.31.) reaching an average of up to 
7-fold increase in E. bovis infected cells.  
      
Fig. 4.1.31. Transcriptional pattern of the LDLR and OLR1 genes during E. bovis macromeront 
formation in vitro 
 
 
 
Overall, the gene transcription data strongly suggest that E. bovis expoits both 
mechanisms of cholesterol acquisition, i. e., host cell de novo synthesis and 
receptor-mediated internalization of extracellular lipid sources. 
  
ig. 4.31. Transcriptional pattern of the LDLR and OLR1 genes during E. bovis 
macromeront formation in vitro  
E. bovis-infected BUVEC were analyzed for LDLR and OLR1 gene transcription at 
different time points of meront I formation (12, 14, 17 and 20 days p. i.) applying 
realtime qPCR. Data represent means of three BUVEC isolates ± SD. 
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4.5.3 Protein expression of ACAT1, CH25H, OLR1 and SOAT1 in E. bovis-
infected BUVEC 
To confirm the transcriptional data on protein level, the expression levels of 
ACAT1, CH25H, OLR1 and SOAT1 were determined via semiquantitative 
Westernblot analysis in E. bovis-infected BUVEC and in non-infected control 
cells in parallel. Therefore, the date of maximum gene transcript up-regulation (17 
days p. i.) was chosen. Given that only a limited panel of commercial antibodies is 
available in the bovine system, we had to restrict our analyses on ACAT1, 
CH25H, OLR1 and SOAT1. As illustrated in Fig. 4.32. ACAT1, CH25H, OLR1 
and SOAT1 protein expressions were all found up-regulated in E. bovis-infected 
BUVEC at times of meront I formation confirming previous transcriptional data 
(see 4.5.2). The most prominent signals were observed for CH25H, which is also 
in agreement with gene transcription profiles. It is worth noting, that ACAT1, 
CH25H and SOAT1 were expressed at a low level in non-infected cells, whilst 
OLR1 showed strong signals already in the controls indicating a general high 
abundance of this scavenger receptor in the endothelial cell type.  
 
Fig. 4.1.32. ACAT1, CH25H, OLR1 and SOAT1 expression in E. bovis-infected cells 
  
Fig. 4.32. ACAT1, CH25H, OLR1 and SOAT1 expression in E. bovis-infected cells 
E. bovis-infected BUVEC (17 days p. i., n = 3) were harvested for total protein isolation and 
processed by Western blot analysis applying primary antibodies directed against ACAT1, 
CH25H, OLR1 and SOAT1. Figure shows an expemplary Western blots of ACAT1, CH25H, 
OLR1 and SOAT1 expression. 
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4.6 Inhibition of E. bovis in vitro development by interference with the 
mevalonate biosynthesis pathways and fatty acid synthesis 
4.6.1 Evaluation of adequate inhibitor concentrations 
Given that primary endothelial cells generally react very sensitive and do not 
tolerate common inhibitor concentrations, we here performed cytotoxicity assays 
for each inhibitor (lovastatin, zaragozic acid, CI976 and C75). As depicted in Fig. 
4.33. high mortality rates were induced in BUVEC by concentrations ranging 
from 200 to 12.5 µM irrespective of the type of inhibitor. Whilst a concenctration 
of 6.25 µM of zaragozic acid, CI976 and C75 treatments induced little cell death 
in BUVEC, lovastatin concentrations had to be lowered to 1.58 µM to achieve 
comparable effects (Fig. 4.33.C). Considering these results, the following 
inhibitor concentrations were chosen for E. bovis-related inhibition experiments: 
1 µM for lovastatin and 5 µM for zaragozic acid, CI976 and C75 treatments. 
 
Fig. 4.1.33. Cytotoxicity of CI976 (A), zaragozic acid (B), lovastatin (C) and C75 (D) for BUVEC 
 
Fig. 4.33. Cytotoxicity of CI976 (A), zaragozic acid (B), lovastatin (C) and C75 (D) 
for BUVEC 
BUVEC were treated with different concentrations of lovastatin, zaragozic acid, CI976 
and C75 for indicated days before being processed for MTT test. 
A B 
C D 
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4.6.2 Establishment of Ebmic4-based qPCR for merozoites I quantification 
To avoid laborious manual counting of offspring production, an Ebmic4-based 
realtime qPCR was established for merozoite I quantification. Therefore, 
efficiency and sensitivity analyses were performed. To calculate the qPCR 
efficiency, titration assays were performed covering at least 6 magnitudes orders 
of 10-fold dilutions of DNA derived from manually pre-counted merozoites I 
(ranging from 1.6 x 106 - 1.6 x 101 specimens) and of plasmid DNA (Fig. 4.34.). 
The efficiency of the Ebmic4-PCR system was estimated by plotting Ct values 
against DNA concentrations (Fig. 4.34.).  
 
Fig. 4.1.34.Efficiency plots of the Ebmic4-specific qPCR system 
 
 
 
For both sample types the Ebmic4-based qPCR proved high efficiency. Thus, 
PCR efficiencies ranged from 0.99 to 1.11 (r2: 0.97-0.99) when using plasmid 
DNA as template and from 0.93-1.03 (r2: 0.98-0.99) when merozoite I DNA was 
tested. Addionally, the Ebmic4-based PCR system showed a high sensitivity since 
at least 6 plasmids and 2 merozoites I were detected in a 5 µl-sized sample (this 
volume was generally applied per reaction in respective PCR experiments).  
Furthermore, the reproducibility of the standard curves was good as tested by 
three independent titration experiments using merozoite I DNA (Fig. 4.35.A). In 
general, a titration of merozoite I DNA was included in each PCR experiment as 
Fig. 4.34. Efficiency plots of the Ebmic4-specific qPCR system 
Merozoite I (A) and Ebmic4 plasmid (B) DNA titrations covering 6 magnitude orders of 
10 fold dilutions were processed by Ebmic4-specific realtime qPCR. Data were analyzed 
for amplification efficiency and illustrated by efficiency plots.
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standard. As depicted in Fig. 4.35.C, the Ct values of randomly chosen, culture-
derived test samples fitted well to those of the standard curve and allowed for 
reliable merozoite I quantification. 
      
   
Fig. 4.1.35. Merozoite I-based standard curve amplification and reproducibility and offspring 
quantification in test samples 
 
Fig. 4.35. Merozoite I-based standard curve amplification and reproducibility 
and offspring quantification in test samples 
(A) Amplification plot of 10-fold dilutions of merozoites I ranging from 1.6 x 106- 
1.6 x 101 specimens, (B) Ct values of three independent titration experiments plotted 
against merozoite numbers, (C) Comparative plot of Ct values of exemplary test 
samples (red quarders) plotted on standard Ct values (blue quarders).  
A 
B 
C 
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4.6.3 Inhibition of HMGCoA reductase 
Lovastatin treatments of E. bovis-infected BUVEC exhibited significant effects on 
both, the rate and the size of developing macromeronts (Fig. 4.36.). As such, the 
rate of cells carrying developing macromeronts was significantly lower in treated 
cultures compared to non-treated ones at most time point tested (10, 26 and 30 
days p.i.: p < 0.01; 14, 18 and 22 days p. i.: p < 0.0001, Fig. 4.36.) indicating an 
arrest of development and degradation of E. bovis meronts (for illustration see 
Fig. 4.36.B). In fact, the rate of meront carrying host cells was below 2 % at 30 
days p. i. compared to 8.2 % in the controls (Fig. 4.36.). Also the growth of 
meronts was arrested by lovastatin treatments and, consequently, the meront sizes 
did not improve any further towards the end of the incubation period (14 days p.i.: 
p < 0.05; 22 days p.i: p < 0.01; 18, 26 and 30 days p.i.: p < 0.0001, Fig. 4.36.).  
 
Fig. 4.1.36. E. bovis macromeront development in lovastatin-treated BUVEC cultures 
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In addition, lovastatin treatments effectively inhibited the E. bovis merozoite I 
production (Fig. 4.37.). These effects were dose-dependent since increasing 
concentrations of lovastatin showed enhanced effects on parasite replication (Fig. 
4.37.A). Thus, significant effects were determined at lovastatin concentrations of 
≥ 0.05 µM (0.05 µM: p < 0.05, 0.1 µM: p < 0.01, 0.5 µM and 1 µM: p < 0.0001). 
Compared to non-treated controls, a reduction of 99.6 ± 0.1% of total merozoite I 
production was achieved via lovastatin (1 µM) treatment. Based on the inhibition 
of merozoite production an IC50 of 0.1 µM (r2 = 0.9) was calculated for lovastatin 
treatments (Fig. 4.37.B). 
  
Fig. 4.1.37. Effects of lovastatin treatment on the merozoite I production 
  
Fig. 4.36. E. bovis macromeront development in lovastatin-treated BUVEC cultures 
E. bovis-infected BUVEC (n = 5) were treated with lovastatin (1 µM) from 1 day p. i. 
onwards (B) and compared to non-treated E. bovis-infected cultures (A). The effects of 
treatment (C) were assessed microscopically by estimating the rate of macromeront-
carrying host cells (black bars: lovastatin-treated infected cells, white bars: non-treated 
infected controls) and by measuring the size of developing macromeronts (black circles: 
treated cultures, open circles: controls). (A) and (B) show exemplary illustrations of 
non-treated and treated E. bovis-infected (17 days p. i.) BUVEC, respectively. Scale 
bars: 20 µm. 
ig.4.37 ffects of lov statin tr atment on the merozoite I production 
E. bovis-infected BUVEC (n = 5) were treated with different doses of lovastatin and 
assessed for merozoite I production (A) using Ebmic4-based qPCR (see 3.7.2.). To 
calculate the IC50 of lovastatin treatment, inhibitor doses were plotted against the 
respective reduction of merozoite I production (relative to non-treated, E. bovis-infected 
cultures). 
A B 
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4.6.4 Inhibition of squalene synthase 
Treatments of E. bovis-infected BUVEC with zaragozic acid also resulted in a 
significant reduction of the rates of host cells carrying developing macromeronts 
and in significantly decreased macromeront sizes (Fig. 4.38.) underlining the key 
role of the cellular de novo cholesterol biosynthesis for successful parasite 
replication. The overall effects of zaragozic acid supplementation appeared less 
prominent than those induced by lovastatin treatment. Thus, the enlargement of 
developing macromeronts moderately improved with ongoing in vitro culture and 
significant differences in comparison to non-treated controls were achieved only 
towards the end of macromeront maturation from 26 days p. i. onwards (26 days 
p.i.: p < 0.0001; 30 days p. i.: p < 0.01, Fig. 4.38.). In addition, zaragozic acid 
treatment had less dramatic effects on infection rates at the meront stage than 
lovastatin treatments (14, 18 and 26 days p.i.: p < 0.01; 22 days p.i.: p < 0.0001, 
Fig. 4.37.). Nevertheless, we observed a significant inhibition of macromeront 
formation and clear detrimental effects on macromeront development as 
visualized by meront shrinkage and blebbing (for illustration, see Fig. 4.38.B).  
 
Fig. 4.1.38. E. bovis macromeront development in zaragozic acid-treated BUVEC cultures 
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In addition, the total merozoite I production of infected host cells was 
significantly inhibited in zaragozic acid treated cultures (Fig. 39.B). This effect 
proved to be dose-dependent (2.5 µM: p < 0.01; 5 µM:p < 0.0001) and resulted in 
a 70.2 ± 11.6% reduction, when zaragozic acid was applied at 5 µM final 
concentration (Fig. 39.B). Based on the inhibition of merozoite I production we 
calculated an IC50 of 3.32 µM (r2= 0.96) for zaragozic acid treatment. 
    
Fig. 4.1.39. Effect of zaragozic acid treatment on the merozoite I production 
 
 
 
  
Fig. 4.38. E. bovis macromeront development in zaragozic acid-treated BUVEC 
cultures 
E. bovis-infected BUVEC (n = 5) were treated with zaragozic acid (5 µM) from 1 day p. 
i. onwards (B) and compared to non-treated E. bovis-infected cultures (A). The effects of 
treatment (C) were assessed microscopically by estimating the rate of macromeront-
carrying host cells (black bars: zaragozic acid -treated infected cells, white bars: non-
treated infected controls) and by measuring the size of developing meronts (black 
circles: treated cultures, open circles: controls). (A) and (B) show exemplary illustrations 
of non-treated and treated (note strong degradation as indicated by arrows) E. bovis-
infected (17 days p. i.) BUVEC, respectively. Scale bars: 20 µm (A) and 10 µm (B). 
ig. 4.39. Effect of zaragozic acid treatment on the merozoite I production 
E. bovis-infected BUVEC (n = 5) were treated with different doses of zaragozic acid and 
assessed for merozoite I production (A) using Ebmic4-based qPCR (see 3.7.2). To 
calculate the IC50 of zaragozic acid treatment, inhibitor doses were were plotted against 
the respective reduction of merozoite I production (relative to non-treated, E. bovis-
infected cultures). 
A B
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4.6.5 Inhibition of acyl-CoA cholesterol acyltransferase 
Treatments with CI976 were applied to inhibit cholesterol esterification within 
infected host cells via blockage of acyl-CoA cholesterol acyltransferase. We here 
chose two different time points of treatment onset with 1 and 10 days p. i. in order 
to affect both, trophozoite and macromeront formation.  
Overall, both CI976 treatments led to an arrest of parasite development (treatment 
since 1 day p.i.= 10 and 14 days p.i.: p < 0.01; 18, 22, 26 and 30 days p. i.: p < 
0.0001; treatment started from 10 days p.i.= 18 and 22 days p.i: p < 0.01; 26 and 
30 days p.i.: p < 0.0001, Fig. 4.40.) since no significant development or 
macromeront growth was observed throughout the investigation period compared 
to control monolayers (for illustration see Fig. 4.40.B, C). When treatment started 
at 1 day p. i. sporozoites failed to develop any further and occasionally showed an 
untypically enlarged, round-shaped PV being accompanied by a cashew-shaped 
distorsion of the host cell nucleus (Fig. 4.40.C). In macromeronts being arrested 
in their development via CI976 treatment beginning at 10 days p. i., we 
consistently observed persistent round-shaped bodies within the macromeronts 
(Fig. 4.40.B) that may be considered as remaining refractile bodies of the parasite 
and, as such, are not visible in non-treated controls. Besides macromeront 
formation, CI976 treatments effectively inhibited merozoite I production in a 
dose-dependent manner (5 µM, 2.5 µM and 0.5 µM: p < 0.0001; 0.25 µM: p < 
0.01; 0.05 µM: p < 0.05, Fig. 4.42.). Thus, increasing concentrations of CI976 led 
to a significant diminishment of parasite proliferation. Based on the inhibition of 
merozoite I production we calculated an IC50 of 0.34 µM (r2= 0.98) for CI976 
treatment. 
Fig. 4.40. E. bovis macromeront development in CI976-treated BUVEC cultures 
E. bovis-infected BUVEC (n = 5) were treated with CI976 (5 µM) from day 1 (C) or 10 
(B) p. i. onwards and compared to non-treated E. bovis-infected cultures (A). The effects 
of treatment (D) were assessed microscopically by estimating the rate of macromeront-
carrying host cells (black bars: day 1 p. i. onwards, grey bars: 10 day 1 p. i. onwards, 
white bars: controls) and by measuring the size of developing meronts (black triangles:  
day 1 p. i. onwards, black circles: 10 day 1 p. i. onwards, white circles: controls). A-C 
show exemplary illustrations of non-treated and treated (B: from 1 day p. i. and C: from 
10 days p.i. onwards) E. bovis-infected (17 days p. i.) BUVEC, respectively. Scale bars: 
20 µm. 
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Fig. 4.1.40. E. bovis macromeront development in CI976-treated BUVEC cultures 
Inhibition of macromeront maturation via CI976 treatment coincided with reduced 
LD/neutral lipid (NL) deposition in infected host cells as confirmed by Nile red 
staining (Fig. 4.41.). Thus, non-treated E. bovis-infected host cells showed 
significantly increasing accumulation of LD-/NL-rich areas (p < 0.0001) with 
ongoing in vitro macromeront growth (Fig. 4.41.D). In contrast, CI976 treatments 
led to an immediate abrogation of LD/neutral lipid deposition irrespective of the 
onset of CI976 supplementation. In addition, throughout treatment, LD/NL 
deposition did not recover and remained on the same low level (Fig. 4.41.D). 
Microscopic analyses revealed a spotty appearance of LD-/NL-rich areas within 
infected control host cells carrying mature meronts (Fig. 4.41.A), whilst in treated 
Results 
 
97 
 
ones the reaction pattern were more homogeneous in immature meronts (Fig. 
4.41.B) or were restricted to the refractile bodies of intracellular sporozoites (Fig. 
4.41.C), all being arrested in their development when treatment was applied at 1 
or 10 days p. i., respectively. 
 
 
Fig. 4.1.41. Effects of CI976 treatments on lipid droplet (LD) deposition in E. bovis infected host cells 
  
 
 
Fig. .41. fects of CI976 treatments on lipid dro let (LD) deposition in E. bovis 
infected host cells 
E. bovis-infected BUVEC were treated with CI976 (5 µM) from days 1 and 10 p. i. 
onwards. At different time points after infection (2, 4, 6, 10, 14, 18 days p. i.), cells were 
stained with Nile red for LD detection (for illustration see A: non-treated controls, 18 days 
p. i.; B: infected cells treated with CI976 from 10 days p. i. onwards, 18 days p. i.; C: 
infected cells treated with CI976 from 1 days p. i. onwards, 18 days p. i.). The amount of 
LDs (D) was estimated on single cell level via software-assisted measurements of 
fluorescence intensities in 10 cells per infected sample. 
Results 
 
98 
 
     
Fig. 4.1.42. Effects of CI976 treatment on the merozoite I production 
 
 
 
 
4.6.6 Inhibition of fatty acid synthase 
The compound C75 blocks fatty acid synthesis thereby interacting indirectly with 
cholesteryl ester synthesis. Overall, the C75-treatment of E. bovis-infected host 
cells resulted in a significantly reduced parasite growth as estimated by 
macromeront sizes (10, 14 and 22 days p. i.: p < 0.01; 18,  26 and 30 days p. i: p < 
0.0001, Fig. 4.43.). However, although this effect was earlier observed than in 
zaragozic acid treatments (Fig. 4.38.), the sizes slightly recovered beginning with 
22 days p. i. but did not reach the values of the non-treated controls. Furthermore, 
the rate of cells carrying developing macromeronts was significantly lower in 
treated cultures when compared to non-treated ones from 18 days p. i. onwards 
(18, 22 and 26 days p.i.: p < 0.01, Fig. 4.43.) indicating macromeront degradation. 
Accordingly, microscopic analyses revealed a strong vacuolization of the 
macromeronts (Fig. 4.43.B).  
Fig. 4.42. Effects of CI976 treatment on the merozoite I production 
E. bovis-infected BUVEC (n = 5) were treated with different doses of CI976 and 
assessed for merozoite I production (A) using Ebmic4-based qPCR (see 3.7.2.). To 
calculate the IC50 of CI976 treatment, inhibitor doses were plotted against the respective 
reduction of merozoite I production (B) (relative to non-treated, E. bovis-infected 
cultures). 
A B
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Fig. 4.1.43. macromeront development in C75-treated BUVEC cultures 
 
Fig. 4.43. E. bovis macromeront development in C75-treated BUVEC cultures 
E. bovis-infected BUVEC (n = 5) were treated with C75 (5 µM) from 1 day p. i. onwards 
(B) and compared to non-treated E. bovis-infected cultures (A). The effects of treatment 
(C) were assessed microscopically by estimating the rate of macromeront-carrying host 
cells (black bars: C75-treated infected cells, white bars: non-treated infected controls) 
and by measuring the size of developing meronts (black circles: treated cultures, open 
circles: controls). (A) and (B) show exemplary illustrations of non-treated and C75-
treated (note strong vacuolization as indicated by arrows) E. bovis-infected (17 days p. i.) 
BUVEC, respectively. Scale bars: 20 µm. 
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In addition, C75 treatments effectively inhibited merozoite I production in a dose-
dependent manner (Fig. 4.44.). Thus, increasing concentrations of C75 led to a 
significant diminishment of parasite proliferation (5 and 2.5 µM: p <0 .0001; 0.5 
µM: p < 0.01; 0.25 µM: p < 0.05). The C75 treatments resulted in a marked 
reduction of merozoite I production (84.6 ± 5.32%), when being applied at 5 µM 
final concentration. Based on the inhibition of merozoite I production we 
calculated an IC50 of 1.28 µM (r2= 0.97) for C75 treatment. 
  
Fig. 4.1.44. Effects of C75 treatment on the merozoite I production 
 
 
 
Overall, all compounds tested in this investigation showed significant efficacies 
against E. bovis when estimated on the level of merozoite I production inhibition. 
The comparison of the dose-effect-curves and respective IC50 values revealed 
lovastatin as the most effective compound, being followed by CI976, C75 and 
zaragozic acid. 
i . 4.  fects of C75 treatment on the merozoite I production 
E. bovis-infected BUVEC (n = 5) were treated with different doses of C75 and assessed 
for merozoite I production (A) using Ebmic4-based qPCR (see 3.7.2.). To calculate the 
IC50 of C75 treatment, inhibitor doses were plotted against the respective reduction of 
merozoite I production (B) (relative to non-treated, E. bovis-infected cultures). 
A B 
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5 Discussion 
 
 
5.1 Free cholesterol and lipid droplets accumulate in E. bovis-infected host 
cells and reveal as key factors of parasite replication 
Within the first merogony, E. bovis forms macromeronts in lymphatic endothelial 
host cells. During this developmental phase, the host cell is heavily enlarged since 
intracellular mature macromeronts may account for up to 400 µm (Hammond et 
al., 1946, Hammond et al., 1966) inducing a 10-15-fold aggrandisement of the 
host cell. Additionally, more than 120,000 merozoites I may be formed 
(Hammond et al., 1946). These developmental features all bear an enormous 
demand for cholesterol. Overall, cholesterol is needed for three main reasons: i) 
the massive enlargement of the host cell membrane, ii) the formation and 
enlargement of the PV and iii) the formation of large numbers of merozoites I. 
5.1.1 Free cholesterol accumulation in parasite stages 
In order to reveal free cholesterol existence and distribution within E. bovis stages 
filipin staining was used. Filipin forms a complex with free 3′-OH-groups of 
cholesterol and is routinely used as a tracer for free cholesterol (Gimpl and 
Gehrig-Burger, 2011). For this purpose it has also been applied for some other 
apicomplexan parasites, such as Plasmodium yoelii, T. gondii or C. parvum 
(Coppens and Joiner, 2003, Labaied et al., 2011, Ehrenman et al., 2013). 
In the case of E. bovis, sporozoites and merozoites I were intensively labelled in 
their apical part and in their outer membrane, indicating that cholesterol is not 
homogenously distributed within the parasite but predominantly occurs within the 
apical complex and the pellicle. In contrast to P. yoelii free sporozoites lacking 
filipin staining (Labaied et al., 2011), this is in line with tachyzoites of T. gondii, 
where cholesterol is enriched in the anterior apical complex exhibiting a high 
cholesterol/phospholipid ratio of 1.5/1 (Foussard et al., 1991b). Within this 
complex, cholesterol appears to accumulate in the rhoptries. Thus, the 
cholesterol/phopholipid ratio in these organelles was higher than in the total 
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tachyzoite (Foussard et al., 1991b). In agreement, rhoptry-enriched fractions of 
purified T. gondii tachyzoites also identified cholesterol as the most abundant 
lipid component (Besteiro et al., 2008). However, T. gondii rhoptries do not 
appear to function as cholesterol-storing organelles since filipin-derived reactions 
originated mainly from the basal bulbous portions of rhoptry membranes whilst 
their lumen was free of cholesterol (Coppens and Joiner, 2003). Furthermore, by 
considering the apical organelle distribution, the signals in E. bovis stages may 
additionally have originated from dense granules since these organelles have also 
been reported as filipin-positive in T. gondii tachyzoites (Coppens and Joiner, 
2003). Unfortunately, laser-assisted fluorescence-based microscopic analyses 
allowing for higher resolution and thereby for organelle identification cannot be 
performed using filipin-stained samples owing to the fast bleaching of this 
compound. Nevertheless, the reaction pattern of E. bovis merozoites I were rather 
similar to those of newly egressed tachyzoites of T. gondii which exhibit 
prominent filipin signals in the nascent apical complex and in the remaining 
residual body of the mother cell (Coppens et al., 2000). 
The outer membrane of E. bovis sporozoites and merozoites I also reacted with 
filipin indicating free cholesterol to be located in the pellicula. Overall, these 
reactions were consistant but rather weak when compared to the signals of the 
apical region suggesting rather low contents of free cholesterol in the pellicle. In 
line with these findings, tachyzoites of T. gondii exhibited similar reaction 
patterns (Coppens and Joiner, 2003) and purified pellicles of tachyzoites showed 
low free cholesterol contents since the cholesterol/phospholipid ratios were rather 
low (0.2-0.36), indicating a high level of fluidity of these membranes (Foussard et 
al., 1991a, b). Furthermore, filipin-derived fluorescence of E. bovis sporozoite and 
merozoite I outer membranes appeared rather heterogenous suggesting areas of 
cholesterol-rich microdomains as generally observed in the eukaryotic system 
(Albert, 2008). In agreement, transmission electron microscopic analyses showed 
discontinued filipin/sterol complexes in the parasite plasma membrane and inner 
membrane complex of T. gondii tachyzoite pellicles (Coppens and Joiner, 2003). 
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After host cell invasion, E. bovis sporozoites are generally located close to the 
host cell nucleus. One day after infection, an intense filipin labelling was observed 
in the area directly surrounding newly invaded sporozoites. Owing to insufficient 
microscopic resolution it cannot be concluded whether these reactions origin from 
the PV space, the PVM or from host cell-derived organelles, such as mitochondria 
or lysosomes which are known to be recruited in high numbers close to the PV in 
the case of T. gondii (Sinai and Joiner, 2001, Coppens et al., 2006) or E. bovis (C. 
Hermosilla, personnel observation). However, the occasionally hackly, non-
circular appearence of filipin-positive areas surrounding the sporozoite rather 
argues against a sole PV origin. 
As intracellular stage, E. bovis resides within its obligatory PV. In general, the PV 
lumen of coccidians is filled with electron dense material, intravacuolar tubules 
and structures extending from the PV membrane (Dubremetz and Elsner, 1979). 
The PV enlarges with ongoing development and often surpasses the original size 
of the host cell (Beyer et al., 2002, Entzeroth et al., 1998, Hermosilla et al., 2002, 
Ruiz et al., 2010). E. bovis macromeronts exhibit differential morphologies in in 
vitro cultures (Hermosilla et al., 2002). Some macromeronts contain several 
septae that may originate from PVM protrusions. In the current experiments both, 
the PV and meront-derived septae exhibited strong filipin staining in developing 
macromeronts. In principle, this is in accordance to findings on T. gondii showing 
that the PVM contains cholesterol (Coppens and Joiner, 2003). In addition, the PV 
of P. yoelli, P. berghei and C. parvum merozoite membranes revealed filipin-
positive reactions (Labaied et al., 2011, Ehrenman et al., 2013). However, it has to 
be kept in mind that in contrast to TEM-based findings of clearly defined 
organelles and membranes bearing filipin-derived signals in the case of T. gondii 
(Coppens and Joiner, 2003), a clear distinguishment between the host cell 
membrane, PVM, PV space or even the inner part of the developing macromeront 
can not be performed based on the current experiments. Nevertheless, it is 
undoubted that enhanced levels of free cholesterol are detected in infected host 
cells compared to non-infected controls. Furthermore, the total intensities of 
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filipin signals per host cell representing free cholesterol accumulation appeared to 
increase with the ongoing E. bovis macromeront maturation process leading to the 
most intense reactions in fully mature macromeronts. It is tempting to speculate 
that this phenomenon directly mirrors the parasites need for cholesterol for the PV 
enlargement and numerous offspring assembly. Quantitative analyses on 
cholesterol contents (free + esterified form) ascertained the general phenomenon 
of cholesterol accumulation in E. bovis-infected host cells and quantitatively 
confirmed the qualitative impression of increasing cholesterol deposition 
paralleling ongoing macromeront maturation. Given that the parasite is in need of 
cholesterol for successful development, we used cholesterol- and desmosterol- (a 
cholesterol precursor) supplemented cell culture medium to enrich host cells prior 
to and throughout infection. In accordance to T. gondii (Coppens et al., 2000), 
excess exogenous cholesterol resulted in significantly enhanced offspring 
production confirming the key role of high cholesterol abundance for successful 
E. bovis macromeront development.  
Pulse-labelling analyses using the fluorescent cholesterol analogue dansyl 
cholesterol demonstrated the capacity of E. bovis sporozoites to incorporate and 
distribute free cholesterol to diverse compartments, i. e., to the plasma membrane, 
the apical complex and to the refractile bodies. Since refractile bodies have 
previously been shown to lack free sterols by filipin staining, these data suggested 
that E. bovis may use free sterols either as substrate to form cholesteryl esters or 
directly integrate them in several membraneous structures. Even more evidence of 
differential parasite-driven cholesterol utilization was shown by pulse-labelling 
experiments of meront-carrying host cells where fluorescence was clearly detected 
in LD-like structures indicating that dansyl-cholesterol served as substrate for 
cholesteryl ester formation and subsequent deposition in LDs. These data are in 
accordance to findings in T. gondii-infected cells showing that NBD-cholesterol 
was inserted into tachyzoite membranes but was also modified and found in LD-
like cytoplasmic structures (Charron and Sibley, 2002). In contrast, in P. yoelii 
and P. berghei-infected hepatocytes NBD-cholesterol occurred the developing 
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schizonts (Labaied et al., 2011) but was not utilized for cholesteryl ester 
production (Nawabi et al., 2003, Palacpac et al., 2004, Vielemeyer et al., 2004). 
Intracellular life of E. bovis sporozoites begins with active host cell invasion. To 
assess the role of cholesterol in the initial phase of intracellular parasitism, host 
cell-or parasite-derived cholesterol was depleted by MBCD treatments prior to 
infections and the effects on subsequent infection rates were observed. Indeed, 
host cell cholesterol depletion resulted in significantly reduced infection rates 
when compared to non-treated control cells indicating a certain role of host cell-
derived cholesterol in parasite invasion and intracellular establishment. Thus, in 
line with other apicomplexa (Suss-Toby et al., 1996, Lauer et al., 2000, Coppens 
et al., 2003, Sinai, 2008) host cell-derived cholesterol may be involved in E. bovis 
PV formation. Indeed, we could show that by exclusively labelling host cell 
cholesterol with rhodamin cholestanol prior to infection, cholesterol of host cell 
origin was detected in close proximity to the sporozoite, most probably within the 
PV. In agreement, other studies showed that host cell cholesterol or cholesterol-
rich domains of host cells (lipid rafts) are important for intracellular establishment 
of several parasites. Thus, cellular lipid raft alteration reduced T. gondii invasion 
in macrophages and epithelial cells (Cruz et al., 2013) and MBCD treatments of 
fibroblast also diminished T. gondii invasion (Coppens and Joiner, 2003). 
Furthermore, Plasmodium merozoites were shown to integrate lipids derived from 
the erythrocyte membrane into the nascent PV (Ward et al., 1993) and MBCD-
treated Vero and HeLa cell lines revealed less succeptible for T. cruzi invasion 
(Fernandes et al., 2007). Cholesterol depletion from macrophage plasma 
membranes via MBCD also resulted in a significant reduction in the extent of 
leishmanial infection (Pucadyil et al., 2004). 
E. bovis sporozoite cholesterol depletion also had a significant impact on active 
parasite host cell invasion. Referring to subsequent infection rates, the effects of 
parasite depletion accounted even higher than those of host cell depletion 
although sporozoite viability was not affected by MBCD treatment. Given that 
MBCD treatments do not only alter plasma membrane cholesterol contents but 
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may also affect cholesterol present at endocellular membranes (Zidovetzki and 
Levitan, 2007), respective treatments of sporozoites may have altered the 
membrane integrity of organelles which are required for gliding motility and 
invasion, such as micronemes or rhoptries. Since rhoptries are known to 
contribute to PV formation (Nichols et al., 1983, Porchet-Hennere and Nicolas, 
1983, Carruthers and Sibley, 1997) and have been reported to contain cholesterol 
(Besteiro et al., 2008), Coppens and Joiner (2003) investigated the role of rhoptry 
cholesterol in PV formation and showed that these molecules are not necessary for 
PVM formation whilst host cell plasma membrane-derived cholesterol is 
incorporated into the forming PVM during invasion. In contrast, it rather seems to 
be involved in membrane plasticity and protein translocation during the invasion 
process (Besteiro et al., 2008, Ngo et al., 2004).  
 
5.1.2 Lipid droplet formation in parasite stages and infected host cells 
To account for neutral lipids, E. bovis free stages were stained by Nile Red, 
osmium tretroxide and bodipy 493/503. Respective reaction patterns differed 
entirely from those induced by filipin staining suggesting a differential 
distribution of free cholesterol and neutral lipids in E. bovis sporozoites and 
merozoites I. Thus, neutral lipids exclusively occurred in the refractile bodies of 
sporozoites (merozoites generally lack refractile bodies) and in cytosolic LD-like 
structures of sporozoites and merozoites I. This is in line with observations on 
E. tenella sporozoites (Lemgruber and Lupetti, 2012, de Venevelles et al., 2006) 
and with reports on LDs in the cytoplasm of T. gondii tachyzoites (Coppens et al., 
2000, Sonda et al., 2001, Charron and Sibley, 2002). As described for T. gondii 
tachyzoites, containing 1-4 LDs per cell (Coppens et al., 2000, Sonda et al., 2001), 
E. bovis sporozoites and merozoites I-derived LDs also differed in their numbers 
accounting for up to 8 LDs per specimen. Given that the parasite expresses LDs 
itself, it is likely to assume that these organelles play a role in parasite lipid 
homeostasis. The fact that intracellular C. parvum merozoites form large cytosolic 
LDs in response to excess LDL in the cell culture medium (Ehrenmann et al., 
2013) confirms that coccidian parasites principally are equipped to store lipids 
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and that they may benefit from lipid super abundance by actively forming new or 
larger LDs. 
Neutral lipid/LD abundance also revealed as key factor in E. bovis intracellular 
stages. Overall, a striking stage-dependent increase of LD formation was observed 
throughout macromeront development. Shortly after invasion, the refractile bodies 
of the sporozoites still showed strong Nile Red/bodipy 493/503 staining but, 
interestingly, the numbers of refractile bodies per intracellular parasite stage were 
reduced, i. e., only the posterior refractile body seemed to persist in infected cells. 
This is in line with other authors describing that, after sporozoite invasion, the 
anterior refractile body may either be divided into several small refractile bodies 
or the anterior refractile body might fuse with the posterior refractile body 
(Roberts and Hammond, 1970, Hammond et al., 1970, Dubremetz and Elsner, 
1979). So far, the reason for refractile body disappearance is not known, however, 
it may be related to the parasites needs for lipids even in the early phase of 
development. 
The induction of LD formation in E. bovis-infected host cells revealed as a stage-
dependent process since beginning with parasite proliferation, a striking 
enhancement of LD formation occurred in infected host cells. This is in principle 
in line with reports on P. falciparum-infected erythrocytes which also reported on 
a stage-dependent increase of LDs (Vielemeyer et al., 2004, Nawabi et al., 2003, 
Palacpac et al., 2004). Interestingly, the maximum LD generation in E. bovis-
infected host cells is observed in late immature meronts, i. e., at times when 
merozoites I are about to be formed. In contrast, in mature macromeronts carrying 
fully developed merozoites I, structurally defined LDs were hardly observed, 
suggesting that LD contents were almost totally consumed for merozoite I 
formation. Given that lipids were incorporated in newly developed merozoites I, a 
more homogeneous but bright fluorescence of the total mature macromeront 
occured which corresponded to the more homogeneous reactions found in single 
merozoites I. Bodipy 493/503 and osmium tetroxide stainings of infected host 
cells additionally revealed that LDs may be differentially distributed within the 
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parasite stage since they were either homogeneously spread or clustered in certain 
areas of the macromeronts. So far, the meaning of this observation is not clear. 
LD dense regions may overlap with areas of merozoite I budding, however, these 
phenomena have to be further analysed to allow for any assumption. 
Confocal analyses revealed considerable variations of LD sizes in meront-carrying 
host cells, ranging from submicrometer diameters to large sizes of ≥ 5 µm (these 
estimations rather have to be interpreted as approximations since absolute 
measurements were not performed). Accordingly, “gigantic” LDs of up to 4 µm 
size were described in T. cruzi-infected host cells (Melo et al., 2006). 
Interestingly, Melo et al. (2006) found maximum LD sizes in irradiated 
macrophages which allowed for higher parasite burdens and offspring production, 
i. e., a situation that obviously parallels that of E. bovis replication. However, 
differing sizes are a common finding in these organelles (Melo et al., 2011) and 
are either based on enhanced localized lipid synthesis (Kuerschner et al., 2008) or 
on LD fusion (Olofsson et al., 2009). 
Confocal analyses also revealed that LDs are mainly equally distributed 
throughout the macromeront body. Given that the developing macromeront 
pushes host cellular contents aside owing to its enormous size (see Fig. 4.7.C) and 
since LDs were detected in almost each Z-stack layer, it could be demonstrated 
that LDs indeed originated from the parasite itself.  
Significant quantitative differences in bodipy 493/503-stained infected BUVEC 
were measured using FACS analyses confirming recent microscopic observations. 
Thus, significantly enhanced reactions were detected in immature meronts but 
even higher signals were found in mature macromeronts. Since FACS analysis 
merely measures fluorescence intensities and does not account for homogeneous 
or structured distributions, this is in line with the microscopic observations.  
Infection-induced enhancement of LD abundance in infected host cells has also 
been reported for other protozoan parasites. Thus, acute infections with T. cruzi 
significantly induced LD formation in macrophages in vivo (Melo et al., 2003, 
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2006). Abundant LDs were also reported for T. gondii-, P. berghei- or P. 
falciparum-infected host cells (Rodriguez-Acosta et al., 1998, Vielemeyer et al., 
2004, Jackson et al., 2004, Coppens, 2006, Gomes et al., 2014). However, the 
degree of LD enhancement in those cases was not at all comparable to E. bovis 
infections. Whilst in T. cruzi-infected macrophages the numbers of LDs increased 
from 2 in controls to a maximum of 18 in infected cells (Melo et al., 2003), in T. 
gondii-infected skeletal muscle cells from 4 to ~16 LDs in infected cells (Gomes 
et al., 2014) and in P. falciparum-infected erythrocytes to ≥ 10 LDs (Vielemeyer 
et al., 2004), LD numbers in immature E. bovis meronts revealed vastly higher 
(but uncountable owing to the thickness of the specimens). The striking dimension 
of E. bovis-triggered upregulation of LD formation obviously reflects the 
enormous demand for lipids for offspring production counting much higher in 
E. bovis than in any other here mentioned parasite. Furthermore, it is noteworthy 
that, in most cases, the above mentioned authors reported on enhanced numbers of 
LDs in the cytoplasm of respective host cells, whilst in the case of E. bovis 
macromeronts LD-like structures were definitively situated within the parasite 
stage itself. 
Details on the LD formation process and the precise function of these organelles 
within parasitic stages are scarce. Especially in the case of E. bovis it remains to 
be elucidated whether LDs are formed by the parasite itself of whether they may 
be internalized from the host cell compartment. In the case of T. gondii-infected 
skeletal muscle cells increasingly formed LDs were observed in direct contact 
with the PVM, the vacuolar matrix and the parasite membrane and the authors 
speculate that recuited LDs directly deliver their contents to the PV (Gomes et al., 
2014). 
T. gondii-derived LDs contain cholesteryl esters (Charron and Sibley, 2002, 
Nishikawa et al., 2005, Lige et al., 2013) whilst these are absent in LDs of 
Plasmodium-infected cells (Jackson et al., 2004, Nawabi et al., 2003, Palacpac et 
al., 2004). Thus, NBD-labelled cholesterol is incorporated into intracellular T. 
gondii membranes and is also metabolized to cholesteryl esters as observed by 
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thin layer chromatography (Charron and Sibley, 2002). The fact that host cell 
SOAT1 is clearly upregulated in E. bovis-infected BUVEC at times of enhanced 
LD formation may argue for the storage of cholesteryl esters in these organelles. 
Interestingly, T. gondii is reported to express parasite-own SOAT-like molecules 
(Nishikawa et al., 2005, Lige et al., 2013), which may contribute to LD-derived 
cholesteryl ester storage. In the case of E. tenella, there is evidence of several 
peptides isolated from refractile bodies which are homologous to acyl-CoA 
synthases (de Venevelles et al., 2006). Furthermore, a sterol O-acyltransferase 
was predicted in the E. tenella genome (Bushkin et al., 2013) indicating that also 
Eimeria species may have the capacity to actively form cholesteryl esters by 
themselves and to store these molecules in LDs. Given that dansyl-cholesterol- 
(which is not esterified) derived signals occur in free sporozoite refractile bodies, 
which are devoid of free cholesterol as determined by the lack of filipin staining, 
rather argues for the existence of enzymes that metabolize free cholesterol to 
biochemical neutral forms, such as cholesteryl esters, in E. bovis stages. Referring 
to the facts mentioned above, it is tempting to assume that E. bovis is also 
equipped with parasite-derived SOAT-like molecules which contribute to LD 
formation. However, this item should be adressed in future studies. 
The precise function of LDs in E. bovis macromeront development has not been 
defined yet. Assuming that the parasite has a high demand for lipids, it appears 
most likely that the large abundance of LD contents is consumed for the 
considerable enlargement of the host cell membrane, for the formation and 
enlargement of the PV and, probably most importantly, for the formation of large 
numbers of merozoites I. Accordingly, morphologically defined LDs disappear in 
macromeronts when mature merozoites I have been formed and parasite 
development fails when fatty acid synthesis as well as cholesterol synthesis or 
esterification is chemically blocked via inhibitors. Thus, the lipid storage capacity 
appears the most prominent function of LDs in E. bovis-infected cells and 
enhancement of LD formation may mirror the nutritional needs of the parasite. To 
analyze the actual role of LDs as “feeder organelles”, we took advantage of 
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artificial LD enhancement via oleic acid treatments of host cells prior to E. bovis 
infection and throughout intracellular development. The treatment of eukaryotic 
cells with oleic acid is a well-known tool for the stimulation of cytosolic LD 
formation and is often used as positive control in LD-related experiments (Seo et 
al., 2001). Indeed, oleic acid-triggered induction of LD formation significantly 
improved parasite proliferative capacities, since a 7-fold up-regulation of 
offspring production was observed when compared to non-induced host cells. 
These data clearly strengthen the assumption of LDs mainly functioning as lipid 
storage and “feeder” organelles in E. bovis macromeronts. 
 
LDs have been described as very active and dynamic inclusion bodies (Martin and 
Parton, 2006, Fujimoto et al., 2008, Farese and Walther, 2009, Murphy et al., 
2009, Olofsson et al., 2009, Fujimoto and Parton, 2011, Jungst et al., 2013) that 
are also involved in innate immune reactions of inflammatory leukocytes (d’Avila 
et al., 2008, Melo et al., 2006). Thus, nascent lipid bodies, the formation of which 
can be induced by different immunoactive stimuli, such as eicosanoids, 
chemokines, cytokines (eotaxin/RANTES, IL-5, IL16) or fatty acids, are reported 
as sites of enzyme localization (such as cyclooxygenase, prostaglandin E2 
synthase or leukotriene C4 synthase), eicosanoid production, as well as cytokine 
storage (reviewed in Bozza et al., 2007). Whilst the production of PGE2 was 
positively correlated with enhanced LD formation in T. cruzi-infected 
macrophages (Melo et al., 2003), no data on LD-produced immunomodulatory 
molecules are available on Eimeria-infected host cells and, in consequence, 
immunoreactive functions of E. bovis-induced LD should also be considered and 
further analyzed in future experiments.  
 
Discussion 
 
112 
 
5.2 E. bovis up-regulates both host cell cholesterol de novo synthesis and 
LDL-mediated uptake 
5.2.1 Up-regulation of the mevalonate biosynthesis pathway and of host 
cellular cholesterol processing by E. bovis infections 
Gene transcription profiling of E. bovis-infected endothelial host cells showed that 
all molecules being involved in the mevalonate biosynthesis pathway (HMGCR, 
HMGCS1, SQLE) or in the formation of early substrates for this pathway 
(ACAT1, 2) where predominantly found up-regulated in times of merozoite I 
formation (17 days p. i.) indicating a significant induction of host cell de novo 
synthesis to satisfy the parasites demand for high cholesterol abundance. 
Accordingly, an enhancement of ACAT1 was also confirmed on the protein level 
at 17 days p. i. However, it has to be noticed that actual enzymatic activities of 
these enzymes were not estimated. Thus, the current results may not necessarily 
mirror respective biochemical activities of the host cells. Nevertheless, HMGCS1 
and SQLE inhibition studies clearly confirmed the relevance of cholesterol de 
novo synthesis in E. bovis-infected host cells (see 4.6). In T. gondii-infected host 
cells the data on mevalonate biosynthesis pathway induction are somewhat 
conflicting. Whilst Coppens et al. (2000) negated any involvement of cholesterol 
de novo synthesis to satisfy the parasites need for cholesterol, other authors 
(Martins-Duarte et al., 2006, Blader et al., 2001, Nishikawa et al., 2011) presented 
data indicating that host cholesterol synthesis does indeed contribute to the growth 
of intracellular T. gondii. Thus, the gene transcriptions of HMGS1, HMGCR and 
SQLE genes were found up-regulated in times of tachyzoite formation (Blader et 
al., 2001) and blockage of HMGCR or SQLE inhibited T. gondii growth (Martins-
Duarte et al., 2006, Nishikawa et al., 2011). However, given that different host 
cell types were used in these investigations, the different outcomes may rely on 
cell-type specific utilization of different pathways of cholesterol acquisition. In 
the case of E. bovis, the current data clearly argue for an up-regulation of the 
mevalonate biosynthesis pathway to promote parasite replication. 
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Gene transcription profiling also suggested enhanced cholesterol modification on 
the level of esterification and hydroxylation in E. bovis-infected host cells. Thus, 
SOAT1 and CH25H gene transcripts were significantly up-regulated at times of 
macromeront formation, paralleling those of molecules being involved in host cell 
de novo synthesis. In eukaryotic cells, excess cellular cholesterol is toxic and 
therefore de novo synthesis must be tightly regulated and coupled to pathways that 
enable removal of cholesterol (for review see Ikonen, 2008). Given that excess 
free cholesterol is indeed synthesized in infected host cells, it appears likely that 
these molecules are further processed e. g. by esterification and oxidation. In line 
with these assumptions a significantly enhanced LD formation was observed, 
representing the site of cholesteryl ester storage (see 4.2.2.). In line with other 
apicomplexan parasites (Sonda et al., 2001, Nishikawa et al., 2005) the key role of 
cholesterol esterification in E. bovis-infected host cells was furthermore 
confirmed by SOAT inhibition experiments as showed in chapter 4.6.5. 
The overall predominant up-regulation of gene transcripts and proteins concerned 
CH25H (up to 52.69-fold increase) suggesting enhanced 25-OH-cholesterol (25-
OHC) synthesis in E. bovis-infected host cells since the formation of different 
oxysterols is specifically mediated by different enzymes (Brown and Jessup, 
2009). Again, it has to be mentioned that gene transcription and protein 
expression analyses do not necessarily reflect cellular enzyme activities. However, 
preliminary results on biochemical measurements of 25-OHC end product 
confirmed significantly enhanced concentrations of this molecule, but not of other 
oxysterols, such as 24-OHC or 27-OHC, in E. bovis-infected host cells (A. 
Taubert, unpublished data). Furthermore, these data are in line with previous 
studies on E. bovis-mediated host cell transcriptome alterations (Taubert et al., 
2010).  
Oxysterols are typically present in cells in minor amounts [(approximately 1:1000 
compared to cholesterol, (Ikonen, 2008)] and in general exhibit different functions 
in eukaryotic cells. Thus, they may act as immunomodulators since they induce 
the synthesis of inflammatory cytokines such as tumor necrosis factor, 
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chemokines and adhesion molecules and alter B-, T- and dentritic cell functions 
(Spann & Glass, 2013, Poli et al., 2013). Furthermore they are described as 
regulators of the cholesterol metabolism by blocking the expression of genes 
involved in cholesterol synthesis via modulating the sequestration of cholesterol 
regulatory elements [(SREBPs), for review see Brown and Jessup, 2009]. In 
addition, they regulate the degradation of HMGCR, the rate-limiting enzyme of 
cholesterol synthesis. Given that the additional hydroxyl group renders oxysterols 
more hydrophilic, these molecules move more freely in the cytoplasmic 
environment than cholesterol and may function as membrane solubilizer (Ikonen, 
2008). In mammalian cells, 25-OHC is an indicator of high cellular cholesterol 
levels, it can be esterified by sterols esterifying enzymes and also may act as 
cholesterol biosynthesis repressor (Brown and Jessup, 2009). So far, the precise 
role of 25-OHC in E. bovis-infected host cells is not known. However, since 25-
OHC has also been shown to stimulate cholesterol esterification via SOAT 
(Brown, Dana and Goldstein, 1975), which may, in turn, be directly linked with 
enhanced LD formation, it is tempting to suggest a pivotal role for 25-OHC in 
cholesterol regulation of E. bovis-infected host cells.  
It is worth noting that oxysterols are transported by cytosolic receptors, the 
oxysterol binding proteins (OSBPs) (Kandutsch and Shown, 1981). Interestingly, 
several OSBP-related proteins (ORPs) were identified in apicomplexan parasites, 
such as C. parvum, Plasmodium spp., T. gondii and E. tenella (Zeng, 2006). The 
fact that a C. parvum-derived ORP was reported to be localized in the PVM, 
suggests a role of these molecules in direct oxysterol uptake from the cytosol 
(Zeng and Zhu, 2006). However, future genome analyses have to clarify whether 
E. bovis also possesses ORPs and may therefore directly benefit from enhanced 
oxysterol synthesis. 
Gene transcription and protein expression analyses also indicated an involvement 
of LDL-promoted up-take of cholesterol since both, LDLR and OLR1 gene 
transcripts and proteins were found up-regulated in E. bovis-infected host cells. 
Interestingly, the significant enhancement of LDLR and OLR1 gene transcripts 
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started 5 days earlier during macromeront development than that of de novo 
synthesis-associated molecules suggesting a defined chronology of cholesterol 
acquisition. Thus, the LDL-related pathway may represent the first action for 
cholesterol up-take in times of beginning parasite proliferation and afterwards, in 
times of maximum cholesterol need, i. e. when merozoites I are about to be 
formed, host cell de novo synthesis may additionally be triggered to satisfy the top 
demands. In accordance, enhanced levels of LDLR and OLR1 gene transcripts 
were also detected in T. cruzi-infected macrophages (Chiribao et al., 2014). 
Cholesterol acquisition via the LDL-incorporation is a common feature in 
apicomplexan parasites and will be discussed more in detail in chapter 5.2.3. 
 
5.2.2 Inhibition of host cellular cholesterol de novo synthesis and 
esterification blocks parasite growth 
Inhibitor experiments were performed to verify the actual role of different steps of 
host cellular de novo cholesterol biosynthesis as well of cholesterol esterification 
and fatty acid synthesis in E. bovis macromeront formation. Thus, different 
inhibitors were applied targeting HMG-CoA reductase (lovastatin), squalene 
synthase (zaragozic acid), acyl-CoA cholesterol acyltransferase (CI976) and fatty 
acid synthase (C75).  
Intracellular E. bovis macromeront formation is a long lasting process that may 
take up to 30 days in vitro. This has important implications on inhibitor 
experiments since the compounds have to act for many days without exhibiting 
detrimental effects on the cultures themselves. Therefore extensive experiments 
were performed to estimate toxic effects of long-term treatments with lovastatin, 
zaragozic acid, CI976 and C75 in bovine endothelial cell cultures. Overall, 
BUVEC reacted rather sensitive and, in most cases, did not tolerate compound 
concentrations used in other reports dealing with other coccidian species in 
different host cell types (Ehrenman et al. 2013, Nishikawa et al. 2011, Sonda et al. 
2001) when being continuously treated for at least 15-20 days. In consequence, a 
final concentration of 1 µM (lovastatin) and 5 µM (all other compounds) was used 
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in the current inhibition study. Compared to other reports this rather signifies low 
dose treatments. 
Referring to dose effect curves and calculated IC50 values, lovastatin proved as the 
most effective anti-proliferative compound. Lovastatin belongs to the well-known 
group of statins, a class of drugs widely used to lower plasma cholesterol levels 
(Brown, 2001, Brautbar and Ballantyne, 2011). Statins are reversible inhibitors of 
the microsomal enzyme HMG-CoA reductase, which represents the early rate-
limiting step in cholesterol biosynthesis (Istvan and Deisenhofer, 2001). It has to 
be mentioned that mevalonate is not exclusively used as substrate for sterol 
synthesis but is also needed for protein isoprenylation and the synthesis of non-
sterol products that are critical for the growth and proliferation of eukaryotic cells 
(Liao, 2002). Consequently, effects may partially also be attributed to the 
blockage of other molecules than cholesterol. However, low dose (1 µM) 
treatments of E.bovis-infected endothelial host cells resulted in a significant arrest 
of meront formation and almost total blockage of merozoite production (>99 % 
reduction). Interestingly, E. bovis-infected host cells appear to be significantly 
more sensitive to this drug (IC50: 0.1 µM) than other coccidian species, since the 
IC50 value of lovastatin was approximately 170-fold higher for T. gondii-infected 
macrophages (Nishikawa et al., 2011, IC50 = 17,1 µM) and the use of 10-fold 
doses of lovastatin resulted only in a 50 % reduced filipin staining and a 2.5-fold 
reduction of the PV size of C. parvum in epithelial cells (Ehrenman et al, 2013). 
In agreement, treatments of T. gondii-infected macrophages with different statins 
resulted in >50% inhibition in the case of simvastatin only at doses of 30-40 
µg/ml (corresponds to 72-96 µM) whilst rosuvastatin and atorvastatin even failed 
to do so (Cortez et al., 2009). The higher sensitivity of E.bovis may be explained 
by the fact that the numbers of merozoites I to be produced per infected host cell 
is at least 1000-fold higher than in T. gondii or C.parvum, and most probably 
result in a much higher need for cholesterol for membrane biogenesis in the 
replicative phase of infection. 
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Zaragozic acid affects with squalene synthase the first enzymatic step of the 
mevalonate pathway, which directly targets sterol synthesis and therefore is 
considered as more specific for cholesterol blockage than statin treatments 
(Lindsey and Harwood, 1995). In infected BUVEC, 5 µM zaragozic acid 
treatments resulted in an arrest of meront formation and induced strong anti-
proliferative effects (reduction of 70.2 % of merozoite I production) confirming 
that E. bovis development clearly depends on host cell de novo synthesis. 
However, the fact that meront growth is not completely blocked after zaragozic 
acid treatment and and still produces smaller (but mostly degraded) meronts I 
argues for an additional source of cholesterol than de novo synthesis. Thus, the 
simultaneous exploitation of the LDL-mediated pathway may help in forming 
smaller meronts, but, however, the parasite finally fails to produce adequate 
numbers of offspring. 
In contrast to E. bovis, only moderate effects of 15 µM zaragozic acid treatments 
(as indicated by 25 % of growth delay) were estimated in C. parvum-infected 
epithelial cells (Ehrenman et al., 2013). Comparable rates of reduction were also 
reported in T. gondii-infected macrophages applying 1-10 µM zaragozic acid 
(Nishikawa et al., 2011). In addition, squalene synthase-defective CHO cells 
revealed no significant anti-proliferative effects on T. gondii development 
compared to non-defective controls (Coppens et al., 2000). However, Martins-
Duarte et al. (2006) applied two quinuclidine-based inhibitors of squalene 
synthase in T. gondii-infected epithelial cells and reported on anti-proliferative 
effects of both compounds achieving up to 48-58 % reduction of tachyzoite 
replication at 3 µM dosage.  
Overall, the data on lovastatin and zaragozic acid treatments clearly indicate that 
successful E. bovis macromeront development and merozoite I production 
significantly depends on the host cell cholesterol de novo synthesis.  
CI976 is an inhibitor of SOAT that also affects multiple membrane trafficking 
steps, including those found in the endocytic and secretory pathways (Chambers 
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et al., 2005, Kam et al., 1990, Schmidt and Brown, 2009). Treatments of E. bovis-
infected BUVEC resulted in immediate arrest of parasite development irrespective 
of the onset of treatment. Overall, 5 µM CI976 treatments induced strong anti-
proliferative effects since it almost entirely blocked merozoite I production 
(> 99 % reduction) indicating that cholesterol esterification and storage is of high 
relevance for successful E. bovis development and that SOAT may represent a 
key molecule in this aspect. In agreement, LDs/neutral lipids were increasingly 
accumulated in E. bovis meronts with ongoing development and lipid droplet 
deposition in infected host cells was blocked by CI976. These data are in line with 
several reports on T. gondii documenting the essential role of cholesterol 
esterification and lipid droplet formation in optimal parasite proliferation 
(Coppens et al., 2000, Sonda et al., 2001, Coppens and Vielemeyer, 2005, 
Nishikawa et al., 2005). Accordingly, the absence of host cellular SOAT or SOAT 
inhibition induced a considerable decrease of T. gondii replication (Sonda et al., 
2001). However, the merozoite I reduction rates of approximately 60 and 70 % 
induced by 4 µM and 10 µM CI976 treatments, respectively, appeared lower for 
T. gondii than those detected in E. bovis-infected host cells after 5 µM treatments 
indicating a higher sensitivity of E. bovis. Importantly, it was shown for T. gondii 
that the parasite itself is able to synthesize and store cholesteryl esters, if host cell 
cholesterol is available (Sonda et al., 2001, Nishikawa et al., 2005). Given that 
two SOAT-like molecules were identified in T. gondii stages and proved sensitive 
to SOAT inhibitor treatments (Nishikawa et al., 2005, Lige et al., 2013), 
respective molecules may also exist in E.bovis stages. Thus, it remains to be 
elucidated whether the detrimental effects driven by CI976 accounted only to the 
host cell compartment or were also brought about by direct anti-parasitic effects.  
Given that cholesteryl esters play a pivotal role in E. bovis development and that 
precursors thereof are cholesterol and fatty acids, the effects of fatty acid synthase 
blockage was additionaly investigated. Fatty acid synthase is a lipogenic enzyme 
that catalyzes the condensation of acetyl-CoA and malonyl-CoA to generate long-
chain fatty acids (Chirala and Wakil, 2004, Menendez and Lupu, 2007). The 
synthetic α-methylene-γ-butyrolactone compound C75 inhibits fatty acid synthase 
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activity and has been studied for its anti-inflammatory and anti-tumoral activities 
(Kuhajda et al., 2000, Flavin et al., 2010, Matsuo et al., 2014). C75 treatments 
induced dose-dependent anti-proliferative effects on E.bovis merozoite I 
production and impeded proper macromeront development. In contrast, C75 was 
ineffective in directly inhibiting T. cruzi growth in infected macrophages (D'Avila 
et al., 2011). It is noteworthy, that treatments of in vitro parasite cultures with C75 
resulted in enormous morphological alterations as detected by massive 
vacuolization of the E. bovis macromeronts indicating a high relevance of fatty 
acids for optimal intracellular parasite replication. 
In summary, the results indicate that successful development of E. bovis 
macromeronts in endothelial cells significantly depends on host cellular de novo 
synthesis of cholesterol via the mevalonate biosynthesis pathway in addition to 
functional cholesterol esterification, fatty acid synthesis and lipid droplet 
formation.  
 
5.2.3 Key role of host cellular LDL up-take in E. bovis development 
Besides de novo biosynthesis, exogenous cholesterol is acquired mainly via 
cellular lipoprotein internalization. LDL is particularly enriched in free cholesterol 
and cholesteryl esters rendering these molecules as a beneficial source of 
cholesterol. Hence, human LDL contain approximately 350 and 1400 molecules 
of free and esterified cholesterol molecules per particle, respectively, whilst HDL 
particles contain only 30 and 70 respective molecules (Wilson et al., 1992). In the 
blood or lymph, different modifications of LDL occur, such as acetylated (ac) or 
oxidized (ox) LDL. Whilst most cells are able to internalize non-modified LDL 
(Myant, 1990), acLDL up-take is restricted to certain cell types, such as 
endothelial cells and macrophages (Voyta, 1984). In order to address the question, 
whether LDL and acLDL internalization differed in E. bovis-infected endothelial 
host cells and in non-infected controls, we used (bodipy)LDL- and 
(bodipy)acLDL-enriched cell culture media and assayed for lipoprotein binding to 
endothelial (host) cells. Respective analyses revealed that E. bovis-infected host 
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cells were not restricted to LDL or acLDL up-take but showed enhanced 
capacities to scavenge cholesterol from both sources. Thus, fluorescence-based 
LDL and acLDL binding assays showed that both molecules were increasingly 
bound to the surface of macromeront-carrying host cells. Furthermore FACS 
analyses revealed a 37.5-fold and 5.2-fold increase of LDL and acLDL binding, 
respectively. 
The current gene transcription profiles also indicate a role of oxLDL during 
macromeront formation. Thus, in agreement to recent microarray analyses of 
E. bovis-infected host cells (Taubert et al., 2010), a significant up-regulation of 
OLR1 gene transcripts were detected. These data were confirmed by enhanced 
OLR1 protein expression in E. bovis-infected BUVEC at 17 days p. i. To our 
knowledge, this represents the first report on the involvement of OLR1 in 
coccidian host cell infections. OLR1 (syn. LOX-1) is considered as the major 
receptor for oxLDL in vascular endothelial cells (Sawamura et al., 1997, 
Moriwaki et al., 1998, Kume et al., 1998) and belongs to the scavenger receptor 
class E molecules. OLR1 has vastly been investigated on the level of human 
artherosclertic lesions (for review see Pirillo et al., 2013). Given that oxLDL may 
also provide a good exogenous cholesterol source, OLR1-promoted uptake may 
also be involved in E. bovis macromeront formation. However, additional 
experiments are needed to confirm this assumption. 
Prolonged supplementation of bodipy-LDL additionally resulted in signals within 
the meronts which may indicate the utilization of LDL by the parasites 
themselves. LDL has also been reported to serve as exogenous cholesterol source 
for other apicomplexan parasites, such as T. gondii, C. parvum and Plasmodium 
spp. (Coppens et al., 2000, Labaied et al., 2011, Ehrenmann et al., 2013). Thus, 
fluorescence-derived signals of exogenously supplied LDL-incorporated NBD-
cholesterol were detected in the PV or parasite membranes of these parasites 
(Coppens et al., 2000, Labaied et al., 2011, Ehrenmann et al., 2013).  
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Given that LDL is mainly internalized via the classical LDLR we further analyzed 
this receptor in E. bovis-infected host cells. In agreement to recent transcriptome 
data on E. bovis-infected bovine endothelial cells (Taubert et al., 2010), LDLR 
gene transcripts were found significantly up-regulated throughout macromeront 
development. The transcriptional data were confirmed on the protein level since a 
significant, almost two-fold enhancement of surface LDLR expression was 
detected on infected host cells at 17 days p. i. via FACS analysis. The general 
involvement of LDLR in parasite-mediated LDL-uptake is in line with data on T. 
gondii-infected CHO cells showing that antibody-mediated blockage of LDLR 
leads to a dramatic decrease of cholesteryl ester delivery to the parasite (Coppens 
et al., 2000). In contrast, a 70-80 % reduced LDLR expression did not affect the 
liver stage burden in the case of Plasmodium spp. although this parasite in 
principle salvages LDL-derived cholesterol (Labaied et al., 2011). In concert with 
the later findings, T. gondii growth did not change in LDLR-deficient (KO) 
macrophages when compared to wild type cells indicating that parasite-driven 
LDL may also be acquired via other host cell receptors, such as scavenger 
receptors. In this context it is worth noting that the class B type I scavenger 
receptor being able to bind LDL (Horiuchi et al., 2003), was required for P. 
berghei infections (Rodrigues et al., 2008). 
In order to assess whether enhanced disposability of LDL would be of benefit for 
the parasite development, infected host cells were cultured in LDL-enriched 
medium. Indeed, a significantly increased offspring production was detected in 
LDL-enriched cultures confirming the pivotal role of LDL for optimal parasite 
proliferation. Similar results were reported for T. gondii-infected CHO cells on 
the level of tachyzoite numbers per PV (Coppens et al., 2000) whilst excess LDL 
had no stimulatory effect on Plasmodium spp. and C. parvum proliferation 
(Labaied et al., 2011, Ehrenmann et al., 2013). However, exogenous LDL 
treatment also had no beneficial effect on T. gondii proliferation in macrophages 
(Nishikawa et al., 2011) indicating cell type specific reactions. 
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Overall, the current data indicate that E. bovis has the capacity to scavenge 
cholesterol from several sources at a time, which contrasts to T. gondii (Coppens, 
2000) but is in principle in line with findings for Plasmodium spp. (Labaied et al., 
2011). Nevertheless, E. bovis bears significant differences to Plasmodium spp., 
since, based on the enormous demand for cholesterol, E. bovis development 
clearly depends on both, cellular de novo synthesis and the LDL-mediated 
extracellular cholesterol internalization at a time, whilst Plasmodium spp. being 
suggested to exhibit moderate needs of sterols for optimal proliferation (Labaied 
et al., 2011), merely alternatively exploits these scavenger pathways. Given that 
cellular cholesterol synthesis is tightly regulated by a complex network of cellular 
mechanisms, more research is needed to understand how the parasite outwits this 
regulatory network. 
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6 SUMMARY 
 
During first merogony E. bovis forms large-sized macromeronts containing 
>120,000 merozoites. Given thatobligate intracellular replicating coccidians are 
generally considered as auxotrophic for cholesterol synthesis and that asingle 
sporozoite stage cannot provide all components necessary for this nutrient and 
energy demanding process, the parasite needs to scavenge molecules from the 
endothelial host cell. Especially for the massive offspring membrane production, 
large amounts of cholesterol are indispensable for a successful replication process. 
Here, the influence of E. bovis infections on host cell cholesterol metabolism was 
analyzed. 
Free cholesterol and neutral lipids were shown to be differentially distributed in 
sporozoite stages. Thus, free cholesterol mainly occurred in the apical complex 
and in the pellicles of sporozoite and merozoite I stages whilst neutral lipids 
accumulated in refractile bodies of the sporozoites. Both stages showed 
cytoplasmic lipid droplet (LD)-like structures indicating their capability for lipid 
storage. Kinetic analyses revealed enhanced levels of free cholesterol during E. 
bovis macromeront development. A massive increase of LD formation in 
immature macromeronts suggested these organelles and esterified cholesterol 
(which is stored in LDs) as important lipid source for E. bovis. In agreement, an 
artificial increase of cellular LDs led to improved merozoite I production and 
pharmacological blockage of cholesterol esterification abrogated E. bovis 
development.  
Transcriptional profiling of infected host cells in times of macromeront formation 
indicated that E. bovis modulates both pathways of cholesterol acquisition, i. e. 
LDL-promoted uptake of extracellular cholesterol sources and host cellular de 
novo synthesis. Thus, the gene transcription of several molecules being involved 
in cellular cholesterol de novo synthesis via the mevalonate biosynthesis pathway 
(e. g. HMG-CoA synthase, HMG-CoA-reductase and squalene epoxidase) and of 
transcripts of the LDL-receptor (LDLR) and the oxidised LDL receptor 1 (OLR1) 
were equally found up-regulated in infected host cells. Furthermore, cellular 
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cholesterol processing appeared enhanced since key molecules, such as 
cholesterol-25-hydroxylase and acyl-CoA acetyltransferase, were significantly up-
regulated in infected cells, the latter of which promotes cellular cholesteryl ester 
synthesis and lipid droplet biogenesis.  
The key role of cholesterol de novo synthesis and processing was furthermore 
confirmed via pharmacological blockage applying the following inhibitors: 
lovastatin, zaragozic acid, CI976 and C75 targeting HMG-CoA-reductase, 
squalene synthase, acyl-CoA cholesterol acyltransferase and fatty acid synthase, 
respectively. In summary, all inhibitors significantly interfered with E. bovis 
macromeront formation and merozoite I production in a dose-dependent manner. 
Dose effect responses identified lovastatin as the most effective compound, 
followed by CI976, C75 and squalestatin, respectively. Overall, merozoite I 
production was inhibited by 99.6, 99.7, 84.6 and 70.2 % via lovastatin, CI976, 
C75 and zaragozic acid treatments, respectively. Concerning macromeront 
development, both, the rate and size of meronts were affected by inhibitor 
treatments. Respective effects were characterized by developmental arrest and 
meront degradation.  
The pivotal role of LDL-promoted host cellular incorporation of exogenous 
cholesterol for parasite replication was underlined by enhanced binding of non-
modified and acetylated LDL on E. bovis-infected cells. In addition, significantly 
increased levels of surface LDLR expression were detected on meront-carrying 
host cells. Furthermore, cholesterol and LDL enrichments of the cell culture 
medium boosted parasite replication. Besides LDLR, we additionally identified 
the scavenger receptor OLR1 (oxidized LDL receptor 1) as a key molecule of 
parasite-triggered LDL uptake since both, gene transcription and protein 
expression was found enhanced in infected cells. 
Overall, these results indicate that E. bovis massively modulates the host cell 
cholesterol metabolism to guarantee its intracellular growth and replication.
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7 ZUSAMMENFASSUNG 
 
E. bovis bildet als strikt intrazellulärer Erreger im Rahmen der ersten Merogonie 
sog. Makromeronten aus, in denen mehr als 120.000 Merozoiten produziert 
werden. Dieser nährstoff- und energiefordernde Prozess kann nicht von 
Sporozoiten allein getragen werden. Dementsprechend muss der Parasit den 
Wirtszellmetabolismus modulieren, um seine erfolgreiche Replikation 
abzusichern. Dies betrifft aufgrund der massiv geforderten Membranbiogenese für 
die Merozoitenproduktion insbesondere den Cholesterolmetabolismus der 
infizierten Wirtszelle, der Gegenstand dieser Untersuchungen war.  
In freien Stadien von E. bovis (Sporozoiten, Merozoiten I) zeigte sich eine 
unterschiedliche Verteilung von freiem Cholesterol und neutralen Fetten bzw. 
Lipidtröpfchen (LT). Während freies Cholesterol bevorzugt im Apikalkomplex 
und in der Pellikula nachgewiesen wurde, waren Cholesterylester bzw. neutrale 
Fette ausschließlich in refraktilen Körperchen nachzuweisen. Zudem wurden LT-
ähnliche Strukturen im Zytoplasma beider Stadien gefunden, was auf die 
Befähigung zur Lipidspeicherung seitens des Parasiten schließen lässt.  
Analysen zur E. bovis-Makromerontenreifung zeigten eine vermehrte Präsenz von 
von freiem Cholesterol in infizierten Zellen. Ein massiver Anstieg der LT-Bildung 
in immaturen Makromeronten wies auf eine entscheidende Rolle dieser Organelle 
bzw. ihrer Inhalte wie z. B. Cholesterylester als Lipidquelle hin. Die Relevanz von 
LT bzw. Cholesterylestern konnte über artifizielle Steigerung der LT in 
Wirtszellen über gesteigerte Merozoiten I-Produktion als auch über 
pharmakologische Blockade der Cholesterolveresterung mit ausbleibender 
Parasitenproliferation bestätigt werden. 
Analysen zur Gentranskription von Wirtszellen während der 
Makromerontenbildung wiesen auf eine gleichzeitige Modulation beider Wege 
der Cholesterolakquise, d. h. von wirtszellulärer de novo-Synthese als auch der 
LDL-vermittelte Aufnahme exogenen Cholesterols, hin. Entsprechend waren 
Gentranskripte diverser, in die zelluläre de novo-Synthese von Cholesterol 
eingebundener Moleküle (z. B. HMG-CoA-Synthase, HMG-CoA-Reduktase, 
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Squalenepoxidase) als auch von LDL-Rezeptoren (LDL-Rezeptor, oxidised LDL-
Rezeptor 1) gegen Ende der Merontenreifung hochreguliert. Zusätzlich wurde die 
Prozessierung zellulären Cholesterols über E. bovis-Infektionen verstärkt, da 
sowohl die Cholesterol-25-Hydroxylase als auch die Acyl-CoA-Acyltransferase 
hochreguliert wurden, wobei letztere die Synthese von Cholesterylestern sowie 
die Biosynthese der Lipidkörperchen vermittelt. 
Die entscheidende Rolle der wirtszellulären de novo-Synthese von Cholesterol 
wurde zusätzlich über Inhibitionsstudien belegt, bei der Inhibitoren zur Blockade 
der HMG-CoA-Reduktase (Lovastatin), Squalensynthase (Zaragozic Acid), Acyl-
CoA:cholesterol acyltransferase (CI976) and Fettsäuresynthase (C75) verwendet 
wurden. Hier zeigte sich, dass alle verwendeten Inhibitoren einen blockierenden, 
dosis-abhängigen Einfluss auf die Makromerontenbildung und Merozoiten I-
Produktion hatten. So wurde die Merozoiten I-Synthese zu 99,6, 99,7, 84,6 und 
70,2 % überLovastatin, CI976, C75 and Zaragozic Acid gehemmt. Zusätzlich 
wurde die Größenentwicklung der Makromeronten als auch respektive 
Infektionsraten negativ beeinflusst und es zeigten sich Entwicklungsabbrüche als 
auch Degradierungseffekte bei Makromeronten. 
Die entscheidende Rolle der LDL-vermittelten Cholesterolaufnahme für die 
Parasitenproliferation wurde über signifikant gesteigerte Bindungsreaktionen von 
nicht-modifizierten und acetyliertem LDL an Meronten-tragenden Wirtszellen als 
auch über eine signifikant erhöhte Oberflächenexpression von LDL-Rezeptoren 
bei infizierten Zellen untermauert. Zudem führte eine Anreicherung des 
Zellkulturmediums mit LDL oder Cholesterol zu einer gesteigerten Merozoiten I-
Produktion. Neben dem klassischen LDL Rezeptor konnten wir mit OLR1 einen 
zusätzlichen, sog. „Scavenger“-Rezeptor identifizieren, der sowohl auf 
Transkript- als auch Proteinebene in infizierten Zellen hochreguliert war und aller 
Wahrscheinlichkeit nach an die E. bovis-vermittelte Steigerung der wirtszellulären 
LDL-Aufnahme beteiligt ist. 
Zusammenfassend zeigen vorliegende Ergebnisse, dass E. bovis massivst in den 
Cholesterolhaushalt der Zelle eingreift, um sein intrazelluläres Wachstum und 
Entwicklung abzusichern.  
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9 APPENDIX 
 
Statistical analysis 
DATA STATISTIC TEST P VALUE NOTE 
Fig. 4.11 
4 days p.i multiple t-tests with days analyzed individually 0.00565457 significant 
14 days p.i multiple t-tests with days analyzed individually 0.00361334 significant 
17 days p.i multiple t-tests with days analyzed individually 0.00168995 significant 
Fig. 4.12 
controls vs. infected monolayers on 8 
days p.i t-tests 0.1825 not significant 
controls vs. infected monolayers on 17 
days p.i t-tests < 0.0001 significant 
controls vs. infected monolayers on 21 
days p.i t-tests < 0.0001 significant 
Fig. 4.13 
controls vs. cholesterol treated 
monolayer t-tests 0.0150 significant 
controls vs. desmosterol treated 
monolayer t-tests 0.0492 significant 
Fig. 4.14 
controls vs. host depleted t-tests 0.0085 significant 
controls vs. parasite depleted t-tests < 0.0001 significant 
parasite vs. host depleted t-tests 0.0083 significant 
3 groups of treatments one-way ANOVA 0.0045 significant 
Fig. 4.20 controls vs. 17 days p.i-infected monolayer t-tests < 0.000 significant 
Fig. 4.22 controls vs. 17 days p.i-infected monolayer t-tests < 0.0001 significant 
Fig. 4.23 controls vs. 17 days p.i-infected monolayer t-tests < 0.0001 significant 
Fig. 4.24 controls vs. LDL enriched monolayer t-tests 0.0069 significant 
Fig. 4.28 
ACAT1 
12 days p.i multiple t-tests with days analyzed individually 0.104044 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.0490754 not significant 
17 days p.i multiple t-tests with days analyzed individually 0.00096642 significant 
20 days p.i multiple t-tests with days analyzed individually 0.250879 not significant 
ACAT2 
12 days p.i multiple t-tests with days analyzed individually 0.974228 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.140826 not significant 
17 days p.i multiple t-tests with days analyzed individually 0.00301399 significant 
20 days p.i multiple t-tests with days analyzed individually 0.0955433 significant 
Fig. 4.29 
HMGCS1 
12 days p.i multiple t-tests with days analyzed individually 0.316054 not significan 
14 days p.i multiple t-tests with days analyzed individually 0.599271 not significant 
17 days p.i multiple t-tests with days analyzed individually 0.0134597 significant 
20 days p.i multiple t-tests with days analyzed individually 0.00483933 significant 
SQLE 
12 days p.i multiple t-tests with days analyzed individually 0.881355 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.350306 not significant 
17 days p.i multiple t-tests with days analyzed individually 0.00417226 significant 
20 days p.i multiple t-tests with days analyzed individually 0.0149898 significant 
HMGCR 
12 days p.i multiple t-tests with days analyzed individually 0.203995 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.00752577 significant 
17 days p.i multiple t-tests with days analyzed individually 0.00106191 significant 
20 days p.i multiple t-tests with days analyzed individually 0.00526938 significant 
Fig. 4.30 
 
SOAT1 
12 days p.i multiple t-tests with days analyzed individually 0.0395837 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.00141457 significant 
17 days p.i multiple t-tests with days analyzed individually 0.00184057 significant 
20 days p.i multiple t-tests with days analyzed individually 0.12705 not significant 
 
CH25H 
 
 
12 days p.i multiple t-tests with days analyzed individually 0.100908 not significant 
14 days p.i multiple t-tests with days analyzed individually 3.532e-006 significant 
17 days p.i multiple t-tests with days analyzed individually 8.786e-006 significant 
20 days p.i multiple t-tests with days analyzed individually 0.00546593 significant 
Fig. 4.31 
LDLR 
12 days p.i multiple t-tests with days analyzed individually 0.0087123 significant 
14 days p.i multiple t-tests with days analyzed individually 0.401059 not significant 
17 days p.i multiple t-tests with days analyzed individually 0.00360332 significant 
20 days p.i multiple t-tests with days analyzed individually 0.164666 not significant 
OLR1 12 days p.i multiple t-tests with days analyzed individually 0.00082721 significant 14 days p.i multiple t-tests with days analyzed individually 0.0342785 significant 
Appendix 
 
145 
 
17 days p.i multiple t-tests with days analyzed individually 0.00230203 significant 
20 days p.i multiple t-tests with days analyzed individually 0.00576825 significant 
Fig. 4.36 
cells carrying meronts 
2 days p.i multiple t-tests with days analyzed individually 0.915553 not significant 
6 days p.i multiple t-tests with days analyzed individually 0.815788 not significant 
10 days p.i multiple t-tests with days analyzed individually 0.00040596 significant 
14 days p.i multiple t-tests with days analyzed individually 4.027e-006 significant 
18 days p.i multiple t-tests with days analyzed individually 2.177e-006 significant 
22 days p.i multiple t-tests with days analyzed individually 5.544e-008 significant 
26 days p.i multiple t-tests with days analyzed individually 0.00013641 significant 
30 days p.i multiple t-tests with days analyzed individually 0.00332221 significant 
meronts size 
10 days p.i multiple t-tests with days analyzed individually 0.575521 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.0241595 significant 
18 days p.i multiple t-tests with days analyzed individually 9.881e-006 significant 
22 days p.i multiple t-tests with days analyzed individually 0.00021066 significant 
26 days p.i multiple t-tests with days analyzed individually 5.955e-008 significant 
30 days p.i multiple t-tests with days analyzed individually 2.194e-015 significant 
Fig. 4.37 
controls vs. medium 0.04% aceton t-tests 0.4426 not significant 
controls vs. 0.05 μM t-tests 0.4276 not significant 
controls vs 0.01 μM t-tests 0.2055 not significant 
controls vs 0.05 μM t-tests 0.0106 significant 
controls vs 0.1 μM t-tests 0.0016 significant 
controls vs. 0.5 μM t-tests < 0.0001 significant 
controls vs. 1 μM t-tests < 0.0001 significant 
Fig. 4.38 
cells carrying meronts 
2 days p.i multiple t-tests with days analyzed individually 0.945364 not significant 
6 days p.i multiple t-tests with days analyzed individually 0.439344 not significant 
10 days p.i multiple t-tests with days analyzed individually 0.0788531 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.00025488 significant 
18 days p.i multiple t-tests with days analyzed individually 0.0010787 significant 
22 days p.i multiple t-tests with days analyzed individually 7.041e-006 significant 
26 days p.i multiple t-tests with days analyzed individually 0.00013871 significant 
30 days p.i multiple t-tests with days analyzed individually 0.0432414 not significant 
meronts size 
10 days p.i multiple t-tests with days analyzed individually 0.869716 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.293938 not significant 
18 days p.i multiple t-tests with days analyzed individually 0.908454 not significant 
22 days p.i multiple t-tests with days analyzed individually 0.393091 not significant 
26 days p.i multiple t-tests with days analyzed individually 0.00191343 significant 
30 days p.i multiple t-tests with days analyzed individually 6.058e-008 significant 
Fig. 4.39 
controls vs. medium 0.07% ethanol t-tests 0.9769 not significant 
controls vs. 0.025 μM t-tests 0.9902 not significant 
controls vs. 0.05 μM t-tests 0.9702 not significant 
controls vs. 0.25 μM t-tests 0.9509 not significant 
controls vs. 0.5 μM t-tests 0.8436 not significant 
controls vs 2.5 μM t-tests 0.0017 significant 
controls vs 5 μM t-tests < 0.0001 significant 
Fig. 4.40 
cells carrying meronts 
(treatments since 1 day 
p.i) 
2 days p.i multiple t-tests with days analyzed individually 0.915553 not significant 
6 days p.i multiple t-tests with days analyzed individually 0.815788 not significant 
10 days p.i multiple t-tests with days analyzed individually 4.072e-006 significant 
14 days p.i multiple t-tests with days analyzed individually 3.686e-006 significant 
18 days p.i multiple t-tests with days analyzed individually 1.241e-008 significant 
22 days p.i multiple t-tests with days analyzed individually 4.887e-007 significant 
26 days p.i multiple t-tests with days analyzed individually 4.993e-006 significant 
30 days p.i multiple t-tests with days analyzed individually 0.00129247 significant 
meronts size 
(treatments since 1 day 
p.i) 
10 days p.i multiple t-tests with days analyzed individually 0.00749911 significant 
14 days p.i multiple t-tests with days analyzed individually 0.00319473 significant 
18 days p.i multiple t-tests with days analyzed individually 5.489e-008 significant 
22 days p.i multiple t-tests with days analyzed individually 3.058e-005 significant 
26 days p.i multiple t-tests with days analyzed individually 8.532e-009 significant 
30 days p.i multiple t-tests with days analyzed individually 1.336e-016 significant 
cells carrying meronts 
(treatments since 10 
days p.i) 
2 days p.i multiple t-tests with days analyzed individually 0.915553 not significant 
6 days p.i multiple t-tests with days analyzed individually 0.815788 not significant 
10 days p.i multiple t-tests with days analyzed individually 0.831236 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.0582052 not significant 
18 days p.i multiple t-tests with days analyzed individually 0.0010787 significant 
22 days p.i multiple t-tests with days analyzed individually 3.199e-006 significant 
26 days p.i multiple t-tests with days analyzed individually 4.830e-005 significant 
30 days p.i multiple t-tests with days analyzed individually 0.0044847 significant 
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meronts size 
(treatments since 10 
days p.i) 
10 days p.i multiple t-tests with days analyzed individually 0.815806 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.839711 not significant 
18 days p.i multiple t-tests with days analyzed individually 0.00011022 significant 
22 days p.i multiple t-tests with days analyzed individually 0.00172376 significant 
26 days p.i multiple t-tests with days analyzed individually 6.985e-007 significant 
30 days p.i multiple t-tests with days analyzed individually 7.240e-012 significant 
Fig. 4.41 Lipid droplet deposition  (treatments and times dependency) Two-way RM ANOVA < 0.0001 significant 
Fig. 4.42 
controls vs. medium 0.04% DMSO t-tests 0.7893 not significant 
controls vs. 0.025 μM t-tests 0.2480 not significant 
controls vs. 0.05 μM t-tests 0.0170 significant 
controls vs. 0.25 μM t-tests 0.000 significant 
controls vs. 0.5 μM t-tests < 0.000 significant 
controls vs 2.5 μM t-tests < 0.0001 significant 
controls vs 5 μM t-tests < 0.0001 significant 
Fig. 4.43 
cells carrying meronts  
2 days p.i multiple t-tests with days analyzed individually 0.915553 not significant 
6 days p.i multiple t-tests with days analyzed individually 0.815788 not significant 
10 days p.i multiple t-tests with days analyzed individually 0.831236 not significant 
14 days p.i multiple t-tests with days analyzed individually 0.0582052 not significant 
18 days p.i multiple t-tests with days analyzed individually 0.0010787 significant 
22 days p.i multiple t-tests with days analyzed individually 0.00039885 significant 
26 days p.i multiple t-tests with days analyzed individually 0.00073310 significant 
30 days p.i multiple t-tests with days analyzed individually 0.0250967 not significant 
meronts size  
10 days p.i multiple t-tests with days analyzed individually 0.00749911 significant 
14 days p.i multiple t-tests with days analyzed individually 0.00319473 significant 
18 days p.i multiple t-tests with days analyzed individually 5.489e-008 significant 
22 days p.i multiple t-tests with days analyzed individually 0.00062292 significant 
26 days p.i multiple t-tests with days analyzed individually 8.741e-006 significant 
30 days p.i multiple t-tests with days analyzed individually 1.142e-011 significant 
 
Fig. 4.44 
controls vs. medium 0.025% DMSO t-tests 0.7734 not significant 
controls vs. 0.025 μM t-tests 0.6902 not significant 
controls vs. 0.05 μM t-tests 0.5102 not significant 
controls vs. 0.25 μM t-tests 0.0469 significant 
controls vs. 0.5 μM t-tests 0.0013 significant 
controls vs 2.5 μM t-tests < 0.0001 significant 
controls vs 5 μM t-tests < 0.0001 significant 
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